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ABSTRACT 
Anaplastic Thyroid Carcinoma (ATC) is one of the most aggressive tumor 
characterized by an average survival time of 3-6 months after diagnosis. 
Multimodality therapy, which includes surgical debulking, external radiation 
therapy and chemotherapy, has failed to show any improvements in survival. 
Therefore, novel therapies with different mechanisms of action are required. 
Oncolytic viruses (OVs) represent a novel therapeutic tool for the treatment 
of aggressive tumors. OVs as single agents have demonstrated limited efficacy 
in a clinical setting, thus highlighting the need of novel combinatorial therapies 
(i.e. OVs plus a rationally selected drug) with a potential great impact on 
clinical use. In this study, we showed that the oncolytic adenovirus dl922-947 
induces massive S-phase entry in ATC cell lines, followed by an extensive 
DNA damage, quantified by γH2AX staining. Moreover, we demonstrated that 
dl922-947 triggered a DNA damage response, characterized by the activation 
of the checkpoint kinases ATM and Chk1, and at the same time impaired the 
ability of the DNA repair, by affecting MRN complex protein levels. The 
virus-induced single-strand DNA breaks (SSBs) activate the Poly-ADP-Ribose 
Polymerase (PARP) to signal SSBs to the enzymatic machinery involved in 
their repair.  
Here, we demonstrate that the pharmacological inhibition of PARP increases 
dl922-947 cytotoxicity against Anaplastic Thyroid Carcinoma both in vitro and 
in vivo. We also show that PARP inhibitor AZD2281 synergizes with dl922-
947 increasing viral replication and accelerating cell death pathways. 
Furthermore, we showed that the virus as single treatment induced an 
apoptotic-like cell death, as indicated by the presence of Caspase 3 activation, 
PARP cleavage, Annexin V positivity and Cytochrome C release from 
mitochondria, although lacking the morphological features of apoptosis. 
In this regard we also proved that dl922-947 acts on the pathway involved in 
membrane blebbing by inhibiting Myosin Light Chain 2 (MLC2) 
phosphorylation. Using a pan caspase inhibitor, both caspase-dependent and -
independent cell death pathways are found activated upon dl922-947 infection.  
Our data clearly suggest that the combination of the oncolytic adenovirus 
dl922-947 with PARP inhibitor could represent a novel and effective 
therapeutic approach for the treatment of Anaplastic Thyroid Carcinoma.  
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1. INTRODUCTION 
1.1   ANAPLASTIC THYROID CARCINOMA 
Malignant tumors originated from thyroid follicular cell have traditionally 
been classified as well-differentiated thyroid carcinoma, that comprises 
papillary and follicular carcinoma, and Anaplastic Thyroid Carcinoma (ATC). 
ATC is one of the most aggressive solid tumors that affect humans, with a 
median survival time of 3-6 months after diagnosis (Nagaiah et al. 2011). Even 
that ATC counts less than 1–3% of all thyroid cancers, it contributes up to 14–
50% of the annual mortality associated with thyroid cancer (Patel and Shaha 
2006, Nagaiah et al. 2011).  
The mean age at ATC diagnosis is 55 to 65 years, for this reason it is 
considered a disease of the elderly. It is observed that ATC is more common in 
places with endemic goiter (Bakiri 1998). Although its pathogenesis is not 
completely understood, there are evidences suggesting its origin from a pre-
existing well-differentiated thyroid carcinoma, prevalently papillary thyroid 
carcinoma (Patel and Shaha 2006). Macroscopically ATC appears as an 
unencapsulated, tan-white, fleshy tumors that infiltrate into the surrounding 
soft tissue of the neck, microscopically it is characterized by the presence of 
spindle, giant or squamoid cells. All these three types of cells do not have 
thyrotropin receptors, do not transport iodine, and do not produce 
thyroglobulin. Local symptoms of ATC most commonly begin with a rapidly 
evolving central neck mass followed by noticeable dysphagia, voice change or 
hoarseness, and stridor. At the disease presentation, in half of the patients 
metastases were found, with a prevalence in lungs; however also bone and 
brain were often affected (Nel et al. 1985).  
ATC is usually resistant to standard chemotherapy; so far the treatment 
consist of surgery, when feasible, combined with radiation and chemotherapy. 
However this multimodality treatment confers only a short term palliative 
and survival benefit. 
In the last years targeted therapies are appearing in the clinic. There are two 
small-molecule tyrosine-kinase inhibitors in the midst of Phase II clinical trials 
including imatinib mesylate (Gleevac, Novartis) (Podtcheko et al. 2003, 
Podtcheko et al. 2006) and sorafenib (Nexavar, Onyx) (Kim et al. 2007). Other 
agents that have been reported to be effective in in vitro studies include 
replication-competent vaccinia virus (GLV-1h68) (Lin et al. 2007). Moreover 
several preclinical studies have demonstrated the effectiveness of virotherapy, 
alone or in combination with rational choosed drug, for the treatment of 
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anaplastic thyroid carcinoma (Libertini et al. 2007, Lin et al. 2008, Reddi et al. 
2008, Libertini et al. 2011, Reddi et al. 2012). 
1.2   ONCOLYTIC VIRUSES 
Oncolytic viruses (OVs) are replication-selective viruses developed to be 
used as anticancer therapeutics. Nowadays they represent a promising and 
novel approach for the treatment of aggressive tumors both as single agents and 
both in combination with current clinical regimens (Parato et al. 2005, Liu et 
al. 2007) [Table 1]. 
OVs are viral mutants genetically engineered to specifically replicate and 
lyse tumor cells. The selectivity for tumor cells can be achieved using several 
strategies. Among these, the most common strategy is to eliminate viral 
function that are essential for the replication in normal cells, whereas the 
deregulated pathways in cancer cells complement the functions and enable 
viral propagation. Pathways that have frequently been targeted include cell 
cycle and apoptosis, function that are altered in almost all cancer cells 
(Bischoff et al. 1996, Heise et al. 2000, Sherr and McCormick 2002, White 
2006). 
Other approaches include the exchange of viral promoters for tissue/tumor-
specific promoters, inhibition of replication in normal tissue by insertion of 
miRNA target sequences, tropism modifications for selective attachment to 
tumor antigens or a combination of these strategies (Small et al. 2006, Waehler 
et al. 2007, Cawood et al. 2009). 
OVs have several potential benefits as anticancer therapeutics: tumor-
selective replication with up to 10,000-fold amplification of the input dose, 
stimulation of antitumoral immune responses, enhancement of cell killing in 
combination with other cytotoxic agents, efficacy independent of resistance to 
current anticancer therapeutics, no generation of neoplastic cell clones or 
treatment resistance, higher efficacy in cancer stem cells compared to 
conventional therapies in experimental models (Jiang et al. 2007). 
No or mild side effects result from their limited capacity to productively 
infect and spread in normal tissue; although low levels of replication in normal 
cells do not necessarily indicate clinical toxicity (Parato et al. 2005, Liu et al. 
2007). 
 
 
 
6 
 
Table 1. Oncolytic viruses under active investigation 
 
A search was carried out on http://www.clinicaltrials.gov and the clinical trial database of the 
Journal of Gene Medicine (http://www.wiley.com/legacy/wileychi/genmed/clinical/).  
5-FC: 5-fluorocytosine; 5-FU: 5-fluorouracil; β-gal: β-galactosidase; Ca: Cancer; CBDCA: 
Carboplatin; CD: Cytosine deaminase; CEA: Carcinoembryonic antigen; CRC: colorectal 
cancer; GCV: Ganciclovir; Gemzar: Gemcitabine; GFP: Green fluorescent protein; GM-CSF: 
Granulocyte-macrophage colony-stimulating factor; HCC: Hepatocellular carcinoma; HSV: 
Herpes simplex virus; hTERT: Human telomerase reverse transcriptase; ICP: infected cell 
protein; IRES: Internal ribosomal entry site; Mets: metastases; PanCa: Pancreatic cancer; PSA: 
Prostate specific antigen; PTX: Paclitaxel; RT: Radiation; SCCHN: Squamous cell carcinoma 
of the head and neck; Somatostatin R: Somatostatin Receptor; TK: Thymidine kinase; VGF: 
Vaccinia growth factor; Wt: Wild type. 
VIRUS NAME MODIFICATION PHASE TUMOR COMBINATION
TRIAL 
IDENTIFIER
Adenovirus Oncorine (H101) E1B55K-, E3- 2 SCCHN Cisplatin PMID: 14693057
3 SCCHN Cisplatin PMID: 15601557
Onyx-015 E1B55K-, E3- 1 SCCHN PMID: 10741699
1 Sarcoma
Mitomycin-C, dox, 
cisplatin PMID: 15647767
1/2 PanCa Gemzar PMID: 12576418
2 SCCHN Cisplatin, 5-FU PMID: 10932224
2 CRC 5-FU/leucovorin PMID: 15803147
CV706 PSA control 1 Prostate cancer RT PMID: 11606381
CG7870
Rat probasin-E1A, 
hPSA-E1B, E3+ 1/2 Prostate cancer Docetaxel NCT00103428
CG0070 E2F-1,GM-CSF 2/3 Bladder cancer PMID: 16397056
Telomelysin hTERT 1 Solid tumors PMID: 19935775
Ad5-CD/TKrep CD/TK 1 Prostate cancer 5-FC and GCV PMID: 12208748
2/3 Prostate cancer IR NCT00583492
Ad5-Δ24-RGD RGD, delta-24 1 Ovarian cancer PMID: 20978148
1/2 Glioma Recruiting
Ad5-SSTR/TK-RGD SSTR, TK, RGD 1 Ovarian cancer GCV PMID: 16397056
CGTG-102
Ad5/3, GM-CSF, Delta-
24 1/2 Solid tumors PMID: 20664527
Herpes Simplex 
Virus
Talimogene 
laherparepvec 
(OncoVEX)
GM-CSF, ICP34.5-, 
ICP47-, Us11↑ 2 Melanoma PMID: 19915919
3 Melanoma Active
1/2 SCCHN RT, cisplatin PMID: 20670951
G207 ICP34.5-, ICP6- 1/2 Glioma PMID: 18957964
G47Delta From G207, ICP47- 1 Glioma PMID: 11353831
HSV 1716 (Seprehvir) ICP34.5- 1 SCCHN PMID: 18615711
1 Glioma PMID: 15334111
1 Melanoma PMID: 11229673
HF10 HSV-1 HF strain 1 PanCa PMID: 21102422
NV1020 1 CRC liver mets PMID: 19018254
Measles Virus 
(Edmonston) MV-CEA CEA 1 Ovarian cancer PMID: 20103634
Newcastle disease 
virus
NDV-HUJ 1/2 Glioma PMID: 16257582
PV701 1 Solid tumors PMID: 16638865
MTH-68/H 2 Solid tumors PMID: 8275514
NV1020 1 Solid tumors PMID: 11980996
Parvovirus H-1PV 1/2 Glioma PMID: 20299703
Poliovirus (Sabin) PVS-RIPO IRES 1 Glioma PMID: 20299272
Reovirus (Dearing) Reolysin 1/2 Glioma PMID: 18253152
3 SCCHN PTX, CBDCA Recruiting
Seneca Valley virus NTX-010 2
Small cell lung 
cancer PMID: 17971529
Retrovirus Toca 511 CD 1/2 Glioma 5-FC PMID: 16257382
Vaccinia (Wyeth 
strain) JX-594 GM-CSF, TK- 1 HCC PMID: 18495536
Vaccinia (Western 
Reserve) wDD-CDSR
TK-, VGF-, LacZ, CD, 
Somatostatina R 1 Solid tumors PMID: 15336655
Vaccinia (Lister) GL-ONC1 (GLV-h68)
Renilla luciferase, GFP, 
β-gal, β-glucoronidase 1 Solid tumors PMID: 21779374
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Oncolytic mutants in clinical therapies 
At the beginning of 20th century it was observed that tumor regression was 
achieved in two isolated cases of cervical carcinoma and Burkitt’s lymphoma 
after inoculation with attenuated rabies virus (De Pace 1921) and measles virus 
(Bluming and Ziegler 1971) respectively. 
Until the 1970s several preclinical and clinical studies were performed with 
various virus species such as rabies virus (Pack 1950), mumps virus (Asada 
1974), West Nile virus (Southam and Moore 1952), Newcastle disease virus 
(Sinkovics and Horvath 2000) and Adenovirus serotype 4 (Southam et al. 
1956). However the outcomes of these studies were disappointing with severe 
side effects or even deaths of treated patients.  
In the late 1980s, the demonstrated feasibility of gene delivery with viral 
vector renewed the interest in OVs; moreover advancement of viral 
engineering, production, and purification technologies together with a better 
understanding of the molecular alterations in cancer cells further promoted the 
development of viral mutants selectively targeting tumor tissue. 
Oncolytic mutants generated from other viral species rather than adenovirus 
have been or are currently being considered as anticancer agents.  
Herper Simplex Virus HSV-1 mutant G207 was one of the first oncolityc 
virus to enter in clinical trials for the treatment of recurrent gliomas. This 
mutant was deleted in the ICP34.5 loci preventing neurovirulence and in the 
ICP6 gene inactivating ribonucletide reductase allowing selective replication in 
cancer cell (Markert et al. 2000) [Table 1]. 
Based on G207 backbone several HSV mutants have entered in clinical trials 
such as OncoVex GM-CSF (BioVex-Amgen, MA, USA) (Hu et al. 2006). 
Several clinical trials (shown in table 1) have demonstrated OncoVex GM-CSF 
effectiveness and safety with only limited flu-like side effects. 
Attenuated vaccine strains of Vaccinia virus (Poxvirus family) have also been 
evaluated in the clinic. The most promising of these mutants is JX-594 
(Jennerex Biotherapeutics, Inc., CA, USA) of the Wyeth strain, expressing 
GM-CSF and β-galactosidase (Park et al. 2008, Breitbach et al. 2011). JX-594 
bears a deletion of the viral thymidine kinase gene that allow viral replication 
selectively in cancer cells harboring constitutively active epidermal growth 
factor receptor (EGFR)/Ras signalling and elevated nucleotide synthesis (Kim 
et al. 2006). Clinical trials performed with JX-594 [Table 1] showed no major 
toxicity and reported tumor necrosis and stimulation of the immune responses 
related to viral replication. 
The Reovirus subtype Reolysin (Oncolytics Biotech) selectively targets 
neoplastic cells with activated Ras pathway (Coffey et al. 1998). Many clinical 
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trials with Reolysin in combination with cytotoxic drugs have been completed 
[Table 1] and a Phase III trial was approved targeting head and neck cancers 
(http://clinicaltrials.gov/NCT01166542). 
It is worth to note that a first-in-class US approval is expected soon for 
OncoVex, which is being tested in a randomized phase 3 clinical trial for the 
treatment of melanoma that has recently completed accrual 
(http://clinicaltrials.gov/NCT00769704). 
1.3   ONCOLYTIC ADENOVIRUSES 
Adenoviruses 
Among the different OVs, adenoviral mutants were considered better suited 
for therapy of epithelial malignancies, but they show activity also against 
hematological cancer.  
Adenoviruses are non-enveloped icosahedral viruses. Their capsid comprises 
of the structural proteins hexon and penton that bind to Coxsackie and 
Adenovirus Receptor (CAR) and αvβ3,5 integrins respectively for virus 
internalization. Furthermore adenovirus have a double-stranded DNA (dsDNA) 
of approximately 36 Kb. 
The adenovirus life-cycle includes the following steps: (1) virus entry into 
the cell following CAR and integrin binding, (2) release from the endosome 
and subsequent entry into the nucleus, (3) expression of early region gene 
products, (4) cell entry into S phase, (5) prevention of p53-dependent and -
independent apoptosis, (6) shut-off of host cell protein synthesis, (7) viral DNA 
replication, (8) viral structural protein synthesis, (9) virion assembly in the 
nucleus, (10) cell death and (11) virus release [Figure 1].  
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Figure 1. Adenovirus life-cycle 
The adenovirus life-cycle includes the several steps: (1) virus entry into the cell following 
CAR and integrin binding, (2) release from the endosome and subsequent entry into the 
nucleus, (3) expression of early region gene products, (4) cell entry into S phase, (5) prevention 
of p53-dependent and -independent apoptosis, (6) shut-off of host cell protein synthesis, (7) 
viral DNA replication, (8) viral structural protein synthesis, (9) virion assembly in the nucleus, 
(10) cell death and (11) virus release 
Adenoviral replication is divided into early and late phase. Soon after 
infection, Early 1A (E1A) is the first gene to be transcribed.  
The most important E1A function is the induction of S-phase in infected cells 
through the binding of E1A Conserved Region 2 (CR2) and 1 (CR1) to pRb 
and p300/CBP. This binding displaces the transcriptional repressor pRb from 
E2F transcription factors resulting in the auto-stimulation of E1A expression 
and in the activation of the downstream viral expression units E1B, E2, E3 and 
E4 as well as promoting cellular gene expression (Shenk 1996). 
To antagonized E1A-induced apoptosis, adenoviruses have evolved two 
proteins E1B-19K and E1B-55K both encoded by E1B gene. In particular E1B-
19K is an homologue of Bcl2 protein and inhibits apoptosis heterodimerizing 
with Bax and Bak pro-apoptotic proteins (White 2001), whereas E1B-55K 
binds to and inhibits p53 as a transactivator protein (Yew and Berk 1992). 
Fig 1 
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Early E3 protein it is involved in counteracting immune response elicited by 
the host cell against the virus, indeed this protein can block the transport of 
MHC class I heavy chain to cell surface (gp19K) and inhibit TNFα and Fas 
ligand-induced cell death by degradating their receptors (Horwitz 2001). 
E2 region encodes for proteins directly involved in adenoviral replication 
such as preTerminal Protein (pTP), DNA Polymerase (AdPol) and single 
stranded DNA binding protein (DBP) (Liu et al. 2003). Since replicated viral 
DNA tends to form concatamers that are too large to be packed into the virion, 
the protein complex E1B55K/E4orf6 induces the degradation of protein 
involved in concatamers formation (see next paragraphs) (Stracker et al. 2002). 
E4orf6 is one of the six protein, termed as open reading frame proteins 
(E4orf1-6/7), encoded by E4 region. These protein have been shown to be 
regulators of viral and cellular transcription (E4orf4, E4orf6, E4orf6/7), viral 
pre-mRNA splicing (E4orf3, E4orf4, E4orf6), viral and cellular mRNA 
transport (E4orf6), cellular protein degradation (E4orf6), nuclear structure 
organization (E4orf3), and the aforementioned concatamerization (E4orf3, 
E4orf6) (Tauber and Dobner 2001, Stracker et al. 2002). 
Late viral gene encodes for protein involved in encapsidation and maturation 
of the virus particle. 
Oncolytic virotherapy using adenoviruses 
In oncolytic virotherapy, among different viral species, adenoviruses have 
shown several advantages. First of all they have a well characterized small 
linear DNA genome that result easy to manipulate; they do not integrate into 
host genome; they require a simple technology for production to GMP (Good 
Manufacturing Practice) standards; they have a natural tropism for epithelial 
cell and adenocarcinoma. Moreover species C adenoviruses can cause only 
mild flu-like side effect or asymptomatic infections. 
While recent reports demonstrate that serotype 11, 3 and 35 of species B 
might have better efficacy in certain preclinical models (Kim et al. 2011), 
serotype 5 (Ad5) of species C is the most widely used for generation of 
oncolytic mutants. This difference in efficacy could be related to viral uptake 
in tumor cells, indeed species B mutants bind to the ubiquitously expressed 
CD46 receptors (Sirena et al. 2004), while species C binds to CAR that is 
downregulated in some cancers. Furthermore, while most humans have 
neutralizing antibodies towards serotype 5, pre-existing antibodies to other 
serotype are less prevalent (Kueberuwa et al. 2010). Exploiting different 
advantages of various serotype, chimeric mutants have been generated 
resulting in Ad5/3 chimeras that are directed to CD46 receptor, highly 
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expressed on tumor cells, thereby improving antitumor efficacy (Ranki and 
Hemminki 2010). 
The main disadvantage of the use of adenovirus is that intravenous 
administration is less feasible because of the high viral binding affinity for 
complement and other blood factors. This binding is followed by rapid 
elimination by hepatic Kupffer cells (Baker et al. 2007b, Kueberuwa et al. 
2010). However several groups overcame these obstacles coating mutants with 
various polymers followed by retargeting to tumors (Fisher and Seymour 
2010). 
Two broad approaches are currently being used to engineer tumor-selective 
adenovirus replication. One is the use of tumor- and/or tissue-specific 
promoters; the second approach is to delete gene functions that are critical for 
efficient viral replication in normal cells but are expendable in tumor cells. The 
latest approach is based on the observation that many of the same critical 
regulatory proteins, that are inactivated by viral gene products during 
adenovirus replication, are also inactivated during carcinogenesis (Bischoff et 
al. 1996, Heise et al. 2000, Sherr and McCormick 2002). 
To the first group belong, for example, the mutant CG7870, in which the 
expression of the viral E1A gene is under the control of the rat probasin 
promoter, and E1B expression is under the control of the human Prostate-
Specific Antigen (PSA) promoter (Dilley et al. 2005), and OBP-301 in which 
the human TElomerase Reverse Transcriptase (hTERT) promoter drives E1 
gene expression (Hashimoto et al. 2012). 
However the most extensively clinically evaluated replication-selective 
oncolytic viruses to date are engineered using the second approach. In 
particular the first replication-competent adenoviral mutant, dl1520 (Onyx-015 
and H101), is based on chimeric adenoviruses serotype 5 and 2 (Ad5/Ad2) and 
contains a deletion of E1B55K, which normally inhibits p53 to prevent 
premature cellular apoptosis (Heise et al. 1997). In the great majority of cancer 
cells, E1B55K deletion is complemented by functional inactivation of p53 and 
alteration in mRNA nuclear export mechanisms. The E1B55K-deleted H101 
(Shanghai Sunway Biotech) was the world’s first oncolytic virus approved in 
China for cancer treatment. In its phase III clinical trial it is reported a 79% 
response rate for H101 plus chemotherapy, compared with 40% for 
chemotherapy alone in patients with head and neck cancer (Yu and Fang 
2007). 
Although the toxicity profile of dl1520 in over 200 patients treated in phase 
I/II trials was promising, with little dose-limiting toxicity, durable responses to 
single-agent dl1520 were rare; moreover in in vitro studies it has been 
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demonstrated that this mutant can also lyse cancer cells with normal p53 status 
raising questions to its mechanism of action (Kirn 2001). These observations 
have encouraged the search for more effective replicating adenoviral agents. 
A second generation adenoviral mutant, dl922-947, has been engineered 
deleting 24bp in the E1A-CR2 domain. This mutant can replicate only in cells 
with deregulated growth control such as the majority of cancer cells with 
altered G1/S checkpoint and pRb/Ras signaling pathway.  
dl922-947 has superior oncolytic potency both in vitro and in vivo in human 
pancreatic (Bhattacharyya et al. 2011), glioma (Yong et al. 2009, Botta et al. 
2012), thyroid (Libertini et al. 2008, Libertini et al. 2011) and ovarian cancer 
cells (Lockley et al. 2006). 
In contrast, in quiescent normal cells, dl922-947-driven replication was 
significantly less than with Ad5wt (Heise et al. 2000). A similar adenovirus, 
Δ24, with the same deletion in E1A-CR2, has shown activity in preclinical 
models of glioma (Fueyo et al. 2000). 
Ad5ΔCR2, another E1A-CR2-deleted mutant, has been retargeted to 
integrins inserting an RGD sequence (Ad5ΔCR2RGD). This mutant has been 
evaluated in phase I trial for recurrent ovarian cancer showing safe and with 
potential antitumor responses (Kimball et al. 2010); moreover it is currently 
investigated in a second Phase I trial targeting recurrent gliomas 
(http://clinicaltrials.gov/NTC00805376). 
A variant of Ad5ΔCR2RGD armed with the immunostimulatory 
Granulocyte-Macrophage Colony-Stimulating Factor (GMCSF) administered 
to patients with advanced refractory disease prevented tumor progression in 
three out of six patients and stable disease was reported in two additional 
patients (Pesonen et al. 2012). 
AdΔΔ is a mutant double deleted in the E1A-CR2 region and in E1B19K. 
The lack of E1B19K expression prevents viral spread in normal host cell by 
TNF-induced apoptosis, but not in cancer cells due to the frequently inactivated 
apoptotic pathway in these cells (White 2006). AdΔΔ oncolytic potency it has 
been already demonstrated in in vitro and in vivo models of pancreatic 
(Cherubini et al. 2011) and prostate (Oberg et al. 2010) cancer. 
Oncolytic Adenoviruses: combinatorial therapies 
In the last ten years several preclinical and clinical studies have been 
performed to assess the safety and efficacy of oncolytic adenoviruses alone or 
in combination with cytotoxic drugs or radiotherapy [Table 1]. 
These studies have demonstrated the higher efficacy of drug/radiotherapy and 
adenovirus combination compared to single-agent treatment highlighting the 
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evidence that adenoviruses, both wild type and oncolytic mutants, can operate 
in synergy with chemotherapeutic drugs to kill cancer cells. 
Different approaches have been exploited to enhance the effects of oncolytic 
adenoviruses. These approaches include agents able to increase viral entry, 
viral replication or viral diffusion; able to modulate the immune response; able 
to interfere with cell proliferation; or again able to induce a DNA damage and 
the subsequent cell death.  
In the latter approaches are included drugs such as cisplatin, doxorubicin, 
mitomycin-C and ionizing radiation that are already used in the clinic for the 
treatment of several type of cancer. 
In two completed phase II and phase III clinical trials, the oncolytic mutant 
H101 (E1B55k-deleted) has been combined to cisplatin to treat Squamous Cell 
Carcinoma of the Head and Neck (SCCHN). Both studies clearly demonstrate 
the superior efficacy of cisplatin treatment if combined with H101 mutant (Xu 
et al. 2003, Xia et al. 2004). 
Another mutant called Onyx-015 (E1B55k- and E3-deleted) has been 
combined with MAP chemotherapy (Mitomycin-C, Doxorubicin and Cisplatin) 
in a phase I/II trial in patients with advanced sarcoma (Galanis et al. 2005). 
This study showed that ONYX-015 in combination with MAP chemotherapy is 
well tolerated with no significant toxicity; moreover there was evidence of 
antitumor activity in one out of six patients (Galanis et al. 2005). 
The oncolytic adenovirus CV706 (Prostatic-Specific Antigen-regulated 
expression of E1A gene) has been used in combination with radiotherapy in 
patients with prostate cancer in a phase I trial. The intraprostatic delivery of 
CV706 has proved to be safe, even at high doses, and the data also suggest that 
CV706 possesses enough clinical activity, as reflected by changes in serum 
PSA (DeWeese et al. 2001). 
Due to the intrinsic ability of viruses to interfere with cell proliferation, 
agents modulating these cellular steps have been selected to increase the 
efficacy of oncolytic adenoviruses.  
The nucleoside analogue Gemcitabine (marketed as Gemzar) has been 
combined with Onyx-015 in a phase I/II trial for the treatment of pancreatic 
cancer. After combination therapy, 2 patients had partial regressions of the 
injected tumor, 2 had minor responses, 6 had stable disease and 11 had 
progressive disease or had to go off study because of treatment toxicity (Hecht 
et al. 2003). 
5-FluoroUracil (5-FU) is a pyrimidine analog which is used in the treatment 
of cancer. It works through irreversible inhibition of thymidylate synthase 
impeding DNA replication. In a phase II clinical trial have been evaluated the 
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effects of Onyx-015 among metastatic colorectal cancer patients that have 
failed prior treatment with 5-FU/leucovorin. Onyx-015 hepatic artery infusion 
prolonged the median survival to 19 months compared to patients to those 
patients only received 5-FU/leucovorin that was 10.7 months (Reid et al. 
2005). 
In another phase II clinical trial Onyx-015 has been used in combination both 
with a cytostatic agent, 5-FU, both with a cytotoxic agent, cisplatin in patients 
with SCCHN. This combinatorial regimen demonstrate substantial objective 
responses, including a high proportion of complete responses. Moreover, by 6 
months, none of the responding tumors had progressed, whereas all non-
injected tumors treated with chemotherapy alone had progressed (Khuri et al. 
2000). 
The adenoviral mutant CV787 have the viral gene E1B under the control of 
human PSA promoter. This mutant has been used in combination with 
docetaxel in phase I/II trial for the treatment of prostate cancer 
(http://clinicaltrials.gov/NCT00103428). This study is terminated; however 
results are not yet available. 
The history of OVs field suggests that immunosuppressed patients generally 
respond better to oncolytic virus therapy than those with an intact immune 
system. It follows that combining virotherapy with immunosuppressive drugs 
could be useful for enhancing their antitumor activity. Among the different 
immunosuppressive drugs, cyclophosphamide is currently the most favored 
because it has several advantages: is potently toxic both against T and B 
lymphocyte, has direct antitumor activity, has been widely used since 1949 and 
is reasonably priced. A phase I clinical trial to investigate the safety and the 
recommended dose for later use of an oncolytic adenovirus CGTG-102 in 
combination with cyclophosphamide is currently in a recruiting stage 
(http://clinicaltrials.gov/NCT01598129); however several preclinical studies 
have shown that cyclophosphamide can retard immune clearance of OVs, 
enhancing the persistence of virus infection and prolonging therapeutic 
efficacy (Chiocca 2008). 
In addition to combining OVs with drugs, another strategy is to engineer 
prodrug-converting enzyme, such as Cytosine Deaminase (CD) or Thymidine 
Kinase (TK), into the viral genome. Subsequently the selective conversion of 
non-toxic prodrugs to toxic drugs will occur only in tumor cells infected by the 
oncolytic mutant, resulting in greatly reduced systemic drug toxicity. In this 
regard very promising results were reported in a phase I clinical trial for the 
treatment of prostate cancer; indeed the results demonstrate that intraprostatic 
administration of the replication-competent Ad5-CD/TKrep virus followed by 
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2 weeks of 5-FluoroCytosine (5-FC) and ganciclovir prodrug therapy can be 
safely applied to humans and is showing signs of biological activity (Freytag et 
al. 2002). Moreover a modified improved version of this mutant, 
Ad5CD/TKrepADP, has now been approved for phase III trials in combination 
with 5-FC, ganciclovir and radiotherapy 
(http://clinicaltrials.gov/NCT00583492). 
All these extensive studies have demonstrated that adenoviruses are less 
efficacious when administered alone, especially in the treatment of aggressive 
tumors, and that synergistic cell killing occurs when adenoviral mutants are 
combined with other drugs. To improve these combinations or to develop more 
powerful clinical therapies, it is necessary to better understand the interplay 
between oncolytic adenoviruses and the host cell during infection. 
1.4   DNA DAMAGE REPAIR PATHWAYS 
Organisms are permanently exposed to endogenous and exogenous agents 
that damage DNA. If not repaired, such damage can result in mutations, 
diseases and cell death.  
The DNA repair mechanisms have an important role in the innate 
intracellular defense against foreign invaders. For example viral infection and 
replication produce a large amounts of exogenous genetic material, much of 
which with an unusual DNA secondary structure that represent targets for 
cellular proteins involved in the response to abnormal and damaged DNA. 
There are various forms of DNA damage, such as base modifications, single 
strand breaks (SSB), double strand breaks (DSB), crosslinks and mismatches. 
To reply to these different DNA damage, cells have evolved numerous DNA 
repair pathways. The major DNA repair pathways include direct repair (O6- 
MethylGuanine-DNA-MethylTransferase, MGMT), Base Excision Repair 
(BER), Nucleotide Excision Repair (NER), MisMatch Repair (MMR), 
Homologous Recombination (HR) and Non-Homologous End-Joining (NHEJ) 
repair. 
DNA damage recognition 
The first step in DNA repair is the damage recognition. The DNA damage 
response (DDR) is a signal transduction pathway that senses DNA damage and 
replication stress [Figure 2]. It involves several proteins that are grouped into 
four categories based on their activity: sensors, mediators, transducers and 
effectors. 
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Figure 2: DNA-damage-response signal-transduction network.  
The DNA-damage-response network consists of two parallel pathways that respond to different 
types of DNA damage. The ATM pathway responds to the presence of double-strand breaks 
(DSBs). It can activate many of the downstream components of the ATR pathway, which also 
responds to DSBs, but more slowly than ATM. In addition, the ATR pathway can respond to 
agents that interfere with the function of DNA replication forks, such as ultraviolet light and 
hydroxyurea. DNA alkylating agents might activate both pathways, although these types of 
DNA damage impose stress on progressing replication forks, they clearly also could elicit 
strand breaks under some circumstances. The single-stranded DNA-binding protein replication 
protein A (RPA) is required for the recruitment of ATR and its partner protein ATRIP to sites 
of DNA damage and for ATR-mediated CHK1 activation. Full activation of the damage-
response pathway also requires the RAD9–RAD1–HUS1 and RAD17–RFC complexes. 
Sensors MRE11–RAD50–NBS1 complex binds to ATM and DNA. CHK1 and CHK2 lie 
downstream of ATM and ATR. The effectors include proteins that are involved in DNA repair, 
transcription regulation, replication, cell-cycle control and apoptosis, such as BRCA1, 
FANCD2, NBS1, H2AX, BLM1, 53BP1, CDC25 and p53.Dashed lines represent less strong 
interactions. Red lines represent interactions that are supported by only limited data. 
The 9-1-1 heterotrimeric complex (composed by Rad9, Rad1 and Hus1) acts 
as a sensor complex, indeed once DNA is damaged, the 9-1-1 complex is 
recruited to the damage site under the regulation of Rad17 complex (Melo et al. 
2001). The chromatin-bound 9-1-1 complex then facilitates phosphorylation 
mediated by transducer proteins Ataxia Telangiectasia and Rad-3-related 
(ATR) and Ataxia Telangiectasia Mutated (ATM).  
In mammals, there are four mediator-type proteins that contain BRCA1 C-
terminus repeat (BRCT) domains that are involved in protein–phosphoprotein 
interaction (Manke et al. 2003). Mediator of DNA Damage Checkpoint 1 
Fig 2 
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(MDC1) functions as a molecular bridge between histone H2AX 
phosphorylated on serine 139 (called γH2AX) and Nijmegen Breakage 
Syndrome 1 (NBS1) in the MRN complex (MRE11–Rad50–NBS1). Unlike 
sensor proteins that accumulate at the sites of DNA damage in an ATM-
independent manner, recruitment of these mediator proteins depends on the 
phosphorylation of γH2AX by ATM (Niida and Nakanishi 2006). γH2AX 
formation has normally been associated with the induction DSBs after 
exposure to IR or other DNA-damaging agents and marks chromatin regions 
spanning megadaltons of DNA flanking each DSB (Rogakou et al. 1998). 
However, a number of reports have shown phosphorylation of H2AX after 
DNA replication stress (Ward and Chen 2001, Furuta et al. 2003, Ewald et al. 
2007). 
Signals initiated by the sensors are very rapidly transduced to ATM and ATR 
kinases, which are both extremely large proteins that phosphorylate a great 
number of substrates. ATM is activated by DNA-damaging agents (e.g., 
ionizing radiation and genotoxins) that create DSBs, whereas ATR is activated 
following recruitment to RPA-coated ssDNA regions generated at stalled 
replication forks by agents interfering with the function of DNA replication 
forks, such as UltraViolet (UV) light and hydroxyurea (Smith et al. 2010). 
Under unstressed conditions ATM exists as a homodimer in which the kinase 
domain is physically blocked by tight intermolecular binding to a protein 
domain at around Ser1981. DSBs cause a conformational change in the ATM 
protein that stimulates the kinase to phosphorylate Ser1981 by intermolecular 
autophosphorylation, resulting in dissociation of the homodimer. ATM is also 
regulated by recruitment to the substrate sites by binding to MRE11. Activated 
ATM phosphorylates many proteins, including BReast CAncer 1 (BRCA1) 
(Cortez et al. 1999), NBS1 (Lim et al. 2000), Chk2 and p53 (Banin et al. 1998), 
as well as itself (Bakkenist and Kastan 2003). In particular, in response to a 
DNA damage, ATM phosphorylates Chk2 on threonine 68. Even if 
biochemical analyses revealed that activated Chk2 phosphorylates Cdc25A at 
Ser123, Cdc25C on Ser216, BRCA1 at Ser988 and p53 at several sites, 
including Ser20, the examination of Chk2-deficient mice and cells revealed 
that this enzyme functions mainly in p53-dependent apoptosis but not in G2/M 
arrest upon DNA damage (Takai et al. 2002). 
Another important DNA damage signal transducer is ATR. In human cells, 
ATR exists in a stable complex with ATR interacting protein (ATRIP), a 
potential regulatory partner. ATR–ATRIP complex is recruited at sites of DNA 
damage by the binding of ATRIP to RPA and it is implicated in monitoring the 
progression of DNA replication. Once activated, ATR phosphorylate in serine 
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317/345 and activate its main target Chk1. In turn Chk1 has been shown to 
phosphorylate a series of effector proteins such as Cdc25-A, Cdc25-B and 
Cdc25-C, downregulating their phosphatase activity. These phosphatases 
dephosphorylate the Cdks that regulate cell cycle transitions. Therefore Chk1 
seems to be indispensable for the cell-cycle arrest in response to genotoxic 
stresses (Niida and Nakanishi 2006). 
Among the effector proteins, in addition to the already mentioned 
phosphatases and Cdks, the tumor suppressor protein p53 plays a central role in 
the decision of a cell to undergo either cell-cycle arrest or apoptosis after DNA 
damage (Prives and Hall 1999). Moreover, p53 can directly activates repair 
pathways such as NER through regulation of the NER factors XPC and DDB2 
and induces dNTP synthesis (Niida and Nakanishi 2006). During DDR both 
ATM and ATR phosphorylate p53 at Ser15. This phosphorylation inhibits the 
interaction of p53 with Mdm2, resulting in p53 stabilization. Moreover ATM is 
also able to phosphorylate Mdm2 reducing its capability to promote nucleo–
cytoplasmic shuttling and the subsequent degradation of p53 (Maya et al. 
2001). 
ATM and ATR are required for the activation of NHEJ, HR, and NER, as 
well as replication fork stability during unperturbed DNA replication and in 
response to replication blocks. 
Double strand breaks repair: nonhomologous end joining and homologous 
recombination 
DSBs are the most dangerous of all types of DNA damage and arise in cells 
from endogenous (reactive oxygen species) as well as from exogenous 
(Ionizing Radiation, IR, and UV light) attacks on the DNA backbone. When 
unrepaired, DSBs can be lethal and trigger apoptosis. DSB repair occurs 
primarily by two pathways: NonHomologous End Joining (NHEJ) and 
Homologous Recombination (HR). 
NHEJ repair is the result of the direct ligation of the free ends of the DNA 
DSB, whereas HR uses strand invasion of the homologous chromatid to 
synthesize DNA across the DSB using this homologous chromatid sequence as 
a template. Thus, HR can take place only after DNA replication, in S/G2/M 
cell-cycle phases, whereas NHEJ is preferred in G0/G1. Because HR uses a 
homologous template to repair a DSB, it is quite accurate, whereas NHEJ may 
require end trimming that makes it less accurate. Both NHEJ and HR have 2 
subpathways. In NHEJ the choice between classic and alternate pathways is 
regulated by p53 Binding Protein 1 (53BP1), which promotes classic NHEJ, 
and Poly (ADP-ribose) polymerase 1 (PARP-1), which promotes alternative 
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NHEJ. Alternative NHEJ involves more resection of the free DNA ends to find 
microhomologies than classic NHEJ, which directly ligates the free ends. 
Therefore alternative NHEJ is less accurate and can result in large deletions or 
translocations. 
Classic NHEJ is a relatively simple DSB repair pathway. Both ends of the 
break are first bound by the Ku70/Ku80 heterodimer, which then recruits the 
catalytic subunit of the DNA dependent Protein Kinase (DNA-PKcs). If 
necessary, the ends can be trimmed by nucleases (such as Artemis) or filled in 
by DNA polymerases (such as Polμ or Polλ) to create compatible ends. Finally, 
the ligation complex, consisting of DNA ligase IV, X-ray cross-
complementation group 4 (XRCC4) and Xrcc4 like factor (XLF), also known 
as Cernunnos, ligates the ends [Figure 3] (Lieber 2010). 
 
 
Figure 3: Outline of the main players and of the key steps of NonHomologous End 
Joining (NHEJ). 
a) Classic NHEJ pathway efficiently restores genomic integrity without ensuring sequence 
restoration. Association of Ku to DNA ends facilitates the recruitment of DNA-PKcs, a major 
kinase activated by DNA ends and contributing to the efficiency of this repair pathway. DNA-
PKcs promotes end-processing by the Artemis nuclease and subsequent rejoining of broken 
DNA ends by the LigIV/XRCC4/XLF complex; b) The enzymatic activities implicated in 
alternative NHEJ pathway are shown together with their possible contributions in the process. 
Alternative NHEJ pathway requires single-strand end-resection by the 
MRE11/RAD50/NBS1 (MRN) complex, and the CtIP tumor-suppressor. This 
Fig 3 
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resection exposes microhomologies that promote pairing of broken ends, which 
are then ligated by Ligase III/XRCC1 [Figure 3] (Shaheen et al. 2011).  
HR also includes accurate and inaccurate subpathways, both of which require 
extensive single-strand end-resection to allow for invasion by the remaining 
strand of the homologous template (sister chromatids, homologous 
chromosomes or linked or unlinked repeated sequences). End resection occurs 
in 2 phases, with limited resection initiated by MRN/CtIP and extensive 
resection mediated by the BLM helicase and the EXO1 and DNA2 
exonucleases (Shaheen et al. 2011).  
In the accurate HR pathway, homologous DNA sequences are used as 
templates to copy genetic information for repair. After resection, accurate HR 
involves binding of RPA to single strands, and BRCA2-mediated replacement 
of RPA with RAD51 to form a RAD51 nucleoprotein filament, which searches 
for and invades the homologous template. The invading strand is extended by 
synthesis of new DNA. The newly synthesized strand can then anneal with the 
other resected end, and additional synthesis and ligation completes high-
fidelity repair [Figure 4] (Brandsma and Gent 2012).  
Inaccurate HR is termed Single-Strand Annealing (SSA), in which extensive 
resection exposes complementary sequences in linked direct repeats, which 
anneal in a reaction promoted by RAD52. SSA is always inaccurate because it 
deletes one of the repeats and the intervening sequence, or it results in 
translocations when 2 DSBs occur within or near repeats on different 
chromosomes [Figure 4] (Shaheen et al. 2011). 
 
21 
 
 
Figure 4: Homologous Recombination (HR) subpathways. 
a) After detection of the DSB, the 5′ strands are resected, producing long 3′ single-stranded 
DNA tails that then serve as a substrate for assembly of a Rad51 nucleoprotein filament. This 
presynaptic complex also contains Rad52, Rad54, Rad55, and Rad57. This complex searches 
the genome for DNA sequence homology that is then used for subsequent strand invasion. 
Branch migration of this joint DNA molecule, DNA synthesis, ligation, and resolution of 
Holliday junctions restores the DNA templates. b) An alternative HR repair pathway (single-
strand annealing) uses Rad52 to search for homologous sequences on the resected 3′ ends. The 
FEN-1 endonuclease removes the “flap” DNA ends and ligation occurs. This pathway leads to 
DNA sequence deletions. 
The remaining mentioned repair pathways operate on nucleotide lesions 
occurring on single strands. 
Single strand breaks repair: direct repair 
MGMT plays an important biological role in directly repairing O6-
methylguanine in DNA formed by alkylating agents, indeed MGMT removes 
methyl adducts from O6 position of guanine (formed by temozolomide, 
streptozotocin, procarbazine and dacarbazine), as well as O4-methyl thymine, 
O6-ethylguanine (formed by ethylnitrosourea and diethylnitrosamine and 
related compounds) and O6-chloroethylguanine adducts [formed by bis-(2-
cholorethyl)-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-
nitrosourea; CCNU]. Then MGMT transfers the alkyl group from the target 
base to a cysteine residue within its active site and thereby inactivates itself in 
the process [Figure 5] (Madhusudan and Hickson 2005). 
Fig 4 
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Figure 5: Repair of O6-alkylguanine adducts by MGMT. 
MGMT mediates a stoichiometric reaction in which methyl and other alkyl groups bound to 
the O6 position of guanine in DNA via a thioester linkage to a cysteine residue in the active 
site. Alkylation of MGMT leads to rapid degradation of the protein. 
Single strand breaks repair: nucleotide excision repair 
For bulky helix-distorting damage, such as lesions induced by UV light, the 
principal repair mechanism is the evolutionarily conserved NER pathway. 
Essentially it consists of several sequential steps: lesion sensing, opening of a 
denaturation bubble, incision of the damaged strand, displacement of the 
lesion-containing oligonucleotide, gap filling, and ligation. However NER 
recognizes and removes helical distortions in two different modes: throughout 
the genome (global genome repair, GGR), or selectively from the transcribed 
strand of active genes (transcription-coupled repair, TCR) (Kamileri et al. 
2012). In GGR, the DNA is surveyed by two proteic complexes that sense and 
bind the DNA lesion: the xeroderma pigmentosum complementation group C 
(XPC)-RAD23-centrin, EFhand protein, 2 (CETN2) complex, and the UV 
damaged DNA-binding protein (UV-DDB) complex (DDB1-DDB2-containing 
E3-ubiquitin ligase complex). The opening of a denaturation bubble around a 
lesion and the stabilization of the single-stranded DNA require transcription 
factor IIH (TFIIH), a complex containing XPB, p62, p52, p44, p34, p8, XPD in 
addition to the Cdk-activating-kinase (CAK) complex and XPG. Unwinding of 
the DNA mainly relies on the ATPase activity of XPB to form a 27-nucleotide 
bubble that asymmetrically flank the damage. Then damaged DNA is stabilized 
for incision by Replication Protein A (RPA) acting in complex with XPA, XPB 
and XPD. RPA activates XPG and excision repair cross-complementing rodent 
repair deficiency, complementation group 1 (ERCC1)-XPF, structure-specific 
endonucleases that cleave the 30 and 50 side of the 24–32-nucleotide fragment 
containing the damaged DNA. The single-strand gap is then filled by the 
replicative DNA polymerases δ and ε or the translesion DNA polymerase κ; 
Fig 5 
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their polymerase activity is stimulated and coordinated by Proliferating Cell 
Nuclear Antigen (PCNA) loaded onto the DNA by Replication Factors C 
(RFC) and A. The nascent DNA fragment is finally sealed by DNA ligase III-
XRCC1 and DNA ligase I [Figure 6] (Kamileri et al. 2012). 
 
Figure 6: The two subpathways of mammalian nucleotide excision repair (NER). 
In global genome nucleotide excision repair (GG-NER) helix-distorting DNA damage 
anywhere in the genome is recognized by the XPC–HR23B–CEN2 complex. The DDB 
complex, consisting of the two subunits DDB1 and DDB2 (XPE), can facilitate recognition of 
lesions that by themselves cause little distortion of the helix. In transcription-coupled 
nucleotide excision repair (TC-NER) recognition is by the stalling of RNA pol II at DNA 
lesions on the transcribed strand of active genes, facilitated by CSB, CSA and XAB2. Either 
XPC in GG-NER or CSB and CSA in TC-NER recruit TFIIH to the repair site followed by 
converging of the subpathways. The XPB and XPD subunits of TFIIH are DNA helicases that 
unwind the DNA in the immediate vicinity of the lesion. RPA and XPA bind to keep the DNA 
strands apart. For the dual incision, XPA recruits the XPF–ERCC1 endonuclease to incise the 
damaged DNA strand 5′ to the lesion while XPG incises 3′ to it. The lesion is thus excised in 
an oligonucleotide fragment leaving behind a single-strand gap. Repair synthesis is performed 
by DNA polymerase δ and κ, or ɛ (Pol δ/κ/ɛ) with the help of the accessory proteins RFC, 
PCNA and RPA. The remaining nick in the DNA backbone is sealed with ligation by either 
LIG1 or LIG3α–XRCC1. 
GGR and TCR differ only in how helix-distorting DNA lesions are 
recognized. Following damage detection, the two sub-pathways merge into a 
Fig 6
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common mechanism to unwind the DNA around the lesion, to stabilize and 
excise the DNA fragment containing the damage, and to fill in and ligate the 
single strand gap. TCR damage recognition requires RNA polymerase II 
(RNAPII). Stalled RNAPII colocalizes with Cockayne syndrome B (CSB), a 
DNA-dependent ATPase and CSA, a protein that is part of an E3-ubiquitin 
ligase complex. In particular, CSB binds stalled RNAPII and triggers the 
assembly of the remaining NER factors and histone acetyltransferase p300. In 
turn, CSA recruits (together with CSB) the High Mobility Group Nucleosome 
binding domain 1 protein (HMGN1), XPA binding protein 2 (XAB2) and 
TFIIS. Once chromatin is accessible for TCR, the lesion is removed by the core 
NER reaction (Kamileri et al. 2012). 
Single strand breaks repair: DNA mismatch repair 
DNA mismatch repair (MMR) is an evolutionarily conserved process that 
corrects mismatches generated during DNA replication and escape 
proofreading. Repair is initiated when complexes of MutS homologs, either 
MSH2-MSH6 (MutSα) or MSH2-MSH3 (MutSβ), bind to a mismatch. The 
MutSα is involved primarily in the repair of base substitutions and small 
mismatched loops, whereas MutSβ repairs both small loops as well as large 
loop mismatches (∼10 nucleotide loops). MutS heterodimer initially binds 
double-stranded DNA at the site of a mismatch and then recruits MutL. The 
MutL heterodimer is present in a number of forms, including the MutLα 
complex (composed by MLH1 and PMS2), the MutLβ heterodimer (MLH1 
and PMS1), and MutLγ (MLH1 and MLH3). The primary MutL activity for 
mismatch correction is MutLα, with MutLβ apparently providing a minor role, 
whereas MutLγ plays a role in meiosis (Kunkel and Erie 2005). 
As the function of postreplicative MMR is to reverse errors of replication 
(i.e., replication errors that are found in newly synthesized DNA), the MMR 
machinery must be able to distinguish parental DNA from daughter DNA and 
then remove and replace the (presumably aberrant) daughter DNA sequence. It 
is thought that intermittent gaps in DNA in between Okazaki fragments on 
lagging strand DNA could represent a signal that distinguishes parental from 
daughter strand in mammalian MMR. However, the discriminatory signal on 
leading-strand DNA in mammalian cells is still unclear (Martin et al. 2010). 
The DNA exonuclease EXO1, guided by the MutS/MutL, starts removing 
daughter-strand DNA towards and then beyond the site of the mismatch. Once 
the mismatch is removed, the activity of EXO1 is suppressed by MutL, thus 
terminating DNA excision. At the completion of this process, a DNA 
polymerase synthesizes DNA in place of the excised sequence. Finally a DNA 
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ligase joins any remaining gaps in the DNA sequence [Figure 7] (Martin et al. 
2010). 
 
Figure 7: model for mammalian DNA mismatch repair (MMR). 
a) The MSH2–MSH6 (MutSα) complex recognizes base–base mismatches and 1-bp 
insertion/deletion loops (IDLs), and the MSH2–MSH3 (MutSβ) complex recognizes 1-bp IDLs 
as well as 2–4-bp IDLs. b) and c) The interaction of MLH1–PMS2 (MutLα) activates 
downstream repair events that facilitate the excision of the DNA strand carrying the mutant 
base as well as its resynthesis and ligation. Several proteins have been identified by virtue of 
their interaction with either MSH2 or MLH1. EXO1, is a 5′→3′ exonuclease that was shown to 
bind to MSH2, MSH3 and MLH. Another protein known to be capable of interacting with 
MSH3, MSH6 and MLH1 is the proliferating cellular nuclear antigen (PCNA). The role of 
EXO1 and PCNA in these processes is indicated. 
Single strand breaks repair: base excision repair 
About 10 000 spontaneous SSBs occur in each cell every day (Lindahl 1993). 
The BER pathway is the main repair mechanism of these lesions; moreover it 
is involved in correcting base lesions that arise from oxidative, alkylation, 
deamination, and depurination/depyrimidination damage. BER facilitates the 
repair of damaged DNA via two general pathways: short-patch and long-patch. 
The short-patch BER pathway leads to a repair tract of a single nucleotide, 
whereas the long-patch BER pathway produces a repair tract of at least two 
nucleotides. 
A currently accepted model for the core BER pathway reveals five distinct 
enzymatic steps for the repair of damaged bases. The first step in BER is the 
recognition of a damaged base by a DNA glycosylase. After recognition the 
Fig 7 
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glycosylase catalyzes the cleavage of an N-glycosidic bond, effectively 
removing the damaged base and creating an apurinic or apyrmidinic site (AP 
site). However the DNA backbone is cleaved by either a DNA AP 
Endonuclease (APE 1) or a DNA AP lyase, an activity present in some 
glycosylases. The newly created nick is processed by APE1, creating a single-
nucleotide gap in the DNA (Robertson et al. 2009).  
In short-patch BER, XRCC1 is one of the first proteins recruited to the nick 
generated by the action of a glycosylase and/or AP endonuclease and function 
as scaffold interacting with DNA polymerase beta (Polβ). Polβ fills in the gap 
with the correct nucleotide; then a DNA ligase III completes the repair process 
and restores the integrity of the helix by sealing the nick [Figure 8] (Robertson 
et al. 2009). 
In long-patch BER, APEX1 catalyzes the formation of a nick 5’ to the AP 
site. This action recruits Polβ or DNA polymerase delta (Polδ), PCNA, Flap 
structure-specific ENdonuclease 1 (FEN1), and probably the replicative DNA 
ligase I. In particular a PCNA-dependent manner Polβ displaces and 
polymerizes tracts of DNA longer than one base. The strand displacement 
activity of Polβ produces a flapped substrate that is refractory to ligation. FEN1 
is involved in the removal of the flap generated by Polβ [Figure 8] (Robertson 
et al. 2009).  
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Figure 8: Short- and long-patch base-excision repair pathways. 
Short-patch repair, occurring after excision of a damaged base (indirect breaks), involves 
recruitment of poly(ADP-ribose) polymerase 1 (PARP1), or PARP2, which then recruits the 
scaffold protein XRCC1 and DNA polymerase β (Polβ) to replace the damaged nucleotide. 
Finally, DNA ligase III (Lig3) is recruited to ligate the nick, and intact DNA is restored. Long-
patch repair, occurring after direct DNA breaks (for example, after ionizing radiation damage), 
involves recruitment of PARP1 followed by XRCC1, which then recruits polynucleotide 
kinase (PNK) to convert the damaged ends to 5'-phosphate and 3'-hydroxyl moieties. 
Proliferating cell nuclear antigen (PCNA) and DNA polymerase δ/ε (Polδ/ε ) extend and fill 
the gap by 2–15 nucleotides, and flap endonuclease 1 (FEN1) cleaves the resulting flap. The 
nick is subsequently ligated by DNA ligase I (Lig1). 
The switch from short-patch to long-patch BER depends on the relative ATP 
concentration near the AP site, which is apparently modulated by DNA ligase 
III and XRCC1 (Petermann et al. 2003). It was shown that long-patch BER 
occurred more frequently at low ATP concentrations, whereas short-patch BER 
appeared to be the preferred mechanism with elevated concentrations of ATP. 
During BER pathway, Poly(ADP-Ribose) Polymerase 1 and 2 (PARP-1 and 
PARP-2) have a crucial role, indeed they interact with BER factors such as 
XRCC1, DNA polymerase β and DNA ligase III recruiting them at damaged 
sites (Schreiber et al. 2002, El-Khamisy et al. 2003). Moreover, recently, 
Khodyreva et al. (2010) have demonstrated a new role for PARP-1 in the 
Fig 8
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regulation of the BER process through its interaction at the AP site. PARP-1 
interaction at the AP site could protect the site until APE1 becomes available to 
initiate strands incision and BER (Khodyreva et al. 2010). 
1.5   ADENOVIRUSES AND DNA DAMAGE RESPONSE 
Within first few hours of adenovirus infection, the host cell responds to the 
virus, perhaps in recognition of viral DNA or cellular stress, by activating a 
classical damage response. Indeed it is likely that double-stranded DNA 
termini of the adenovirus genome could be perceived by the host cell as a 
double strand break. 
In the case of adenovirus harboring deletion of the open reading frame (ORF) 
within the E4 region, a much more pronounced cellular response can be 
observed, with increased phosphorylation of DDR substrates and concatenation 
of viral DNA (Weiden and Ginsberg 1994, Stracker et al. 2002). Importantly, 
after infection with wild-type (WT) group A and group C viruses, a number of 
cellular proteins such as p53, MRE11, DNA ligase IV and BLM are degraded 
(Querido et al. 1997, Stracker et al. 2002, Baker et al. 2007a, Carson et al. 
2009) ensuring that the HR and NHEJ pathways are incapacitated. Substrates 
amongst the DDR proteins vary with different adenovirus serotypes. Thus p53, 
BLM and MRE11 are not degraded by the group B and group D viruses 
(Forrester et al. 2011) and TOPBP1 appears to be degraded by only the group 
A viruses (Blackford et al. 2010, Forrester et al. 2011). 
It is possible that adenoviruses can inhibit the DDR independently of protein 
degradation. Ad5E4orf6 and Ad5E4orf3 have been shown to bind directly to 
DNA-PK, although they did not appear to inhibit its kinase activity against 
heterologous substrates (Boyer et al. 1999). However, autophosphorylation of 
DNA-PKcs (at Threonine 2609) was reduced during DSB repair (Hart et al. 
2005). Ad5E4orf6 also enhances the DDR by inhibiting protein phosphatase 
2A (PP2A), which leads to prolonged phosphorylation of H2AX, activation of 
PARP and apoptosis (Hart et al. 2007). 
Although adenoviruses inhibit the DDR by promoting the rapid degradation 
of key components, they are also able to affect the localization of various DDR 
proteins. During infection, a number of DDR proteins are recruited to viral 
replication centers (VRCs) (Turnell and Grand 2012). RPA32 is recruited to 
these sites after infection with both WT and mutant viruses (Stracker et al. 
2005). Other DDR proteins recruited to VRCs after WT infection include ATR, 
ATRIP, Rad9, TOPBP1, Rad17 and hnRNPUL1 (Carson et al. 2003, Blackford 
et al. 2008, Carson et al. 2009). As well as initiating protein degradation and 
localization to VRCs, adenoviruses can also promote relocalization to other 
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sites. Promielocytic leukaemia (PML) bodies play a role in sensing DNA 
damage, and a number of DDR proteins localize to them (Lombard and 
Guarente 2000). Following Ad infection, PML bodies are disrupted and the 
PML protein is relocalized into ‘track-like’ structures; this is dependent on the 
activity of the AdE4orf3 protein  [Figure 9] (Carvalho et al. 1995, Doucas et al. 
1996, Leppard and Everett 1999). 
 
Figure 9: Regulation of ATM and ATR signalling pathways by adenovirus.  
E1B55K–E4orf6 complexes recruit cellular ubiquitin ligases to promote the degradation of 
p53, BLM and MRE11, whilst Ad12 E4orf6 recruits an E3 ligase to promote TOPBP1 
degradation and E1B55K recruits an E3 ligase to promote the degradation of DAXX. Ad5 
E4orf3 sequesters MRN to aggresomes to inhibit the MRN-dependent activation of ATR, and 
inhibits p53 epigenetically. Components of the ATM and ATR pathways are recruited to VRCs 
or PML-containing nuclear tracks and aggresomes during infection. MRE11 and p53 are 
regulated differentially by different Ad types (shown in parentheses). E1B-55K also associates 
with TIF1b, hnRNPUL1 and the RPA complex, although the significance of these observations 
awaits clarification. Viral proteins are shown in red; cellular proteins are shown in blue. 
Broken arrows show cellular proteins that are recruited to PMLtracks, aggresomes or VRCs. 
Viral inactivation of cellular proteins is depicted by ‘T’. Arrows linking viral proteins to 
cellular proteins indicate protein–protein interactions whose significance has yet to be fully 
established. 
It has been suggested that, during Ad5 infection, the MRN complex is 
initially localized to ‘nuclear tracks’ by Ad5E4orf3, where it binds to the 
E1B55K protein. Protein complexes containing Ad5E1B55K, Ad5E4orf3, 
Ad5E4orf6 and MRN are then transported to the aggresomes, where MRE11 
undergoes rapid degradation (Evans and Hearing 2005, Liu et al. 2005).  
Fig 9 
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It is clear that different virus species adopt very different strategies to 
modulate the damage response. In the case of adenoviruses, degradation of 
cellular DDR components is a priority and, presumably, this has the effect of 
disabling the cellular response. 
Understanding the relationship between the DNA damage response 
machinery and adenovirus infections will provide insights into viral pathology 
and persistence, but it may also guide the effective design of new oncolytic 
adenoviral mutant for cancer therapy, or may suggest new molecular targets to 
potentiate the cytotoxicity of already existing oncolytic adenoviral mutants. 
1.6   POLY(ADP-RIBOSE) POLYMERASE (PARP) 
Poly(ADP-ribosyl)ation is a ubiquitous protein modification involved in the 
regulation of transcription, cell proliferation, differentiation, DNA methylation 
and apoptosis which modulates protein function by regulating either enzymatic 
activities or macromolecular interactions between proteins, DNA or RNA 
(Hakme et al. 2008). This modification is carried out by the Poly(ADP-Ribose) 
Polymerases (PARPs), also known as ADP-ribosyltransferases (ADPRTs) or 
poly(ADP-ribose) synthetases.  
PARP members are a family of highly conserved enzymes found in plants 
and animals, first described more than 40 years ago (Chambon et al. 1963). 
PARP-1 was the first of this enzyme family to be described. Afterwards, based 
on sequence similarity with PARP-1 catalytic domain, 16 structurally-related 
proteins have been identified (Ame et al. 2004). In addition to the catalytic 
domain, these proteins typically contain one or more additional motifs or 
domains, including zinc fingers, ‘‘BRCA1 C-Terminus-like’’ (BRCT) motifs, 
ankyrin repeats, macro domains and WWE domains (involved in DNA or RNA 
binding, protein–protein interaction or cell signaling), conferring unique 
properties on each PARP protein (Ame et al. 2004).  
Among PARP members only six of these protein may actually be considered 
poly(ADP-ribose) polymerases, whereas the reminder are probably mono-
ADP-ribosyltransferases. These six “true” PARP are subdivided in three 
groups, with PARP-1, PARP-2 and PARP-3 in the first group, PARP-4 (also 
known as vault PARP) in the second, and tankyrase 1 (TNKS1) and TNKS2 in 
the third (Rouleau et al. 2010). 
PARP-1 and PARP-2 are the only ones reported until now to be highly 
stimulated by DNA damage; however PARP-2 is thought to be responsible for 
no more than 15% of the total poly(ADP-ribose) (PAR) synthesis stimulated by 
DNA strand breaks (Shieh et al. 1998).  
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PARP-1 is a 116-kDa protein comprising an N-terminal DNA-binding 
domain, which contain three zinc-binding domain, a central automodification 
domain, which contain several glutamate, aspartate, and lysine residues as 
putative acceptors for auto(ADP-ribosyl)ation, a leucine zipper motif that 
mediates  homodimerization or heterodimerization, a BRCT phosphopetide-
binding motif and a C-terminal catalytic domain that contains three crucial 
residues (an histidine and a tyrosine that are important for NAD+ binding and a 
glutamic acid that is essential for polymerase activity) [Figure 10] (Rouleau et 
al. 2010). 
 
Figure 10: Structural and functional organizations of PARP-1 
a) PARP-1 has a highly conserved structural and functional organization including an N-
terminal DNA-binding domain with two Cys-Cys-His-Cys zinc finger motifs (FI and FII), a 
nuclear localization signal (NLS), a central automodification domain containing a BRCT 
protein-protein interaction motif, and a C-terminal catalytic domain with a contiguous 50-
amino-acid sequence, the “PARP signature” motif, that forms the active site; b and c) PARP-1 
three-dimensional representation. 
Once activated, PARP-1 rapidly catalyzes the transfer of ADP-ribose 
moieties from NAD+ to the acceptor protein, including histones, DNA repair 
proteins, transcription factors and chromatin modulators, resulting in the 
attachment of linear or branched polymers of ADP-ribose. PARP-1 itself is the 
primary target for poly(ADP-ribos)ylation in vivo, with more than 90% of PAR 
being found on PARP-1 (D'Amours et al. 1999). The modifications are 
heterogeneous with respect to length (from a few to 200 ADP-ribose units) and 
Fig 10 
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extent of branching (one branch per 20–50 ADP-ribose units). Poly(ADP-
ribosyl)ation is a dynamic process consuming substantial amounts of NAD+. 
The in vivo half-life of the polymer is less than 1 min with the steady-state 
levels of PAR being regulated by the catalytic reactions of poly(ADP-ribose) 
glycohydrolase (PARG) and possibly the ADP-ribose hydrolase (ARH3). The 
degradation of PAR may begin immediately after the initiation of PAR 
synthesis and can be completed within minutes after the cessation of PAR 
synthesis has occurred (D'Amours et al. 1999). This generates large amounts of 
AMP that in turn activates the bioenergetics sensor AMP-activated protein 
kinase (AMPK). Free or protein-bound PAR polymers work as signal 
transducers by binding other proteins through their conserved PAR recognition 
modules, including PAR-binding motifs (PBMs), PAR-binding zinc finger 
(PBZF) domains, and macrodomains (Kraus 2009). PAR, which is a negatively 
charged polymer, alters the biochemical properties of modified or interacting 
proteins, modulating their structure, function, and localization (Schreiber et al. 
2006).  
As discussed above PARP-1 is a molecular sensor of DNA strand breaks and 
through its ribosylating activity plays a key role in the spatial and temporal 
organization of their repair. Through its own poly(ADP-ribosyl)ation and that 
of histones, PARP-1 loosens the chromatin allowing access to DNA strand 
breaks and is also involved in the recruitment of the components of the 
BER/SSBR pathways (El-Khamisy et al. 2003). The automodification of 
PARP-1 itself promotes its interaction with XRCC1 through its BRCT domain. 
This leads to the recruitment of DNA polymerase β and DNA ligase III thus 
completing the repair of the single-strand break. PARP-1 has also been shown 
to be involved in FEN-1-dependent strand displacement during DNA synthesis 
by DNA polymerase β (Prasad et al. 2001). In addition to its role in BER, 
PARP-1 is involved in several other DNA damage repair processes, including 
the repair of DNA DSBs. For instance, the recruitment of MRE11, NBS1, and 
ATM to DSBs has been reported to depend on PARP-1 activity and PARP-1 is 
a component of an alternative pathway of NHEJ. When essential components 
of the classical pathway of NHEJ are absent, PARP-1 is recruited for DSB 
repair with the ligase III and probably with histone H1. The presence of 
poly(ADP-ribose) chains at the site of DNA damage also acts as an anti-
recombinogenic factor, preventing the inappropriate recombination of 
homologous DNA (Megnin-Chanet et al. 2010). It has been shown that PARP-
1 function also as a transcriptional activator of NF-kB, the transcription factor 
that regulates immune and inflammatory response genes (Hassa and Hottiger 
2002). 
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PARP inhibitors 
Despite the important role of the PARP-1 in DNA damage repair, PARP-1 
deficiency does not seem to be such a problem for nonmalignant cells. As a 
matter of fact, mice engineered to lack PARP-1 enzyme (PARP-1-/-) are both 
viable and fertile (de Murcia et al. 1997, D'Amours et al. 1999). These PARP-
1-/- mice do not seem to develop early onset tumors (Conde et al. 2001). 
However the simultaneous absence in other genes involved in HR pathway 
(such as BRCA1 and BRCA2) confers sensitivity to PARP deficiency or 
inhibition (McCabe et al. 2006). The acquired sensitivity could be explained by 
the concept of synthetic lethality, first described in 1946 by Dobzhansky 
(Dobzhansky 1946), that is a situation when a mutation in one of two genes 
individually has no effect but combining the mutations leads to cell death. 
Indeed cells exposed to a PARP inhibitor are flooded with SSBs that are 
converted into DSBs at replication forks. Normally the repair of DSBs is able 
mainly through HR activity. The HR-deficiency unable to utilize the HR 
pathway. Instead, DSBs are repaired via NHEJ or the SSA sub-pathway of HR 
with large numbers of chromatid aberrations leading to cell lethality. 
These findings raise the possibility that PARP inhibitors may play a role in a 
broad range of tumors with dysfunction of HR or identified as “BRCAness”. 
The use of a PARP inhibitor in a BRCA-deficient cancer is probably the first 
example of the clinical application of the concept of synthetic lethality (Farmer 
et al. 2005). 
Most of the PARP inhibitors in development mimic the nicotinamide moiety 
of NAD+ (Jagtap and Szabo 2005, Peralta-Leal et al. 2009). These molecules 
block the binding of the NAD+ to the enzyme, inhibiting PARP activity. First-
generation inhibitors were developed 30 years ago: nicotinamide, benzamide, 
and substituted benzamide, in particular 3-aminobenzamide (3-AB), were 
shown to be competitive inhibitors of PARP. Benzamides lack specificity and 
potency; moreover they affect cell viability, glucose metabolism and DNA 
synthesis (Milam and Cleaver 1984). A second generation of very potent PARP 
inhibitors was developed in 1990s, producing 170 specific inhibitors. All these 
inhibitors may be classified as analogs of benzamide. A third generation of 
inhibitors, benzamidazoles, not only had potency, but also allowed the 
elucidation of the PARP inhibitor structure-activity relationship. Some of 3rd 
generation agents have entered clinical trials, including AZD2281 
(KuDos/Astra Zeneca) (also known as Olaparib or KU-0059436), AG014699 
(Pfizer), INO-1001 (Inotek/Genentech), ABT-888 (Abbott) and BSI-201 
(BiPar/Sanofi-Aventis). However PARP inhibitors under clinical investigation 
do not discriminate between PARP-1 and 2. 
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Based on the demonstration of the role of BRCA selectivity, it has been 
proposed the use of PARP inhibitors for cancer therapy after selecting for 
BRCA mutations or BRCAness either as single agents or in combination with 
chemotherapy. In this regard, recently, the effect of AZD2281 was 
demonstrated in BRCA2-/- mammary tumors arising spontaneously in a mouse 
model, which is a relevant preclinical model with important advantages over 
the xenograft models (Hay et al. 2009). 
In addition, the synergy of AZD2281 in combination with platinum drugs has 
been demonstrated in vivo with both BRCA1-/- p53-/- mammary tumors 
transplanted into wild-type mice (Rottenberg et al. 2008). Moreover, in vitro 
there is a synergy between AZD2281 and cisplatin in BRCA2-deficient cell 
lines (Evers et al. 2008).  
Before a role for PARP inhibitors was suspected in BRCA-deficient tumors, 
these molecules were developed as chemosensitisers. Experimental data have 
shown a synergistic effect between PARP inhibitors and specific cytotoxic 
agents (Huang et al. 2008, Daniel et al. 2009). Furthermore, several in vitro 
(Calabrese et al. 2004, Dungey et al. 2008) and in vivo (Calabrese et al. 2004, 
Russo et al. 2009) models demonstrate that PARP inhibitors are synergistic 
with radiotherapy. This synergistic effect is supported by the idea that 
radiotherapy damages cells by causing DNA breaks, and PARP inhibitors 
disrupt DNA repair mechanisms leading to cell death.  
It is worth to note that a number of clinical studies have been initiated in 
glioma using PARP inhibitors in combination with temozolomide. This was 
supported by knowledge that DNA repair mechanisms may play an important 
role in the response of glioblastoma to temozolomide. Indeed translational 
studies suggest that epigenetic silencing of the MGMT DNA repair enzyme by 
methylation of its promoter inhibits DNA repair and may lead to enhanced 
response to alkylating agents such as temozolomide and to longer survival in 
patients with glioblastoma, whereas glioblastomas with MGMT intact are 
resistant to alkylating agents (Esteller et al. 2000, Hegi et al. 2005).  
The most important clinical trials with PARP inhibitors have been 
summarized in table 2. 
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Table 2. PARP inhibitor in clinical trials 
 
A search was carried out on http://www.clinicaltrials.gov 
AGENT PHASE TUMOR COMBINATION TRIAL IDENTIFIER
Olaparib, 
AZD2281, 
KU0059436 
(Astra 
Zeneca/KuD
OS Pharm)
II
BRCA-mutated ovarian 
cancer or recurrent high-grade 
ovarian cancer or triple-
negative breast cancer/failed 
standard chemotherapy
NCT00679783
II
Platinum-sensitive ovarian 
cancer NCT00753545
II BRCA-mutated breast cancer NCT00494234
II Ovarian cancer NCT00494442
II
BRCA-positive ovarian 
cancer NCT00628251
II Metastatic colorectal cancer NCT00912743
I
Triple-negative breast 
cancer/neoadjuvante Cisplatin NCT007822574
I
Metastatic triple-negative 
breast cancer Paclitaxel NCT00707707
I Metastatic solid tumors
Carboplatin or paclitaxel or 
carboplatin/paclitaxel NCT00516724
I Pancreas cancer Gemcitabine NCT00515866
I Solid tumors Topotecan NCT00516438
I Colorectal cancer Irinitecan NCT00535353
I Melanoma Decarbazine NCT00516802
I Solid tumors Bevacizumab NCT00710268
II Gastric cancer Paclitaxel NCT01063517
Iniparib,  
BSI-201 
(BiPar 
Sciences/San
ofi-Aventis)
II
BRCA1- or BRCA2-
associated primary peritoneal 
cancers, advanced epithelial 
ovarian cancer
NCT00677079
III Triple-negative breast cancer Gemcitabine/carboplatin NCT00938652
I/II Glioma Temozolomide NCT00687765
Ib/II Metastatic breast cancer Irinotecan NCT00298675
II
Platinum-sensitive recurrent 
ovarian cancer Carboplatin/gemcitabine NCT01033123
AG014699, 
PF-01367338 
(Pfizer)
II
BRCA-mutated breast or 
ovarian cancer NCT00664781
I
BRCA-mutated, hereditary 
breast, ovarian cancer Carboplatin/paclitaxel NCT00535119
II Colorectal cancer Temozolomide NCT01051596
I Solid tumors and lymphoma Cyclophosphamide NCT00810966
I
Solid tumors with brain 
metastasis Whole-brain radiation NCT00649207
II Melanoma Decarbazine NCT00804908
I Lymphoma Irinotecan NCT00576654
II Metastatic breast cancer Temozolomide NCT01009788
I
Metastatic or unresectable 
solid tumors or non-Hodgkin 
lymphoma
Cyclophosphamide/Doxorubicin NCT00740805
MK-4827 
(Merck) I BRCA-mutated cancer NCT00749502
CEP-9722 
(Cephalon) I Advanced solid tumors Temozolomide NCT00920595
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Clinical trials to date have shown that PARP inhibitors in combination with 
chemotherapeutic agents have manageable side effects. However enhanced 
mutation frequency by blocking a DNA repair pathway remains a major 
concern. In addition, early evidence suggests that tumor cells can become 
resistant to PARP inhibition by developing mutations that restore HR. 
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2. AIMS OF THE STUDY 
Current therapies for the treatment of anaplastic thyroid carcinoma confer 
only a short term palliative and survival benefit. Overall, a comprehensive 
understanding of the molecular basis for the development of novel therapeutic 
approaches is still incomplete and urgently required.  
Accordingly, in the present study, the specific aims are as follows: 
 To exploit the potential of the inhibition of Poly(ADP-ribose) 
polymerases (PARP) as a strategy to improve the efficacy of the 
oncolytic adenovirus dl922-947 against ATC cells  
 To investigate in detail study the cell death pathways activated by 
dl922-947, in order to identify novel therapeutic targets, which can be  
assessed for their “druggability”. 
In addition, I have been involved in several projects aimed to identify new 
combinatorial therapy (dl922-947 plus rational chosen drug) for the treatment 
of aggressive tumors such as Anaplastic Thyroid Carcinoma and Glioblastoma 
Multiforme. The resulting publications are attached at the end of the 
dissertation. 
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3. MATERIALS AND METHODS 
CELLS, ADENOVIRUSES AND DRUGS 
Human thyroid anaplastic carcinoma cell lines BHT101-5 and FRO have 
been described and authenticated as shown elsewhere (Schweppe et al. 2008). 
dl922-947 and AdGFP viral stocks were expanded in the human embryonic 
kidney cell line HEK-293, purified and stored as previously reported (Libertini 
et al. 2007). Viral stocks were expanded, purified, stored and quantified as 
previously reported (Botta et al. 2012). Both cell lines were cultured in DMEM 
medium, supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin and incubated in standard culture conditions (95% air 
and 5% CO2 at 37 °C). All cell culture reagents were purchased from 
Invitrogen Gibco, unless otherwise stated. 
For in vitro experiments AZD2281 (Selleck) was dissolved in DMSO to a 
final concentration of 10 mM and stored at -20°C. For in vivo study AZD2281 
was solubilized in DMSO and diluted to 5 mg/mL with PBS containing 10% 2-
hydroxy-propyl-betacyclodextrin (Sigma).  
zVAD-fmk (Tocris bioscence) was dissolved in DMSO to a final 
concentration of 10 mM and stored at -20°C. 
BrdU (Sigma) was dissolved in PBS to a final concentration of 10 mM and 
stored at -20°C. 
Digitonin (Sigma) was dissolved in absolute ethanol to a final concentration 
of 2 mg/mL and stored at -20°C. 
FLUORESCENCE-ACTIVATED CELL SORTING ANALYSIS 
For all FACS experiments FRO and BHT101-5 cells were seeded in 100 mm 
cell culture dish at densities of 4x105 cells/dish and treated as indicated. 
BrdU staining: FRO and BHT101-5 cells were infected with dl922-947 for 
24h. Thirty minutes before harvesting cells were labeled with 10 µM BrdU 
(Sigma). Cells were fixed over-night in ice-cold 70% ethanol (in PBS) at -
20°C. Then cells were washed once with PBS and incubated with 2N HCl to 
denature DNA for 15 minutes at room temperature. Cells were washed with 
PBT (0.5% BSA, 0.1% Tween20 in PBS) and resuspended in PBT containing 
anti-BrdU antibody (Dako, M0744, 1:40). After 30 minutes cells were washed 
twice with PBT, and then resuspended in PBT containing Alexa488 anti-mouse 
(Invitrogen #A11001, 1:100) at dark for 30’. Cells were washed twice with 
PBS, resuspended in PI 0.015 M in PBS for 20’ and analyzed for the emission 
in FL1 and FL3 channels. To remove artifacts—doublets and aggregates—
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from the analysis, an electronic doublet discrimination was performed using 
the area and width of the fluorescence (FL3) pulse. 
γH2AX/PI staining: FRO and BHT101-5 cells were detached and fixed over-
night in ice-cold 70% ethanol at -20°C. Pellet was washed with PBT (0.5% 
BSA, 0.1% Tween20 in PBS) and resuspended in PBT containing anti-γH2AX 
antibody (Millipore #05-636, 1:100). After 1 h incubation at room temperature, 
samples were washed in PBT and then resuspended in PBT containing 
Alexa488 anti-mouse (Invitrogen #A11001, 1:100) at dark. After further 30 
minutes, cells were washed with PBT, resuspended in PI 0.015 M in PBS for 
20’ and analyzed for the emission in FL1 and FL3 channels. To remove 
artifacts—doublets and aggregates—from the analysis, an electronic doublet 
discrimination was performed using the area and width of the fluorescence 
(FL3) pulse.  
AdGFP infection: FRO and BHT101-5 cells were infected with AdGFP (25 
pfu/cell) and harvested 48 hours later. Pellet was resuspended in PBS and 
emission in the FL1 channel analyzed.  
Cell cycle: attached and detached FRO and BHT101-5 cells were collected 
and fixed over-night in ice-cold 70% ethanol at -20°C. Washed pellets were 
resuspended in PBS containing RNaseA 0.4 U (Roche) and propidium iodide 
0.015 M in PBS (Sigma), incubated for 20’ at room temperature, and analyzed 
for emission in the FL3 channel. To remove artifacts—doublets and 
aggregates—from the analysis, an electronic doublet discrimination was 
performed using the area and width of the fluorescence (FL3) pulse. 
Annexin V/PI staining: attached and detached FRO and BHT101-5 cells 
were collected and washed with Annexin V binding buffer (Biolegend). Pellet 
was resuspended in Annexin V binding buffer containing FITC-conjugated 
Annexin V (Biolegend #640906, 1:40). After 15’ incubation at room 
temperature, 250l of propidium iodide solution 0.0015 M in PBS was added 
to each sample just before analysis.  
Cytochrome C release from mitochondria: attached and detached FRO and 
BHT101-5 cells were harvested and treated with digitonin (50µg/mL in PBS 
containing 150mM KCl and 1 mM EDTA) for 10’ on ice. The selective 
permeabilization of the plasma membrane with digitonin allows virtually all of 
the cytoplasmic cytochrome C to diffuse out of the cell. Permeabilized cells 
were fixed in paraformaldehyde (4% in PBS) for 20 minutes on ice, washed 
three times in PBS and incubated in blocking buffer (0.5% saponin, 1% BSA in 
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PBS) for 20’ at room temperature. Cells were then incubated for 2h at room 
temperature with anti-Cytochrome C antibody (BD Pharmigen, #556432, 
1:200) in blocking buffer, washed three times and incubated for 30’ at room 
temperature with Alexa488 anti-mouse (Invitrogen #A11001, 1:100) in 
blocking buffer at dark. Stained cells were washed twice with PBS, 
resuspended in PBS and analyzed by flow cytometry detecting Alexa488 
fluorescencein FL-1 channel. 
All samples were acquired by a BD LSRFortessa (BD Biosciences, San Jose, 
CA, USA) and analyzed using BD FACSDiva Software. 
PROTEIN EXTRACTION AND WESTERN BLOT ANALYSIS 
After the indicated treatments, attached and detached cells were harvested 
and lysates prepared as already described (Botta et al. 2012). 50 µg of lysate 
proteins were probed with the following antibodies: caspase 3 (Abcam 
#Ab13585, 1:500), p-ATM s1981 (Cell Signaling, #4526, 1:1000), p-chk1 s345 
(Cell Signaling, #2348, 1:1000), chk1 (Cell Signaling, #2345, 1:1000),  
MRE11 (SantaCruz, #sc-5859, 1:1000), NBS1 (Novus Biologicals, NB100-
143, 1:1000), p-H2AX s139 (Millipore, #05-636, 1:1000), H2AX (Cell 
Signaling, #2095, 1:1000), PAR (Trevigen, #4336-BPC-100, 1:1000), PARP 
(Cell Signaling, #9542, 1:1000), ROCK1 (BD Biosciences, #611137, 1:1000), 
p-MLC2 thr18/ser19 (Cell Signaling, #3674, 1:1000), α-tubulin (SIGMA 
#T9026, 1:5000). 
VIRAL REPLICATION 
FRO and BHT101-5 cells were infected with dl922-947, media collected 48 
hpi (hours post infection) and viral DNA extracted using the High pure viral 
nucleic acid kit (Roche Diagnostics). Specific primers for the viral hexon gene 
(from 99 to 242 bp) were used to measure viral replication by Real-Time PCR: 
5’-GCC ACC GAG ACG TAC TTC AGC CTG-3’ (upstream primer) and 
5’TTG TAC GAG TAC GCG GTA TCC TCC GCG GTC-3’ (downstream 
primer). A standard curve was constructed by assaying serial dilutions of 
dl922-947. 
IMMUNOFLUORESCENCE STAINING 
To analyze p-chk1 (s345) and p-H2AX (s139) localization FRO cells were 
seeded on cover slips in 24-well dishes and infected with 5 pfu/cell of dl922-
947. After 24h cells were fixed with 4% paraformaldehyde for 15 min at room 
temperature, washed and permeabilized with 0.1% Triton X-100 in PBS. Cells 
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were then blocked with bovine serum albumin (BSA) blotting buffer (0.5% 
BSA in PBS) for 30 min and then incubated with BSA blotting buffer plus 
primary antibody overnight at 4°C (p-H2AX s139, Millipore #05-636, 1:250; 
p-chk1 s345, Abcam Ab47318, 1:200). After washing three times with 0.1% 
Triton X-100 in PBS, cells were incubated with Alexa-488 anti-mouse and 
Alexa-594 anti-rabbit (Invitrogen #A11001 and #A11012 respectively, 1:100). 
Fixed and stained cells were mounted using Vectashield-mounting medium 
with DAPI (Vector Laboratories, H-1200). Images were acquired with a Nikon 
A1R confocal microscope (Nikon), using a 60x oil objective and processed 
with NIS element software (Nikon). 
To analyze nuclear morphology of infected cells, FRO cells were grown on 
cover slips in 24-well dishes and infected with 5 pfu/cell of dl922-947 for 24h 
or incubated over night with 0.5 µM staurosporine (as positive control for 
apoptosis). After treatment cells were fixed with 4% paraformaldehyde for 15 
minutes at room temperature and then mounted using Vectashield-mounting 
medium with DAPI (Vector Laboratories, H-1200). Images were acquired with 
a Leica DMLB microscope and processed with Adobe Photoshope CS software 
(Adobe Systems Incorporated). 
VIABILITY ASSAY AND ANALYSIS OF THE COMBINED DRUG 
EFFECT 
FRO and BHT101-5 cells were seeded in 96-well plates at densities of 500 
cells/well and allowed to attach for 24h. Cells were exposed to graded 
concentrations (six replicates) of AZD2281 or dl922-947 either alone or in 
combination for 6 days. At the end of the treatment, cells were fixed with 50% 
TCA and stained with 0.4% sulforhodamine B in 1% acetic acid as already 
described (Vichai and Kirtikara 2006, Libertini et al. 2008). The percentages of 
surviving cells after treatment were calculated by assuming that the number of 
surviving untreated cells is 100%. The concentration of each agent or of the 
combined treatment required to kill 50% of cells (median lethal dose, LD50) 
was determined by a dose-response curve using GraphPad prism (GraphPad 
Software). 
Drug synergy was determined by the isobologram and combination-index 
methods as previously described (Tallarida 2001). Data obtained from the 
viability assays were used to perform these analyses. The isobologram method 
is a graphical representation of the pharmacologic interaction and is formed by 
selecting a desired fractional cell kill (LD50) and plotting the individual drug 
doses required to generate that LD50 on their respective x- and y-axes. A 
straight line is then drawn to connect the points. The observed dose 
42 
 
combination of the two agents that achieved that particular LD50 is then plotted 
on the isobologram. Combination data points that fall on the line represent an 
additive drug-drug interaction, whereas data points that fall below or above the 
line represent synergism or antagonism, respectively. The combination-index 
(CI) method is a mathematical and quantitative representation of a two-drug 
pharmacologic interaction. Using data from the growth inhibitory experiments 
and computerized software, CI values were generated. A CI of 1 indicates an 
additive effect between two agents, whereas a CI<1 or CI>1 indicates 
synergism or antagonism, respectively. 
GROWTH CURVE 
FRO and BHT101-5 cells were seeded in 12-well culture plates at density of 
1x104 cells/well and allowed to attach for 24h. Cells were then treated with 
zVAD-fmk and dl922–947 alone or in combination as indicated. After 24h, 
48h and 72h attached cells were harvested and a cell count performed using a 
Bürker chamber. 
TUMORIGENICITY ASSAY 
FRO cells in exponential phase were prepared at a concentration of 4x107 
cells/ml in DMEM medium. CD-I athymic mice were obtained from Charles 
River and all experiments were carried out with 6-week-old females. To initiate 
tumor xenografts, 0.2 ml of cell suspension was injected into the right flank of 
60 animals. Tumor diameters were measured with calipers and tumor volume 
(V) was calculated by the formula for a rotational ellipsoid: V=A·B2/2 (A, 
axial diameter; B, rotational diameter). Mice weights were monitored daily. 
Twenty days post-injection mice with similar tumor size were randomized 
into four groups (15 animals/group): untreated, treated with AZD2281, treated 
with dl922–947, or treated with both. AZD2281 (50 mg/kg) was administered 
intraperitoneally three consecutive day a week. A low viral dose (2x106 
pfu/cell) was administered two times a week (the day before and the day after 
AZD2281 administration) by intratumoral injection to avoid any first-pass 
effect (Libertini et al. 2007, Libertini et al. 2008, Libertini et al. 2011). 
AZD2281 vehicle was administered to the control groups. Statistical analysis 
were done by ANOVA (analysis of variance) and the Bonferroni post hoc test, 
using commercial software (Prism 4; GraphPad Software). Differences in the 
rate of tumor growth in mice were assessed for each time point of the 
observation period. 
Mice were maintained at the Dipartimento di Biologia e Patologia Cellulare e 
Molecolare Animal Facility. All animal experiments were conducted in 
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accordance with accepted standards of animal care and in accordance with the 
Italian regulations for the welfare of animals used in studies of experimental 
neoplasia. Study was approved by our institutional committee on animal care. 
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4. RESULTS 
dl922-947 increases the percentage of cells in S-phase 
To investigate the effect of dl922-947 on S-phase in ATC cells, I evaluated 
BrdU incorporation in two different ATC cell lines, FRO and BHT101-5, 24 
hours after infection (hpi). BrdU is an analogue of thymidine that is 
incorporated into the newly synthesized DNA of replicating cells (during the S 
phase of the cell cycle). 
 
Figure 11. Effects of dl922-947 infection on host cell S-phase entry. 
FRO (upper panel) and BHT 101-5 (lower panel) were infected with dl922-947 (5 or 1 pfu/cell, 
respectively) for 24h. Then, cells were pulse labelled with BrdU for 30 minutes. Once 
harvested, cells were stained with a primary antibody anti-BrdU, followed by incubation with a 
secondary antibody (anti-mouse-FITC conjugate) for determination of DNA synthesis, and 
with propidium iodide (PI) for determination of total DNA content. The dot plot represents 
BrdU incorporation (y-axis) vs DNA content, as determined by PI staining (x-axis). DNA 
synthesis (S-phase) was determined by quantifying cells positive for BrdU staining in the dot 
plots. Green numbers represent the percentage of BrdU-positive cells and the standard 
deviation of three independent experiments. 
As shown in figure 11, dl922-947 infection increased the percentage of cells 
in S-phase from ~50% to ~66% in FRO cells, and from ~44% to 58% in 
BHT101-5 cells. 
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dl922-947 induces the accumulation of DNA damage 
Induction of DNA damage has been previously reported in response to 
adenovirus infection (Prakash et al. 2012). Therefore, I tested the effect of the 
adenoviral mutant dl922-947 on DNA damage. To this aim,  I performed a 
Fluorescence-Activated Cell Sorting (FACS) analysis to assess the positivity of 
infected cells for γH2AX (namely, histone H2AX phosphorylated on serine 
139), which marks the spots where foci containing DNA repair enzymes will 
localize. 
 
Figure 12. Effects of dl922-947 infection on the accumulation of DNA damage 
FRO (upper panel) and BHT 101-5 (lower panel) were infected with dl922-947 (10 or 5 
pfu/cell, respectively). 24h later cells were incubated with a primary antibody and a secondary 
antibody anti-mouse-FITC conjugate to quantify the unrepaired DNA damage. To measure the 
total DNA content cells were then stained with propidium iodide (PI). The dot plot represents 
γH2AX positivity (y-axis) vs DNA content, as determined by PI staining (x-axis). The 
percentage of cells with an unrepaired DNA damage was determined by quantifying cells 
positive for γH2AX  staining in the dot plots. Numbers represent the percentage of γH2AX 
positive cells and the standard deviation of three independent experiments.  
A robust increase in the percentage of γH2AX positive cells was found in 
both FRO and BHT101-5 cells 24h after dl922-947 infection [Figure 12], 
suggestive of accumulation of an unrepaired DNA damage.  
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dl922-947 impairs Double Strand Breaks (DSBs) repair pathway 
γH2AX is the main marker of double strand breaks (DSB) (Rogakou et al. 
1998).  As dl922-947 replication lead to H2AX phosphorylation, I decided to 
deepen the analysis of DSB repair pathway, by monitoring the activation of 
some of its crucial mediators. To this aim, I assessed ATM and Chk1 
phosphorylation on serine 1981 and 345 respectively, indicative of their 
activation, and I analyzed the levels of NBS1 and Mre11, in FRO cells, at 
different time point from dl922-947 infection (1, 3, 6 and 24h) .  
 
Figure 13. Effects of dl922-947 infection on DNA damage response pathway 
FRO cells were infected with dl922-947 (5 pfu/cell) at indicated times. Expression of total and 
p- Chk1, total and p- H2AX, phosphorylated ATM, Mre11 and NBS1 were analyzed by 
western blot, using α-tubulin as a loading control. Results shown are representative of three 
independent experiments. 
As shown in figure 13, phosphorylation of both ATM and Chk1 is clearly 
induced 24h after the infection, suggestive of activation of DSB repair 
pathway. However, this effect is paralleled by the degradation of the proteins 
of the MRN complex NBS1 and Mre11, suggesting that dl922-947 may 
hamper the execution of DSB repair. 
To further confirm γH2AX accumulation and Chk1 activation, I performed 
an immunofluorescence experiment in FRO cells infected with dl922-947 for 
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24h [Figure 14]. 
 
Figure 14. Effects of dl922-947 infection on DNA damage response pathway 
FRO cells were infected with dl922-947 (5 pfu/cell) for 24h. p-Chk1 (red) and γH2AX (green) 
were assessed by immunofluorescence assay. Green and red fluorescence was analyzed by 
confocal microscope. Data shown are representative of three independent experiments. 
dl922-947 induces PARP activation 
It has been reported that an unscheduled DNA synthesis -such as the one 
induced by viral infection- can cause the accumulation of replication-
associated DNA lesions, namely single strand break (SSB) (Connell et al. 
2011). SSBs are repaired by the SSB repair machinery, which requires PARP 
(Poly-ADP Ribose Polymerase) activity. 
During DNA damage response, PARP is  mainly responsible for the addition 
of PAR (poly-ADP ribose) residues on the target proteins, including histones, 
DNA repair proteins, transcription factors and chromatin modulators, to 
facilitate the recognition and their access to the site of the damage.  
To investigate the presence of replication-associated DNA lesions, upon 
dl922-947 infection, I evaluated PARP activation in infected cells. To this aim, 
the levels of PARylated proteins in FRO and BHT101-5 cells were analyzed by 
western blot 24h after dl922-947 infection [Figure 15]. 
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Figure 15. Effects of dl922-947 infection on PARP activity 
FRO and BHT101-5 cells were infected with dl922-947 for 24h at indicated pfu/cell. 
Expression of PARylated proteins was analyzed by Western blot using an anti-PAR antibody. 
α-tubulin was used as a loading control. Results shown are representative of three independent 
experiments.  
Interestingly, a robust increase of PARylated proteins levels was observed in 
infected cells compared to uninfected. These data indicate that the virus 
strongly induces PARP activation,  thus leading to the activation of SSB repair 
machinery. 
PARP inhibition increases the percentage of γH2AX-positive cells induced 
by dl922-947 
To inhibit PARP activity, I used AZD2281, a competitive inhibitor of NAD+ 
in the PARP catalytic site (Peralta-Leal et al. 2009). I confirmed the effective 
inhibition of PARP activity by AZD2281, at concentrations used in the 
literature (Senra et al. 2011, Hirai et al. 2012). To this aim, I treated ATC cells 
with both single or combined treatment AZD2281/dl922-947, and evaluated 
PARylated protein levels by western blot 24h after infection.  
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Figure 16. Effects of AZD2281 on PARP activity. 
FRO and BHT101-5 cells were treated with AZD2281 (1 μM) and infected with dl922-947 for 
24h at indicated pfu/cell. Expression of PARylated proteins was analyzed by Western blot 
using an anti-PAR antibody. α-tubulin was used as a loading control. Results shown are 
representative of three independent experiments. 
As shown in figure 16, in both FRO and BHT101-5 cells, AZD2281 
treatment at 1 µM is sufficient to completely revert the increase in PARP 
activity mediated by dl922-947 infection. 
Given these results, I hypothesize that the combined inhibition of SSB repair, 
using the PARP inhibitor AZD2281, and the DSB repair, mediated by dl922-
947, could induce the accumulation of an unrepaired DNA damage, leading to 
an increase in cell death. To test this hypothesis, I analyzed γH2AX levels  by 
FACS analysis in cells undergoing the combined treatment AZD2281/dl922-
947. 
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Figure 17. Effects of the combined treatment dl922-947/AZD2281 on the accumulation of 
a DNA damage 
FRO (upper panel) and BHT 101-5 (lower panel) were infected with dl922-947 (5 or 1 pfu/cell, 
respectively) in the presence or not of AZD2281. After 24h cells were stained with a primary 
anti-γH2AX antibody and a secondary anti-mouse-FITC conjugate antibody for determination 
of unrepaired DNA damage. To measure the total DNA content, cells were also stained with 
propidium iodide (PI). The dot plot represents γH2AX positivity (y-axis) vs DNA content, as 
determined by PI staining (x-axis). The positivity for γH2AX  staining is indicative of the 
percentage of cells with an unrepaired DNA damage. Numbers represent the percentage of 
γH2AX positive cells and the standard deviation of three independent experiments.  
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An increase in the percentage of γH2AX-positive cells is observed in cells 
infected with dl922-947, but not in those treated with AZD2281 [Figure 17]. 
Importantly, the combined treatment led to a much greater increase in the 
percentage of γH2AX-positive cells than in the single dl922-947 treatment, 
(36.4% vs 46.5% and 18.9% vs 26.8% in FRO and BHT101-5 cells, 
respectively) [Figure 17]. 
PARP inhibition has a synergistic effect on dl922-947 cytotoxicity 
To explore the effect of the PARP inhibitor AZD2281 on the oncolytic 
activity of the mutant adenovirus dl922-947, FRO and BHT101-5 were 
infected and treated with AZD2281 at the same time. 
 
Figure 18. Effects of AZD2281 on dl922-947 cytotoxicity 
FRO and BHT101-5 cells were treated with two combination of dl922-947 and AZD2281, and 
cell viability was determined 7 days post infection by sulforhodamine B assay. Dose–response 
curve and LD50 or EC50 values were generated and used to construct isobolograms and 
calculate combination indexes (CI) for each ratio. The shown line connects the LD50 values of 
the virus and EC50 of the drug, both as a single agent. A ratio producing a CI<1 is considered 
synergistic, CI=1 additive, CI>1 antagonistic. A synergistic effect was observed in all used 
combination (CI<1). 
Combination index, calculated by isobologram analysis, showed a potent, 
statistically significant synergy of cell killing in both cell lines, at all 
combinations, after one week treatment [Figure 18]. 
dl922-947 viral replication, but not viral entry, is affected by PARP 
inhibition 
To verify whether the enhanced oncolytic activity in presence of AZD2281 
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was due to an increased viral entry into target cells, I evaluated the infection 
efficiency of ATC cells in presence or not of AZD2281. FRO and BHT101-5 
were treated with 1 µM of AZD2281 and infected with a non-replicating 
reporter adenovirus transducing GFP (AdGFP, 25 pfu/cell). After 48h from 
infection, GFP emission, indicative of viral entry, was evaluated by 
cytofluorimetric analysis. 
 
Figure 19. Effects of AZD2281 on dl922-947 viral entry and viral replication 
A) FRO and BHTH101-5 were treated with AZD2281 (1μM) and infected with 25 pfu/cell of 
AdGFP. The histograms show the fold change GFP emission compared to uninfected cells. 
GFP emission in unchanged in presence of AZD2281. The data shown represent the mean of 
three different experiments.  
B) Real Time PCR genome equivalent analysis. FRO and BHTH101-5 cells were infected with 
dl922-947 (5 or 1 pfu/cell, respectively) in presence or not of AZD2281 (1μM). 
Significant (*p<0.05) differences in viral replication levels were observed in AZD2281 treated 
cells compared to untreated. The data represent the mean of three different experiments.  
Treatment with AZD2281 did not affect viral entry, as indicated by an 
unchanged average of green emission of individual infected cells, in both cell 
lines [Figure 19A].  
Next, the expression of viral hexon gene was quantified by Real-Time PCR 
assay to evaluate viral replication. FRO and BHT101-5 cells were infected with 
dl922-947 (5 and 1 pfu/cell for FRO and BHT101-5 cells, respectively), and 
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treated or not with AZD2281 (1 µM). 48h later, viral genome copies were 
evaluated by Real Time PCR. This analysis revealed that treatment with 
AZD2281 induced a significant (* p<0.05) increase of viral replication in both 
cell lines [Figure 19B]. 
PARP inhibition increases the percentage of cells in sub-G1 phase and the 
percentage of polyploid cells induced by dl922-947 
It has been reported that forcing cells with damaged DNA into mitosis causes 
severe chromosome segregation defects aborting cytokinesis; therefore cells 
enter S phase and become polyploids (Chow and Poon 2010). Since I 
demonstrated that the combined treatment AZD2281/dl922-947 induces the 
accumulation of DNA damage, I evaluated cell cycle profile by FACS analysis. 
FRO and BHT101-5 cell were treated with 1 µM of AZD2281 and infected 
with dl922-947 (5 or 1 pfu/cell, respectively). 72h later cells were stained with 
Propidium Iodide (PI) and cell cycle profile analysed by FACS analysis.  
 
Figure 20. Effects of AZD2281 on dl922-947 viral entry and replication 
FRO (left panel) and BHT 101-5 (right panel) were infected with dl922-947 (5 or 1 pfu/cell 
respectively) for 72h in the presence or not of AZD2281. Sub-G1 and polyploidy are 
represented by histograms. The percentage of cells in sub-G1 phase and polyploid cells was 
significantly (*p<0.05) or highly significantly (**p<0.005) increased by the combined 
treatment compared to the single infection treatment. 
The data are the mean of three different experiments. 
A highly significant accumulation of polyploidy cells was observed in FRO 
cells undergoing the combined treatment compared to those only receiving the 
infection [Figure 20]. In addition, this effect is paralleled by a significant 
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increase in the percentage of cells in sub-G1 phase [Figure 20]. Although 
similar results were obtained using BHT101-5 cells [Figure 20] these cells 
displayed a higher percentage of polyploidy cells and a lower percentage of 
cells in sub-G1 phase than FRO cells. In accordance with the hypothesis that 
polyploidy can result from mitotic defects leading to cell death, the differences 
between FRO and BHT101-5 cells could be explained by a different timing in 
the escape from mitotic block and, subsequently, in cell death activation. 
PARP inhibition increases apoptosis-like cell death induced by dl922-947 
Accumulation of cells in sub-G1 phase is indicative of DNA fragmentation 
and cell death, either by necrosis or apoptosis. I decided to investigate both 
these cell death modalities in infected ATC cells in presence or not of 
AZD2281. To discriminate between necrosis and apoptosis, unfixed cells were 
stained with propidium iodide (PI) and Annexin V. PI can penetrate only in 
non-vital cells, whereas Annexin V binds to living cells with exposed 
phospholipid phosphatidylserine. The exposure of phosphatidylserine is due to 
the loss of membrane asymmetry and is considered to be an early marker of 
apoptosis (Fadok et al. 2001). Necrotic cells are positive for PI, whereas 
apoptotic cells are positive for Annexin V or double positive for Annexin V 
and PI. 
At 72 hpi, an increase in annexin V staining, indicative of apoptosis, was 
observed in the combined treatment with respect to single treatments, in both 
cell lines [Figure 21]. To further investigate the involvement of apoptosis, we 
also analyzed levels of pro- and cleaved caspase 3 by western blot in FRO and 
BHT101-5 cells treated as described above. In parallel, I also evaluated the 
levels of PARP, both full length and cleaved protein. 
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Figure 21. Effects of the combined treatment dl922-947/AZD2281 on phosphatydilserine 
exposition on plasma membrane 
FRO (upper panel) and BHT 101-5 (lower panel) were infected with dl922-947 at indicated 
pfu/cell for 72h in the presence or not of AZD2281. Annexin V binds to living cells with 
exposed phospholipid phosphatidylserine. The exposure of phosphatidylserine is due to the 
loss of membrane asymmetry and is considered to be an early marker of apoptosis. Apoptotic 
cells are positive for Annexin V or double positive for Annexin V and PI (Right quadrants). 
The combined treatment increased the percentage of apoptotic cells with respect to single 
treatments. Green numbers represent the percentage of annexin V positive cells and the 
standard deviation of three independent experiments. 
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Figure 22. Effects of the combined treatment dl922-947/AZD2281 on cell death pathway 
FRO and BHT101-5 cells were infected with dl922-947 at indicated pfu/cell in the presence or 
not of AZD2281 (1μM). After 48 and 72h, PARP and caspase 3 cleavage was analyzed by 
Western blot, using α-tubulin as a loading control.  
A decrease of pro-caspase 3, paralleled by a concomitant slight increase of 
the cleaved form, strongly suggested the activation of caspase 3 in cells 
undergoing the combined treatment compared to single treatments, in both 
FRO and BHT101-5 cell lines [Figure 22]. 
Next, I investigated the presence of another well-known marker of apoptosis, 
mitochondrial permeabilization (Martinou and Green 2001, Waterhouse et al. 
2002). Selective permeabilization of the mitochondrial outer membrane is an 
integral event in apoptosis induced by several stimuli. As a result several pro-
apoptotic proteins, including cytochrome C, are released from the 
mitochondrial intermembrane space to the cytoplasm. To evaluate this 
phenomena, the percentage of cells releasing cytochrome C from mitochondria 
was quantified by FACS analysis in cells undergoing the combined treatment.   
As shown in figure 23, the single treatment with dl922-947, but not with 
AZD2281, increased the percentage of cytochrome C negative cells 72hpi, in 
both FRO and BHT101-5 cells, indicating the presence of mitochondrial 
permeabilization upon infection. This viral effect is further increased by the 
combination with AZD2281 (16.9% vs 24.7 in FRO cells; 24.4 vs 53.8 in 
BHT101-5).  
Overall, the presence of mitochondrial permeabilization, together with the 
cleavage of caspase-3 and the annexin V positivity, clearly indicate a more 
active apoptotic pathway in cells undergoing the combined treatment compared 
with those only infected with dl922-947. 
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Figure 23. Effects of the combined treatment dl922-947/AZD2281 on cytochrome C 
release from mitochondria 
FRO and BHT101-5 cells were infected with dl922-947 at indicated pfu/cell in the presence or 
not of AZD2281 (1μM). After 72h citochrome C release from mitochondria was assessed by 
FACS analysis. Cells with intact mitochondria result positive to the staining for cytochrome C, 
while a lower fluorescence is indicative of cells with higher release of cytochrome C from 
mitochondria (cytochrome C negative cells). The combined treatment increases the percentage 
of cytochrome C negative cells compared to only infected cells. Green numbers represent the 
percentage of cytochrome C negative cells and the standard deviation of three independent 
experiments. 
PARP inhibitor AZD2281 increases dl922-947 oncolytic activity in vivo 
To evaluate the therapeutic potential of synergism between dl922-947 and the 
PARP inhibitor AZD2281, I analyzed the effects of the combined treatment on 
ATC tumor xenografts. 
Athymic mice were inoculated subcutaneously with FRO cells. Mice were 
then randomized into four groups (15 animals/group) with similar average 
tumor size (> 100mm3). In accordance to previous reports (Kortmann et al. 
2011, Senra et al. 2011), animals were injected i.p. with AZD2281 at the dose 
of 50mg/kg three consecutive day/week. dl922-947 (2x106 pfu) was 
administered two times per week (the day before and the day after AZD2281 
treatment) by intratumoral injection. The control group was injected with 
AZD2281 vehicle. dl922-947 was administered by intratumoral injection to 
avoid first pass effect, and the low viral dose (2x106 pfu) was chosen to enable 
a better visualization of the effects of the combined treatment versus dl922-947 
infection alone. 
Tumor diameters were measured every third day to monitor the growth. 
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Figure 24. Effects of the combined treatment dl922-947/AZD2281 on tumor growth 
Animals were injected i.p. with AZD2281 three consecutive days per week; dl922-947 was 
administered two times per week (the day before and the day after AZD2281 treatment) by 
intratumoral injection. The difference between animals receiving the combined treatment and 
single treatment groups and control group becomes statistically significant (*p<0.05) from day 
13. By day 17 growth inhibition was highly significant (**p<0.001) compared to control group 
and AZD2281 group. 
As shown in figure 24, a significant reduction of tumor growth was achieved 
in the combined treatment group compared to those receiving both the single 
treatments and the untreated one. At day 13, The growth inhibition difference 
of the combined treatment group started to be statistically significant (p<0.05) 
compared to single treatments and control group, and became highly 
significant (p<0.001) from day 17 compared to control group and AZD2281 
group. Treated animals did not show any weight loss or dehydration.  
 
Caspase inhibition attenuates dl922-947-induced cell death  
Cell death mechanisms activated by the host cells represent a well-known 
obstacle for viral infection. Accordingly, during their evolution, adenoviruses 
have developed two proteins, E1B-19K and E1B-55K, able to antagonize E1A-
induced apoptosis (Yew and Berk 1992, White 2001). In this study, I 
hypothesized that a deeper mechanistic understanding of the cell death 
mechanism induced by the oncolytic mutant dl922-947 in ATC cell lines may 
allow for novel discovered mediators to be therapeutically exploited,  
ultimately enabling the development of new combinatorial strategies with 
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oncolytic adenoviruses. Given the involvement of several apoptotic markers 
(described above) in dl922-947 infection, I decided to verify whether apoptosis 
is necessary for dl922-947-driven cell death. To this aim, I used zVAD-fmk a 
pan caspase inhibitor.   
ATC cells were infected with dl922-947 in presence or not of zVAD-fmk, 
and caspase 3 cleavage was assessed by western blot 72h later. 
 
Figure 25. Effects of the pan-caspase inhibitor zVAD-fmk on dl922-947-induced apoptosis 
FRO and BHT101-5 cells were infected with dl922-947 at indicated pfu/cell in the presence or 
not of zVAD-fmk (20μM). After 72h PARP and caspase 3 cleavage were analyzed by western 
blot, using α-tubulin as a loading control. 
As shown in figure 25, zVAD-fmk, at 20 µM concentration, effectively 
reverted dl922-947-mediated caspase-3 cleavage in FRO and BHT101-5 cells, 
as indicated by an increase of the procaspase-3 and a reduction of the cleaved 
form. Indeed, it is worth to note that the presence of the upper band of the 
cleaved caspase 3, still detected in presence of zVAD-fmk, is not an active 
form of cleaved caspase 3 and therefore not suggestive of its activation 
(Johnson et al. 2000). Similar results were obtained for PARP cleavage [Figure 
25]. 
Next, we evaluated the cell growth of FRO and BHT101-5 cells infected with 
dl922-947 (5 and 1 pfu/cell, respectively), in presence or not of the caspase 
inhibitor zVAD-fmk (20 µM), for 24, 48 and 72h. 
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Figure 26. Effects of the pan caspase inhibitor zVAD-fmk on dl922-947 oncolytic activity 
FRO and BHT101-5 cells were plated in 12-well plates and infected with dl922-947 in the 
presence or not of zVAD-fmk at indicated time points and concentration. Caspase inhibition 
increased cell viability in presence of the virus compared to only infected cell. The data 
represent the mean of three independent experiments. 
The growth of FRO cells in presence of zVAD-fmk was unchanged  
compared to untreated cells, whereas the drug induced a slight increase of 
BHT101-5 cell growth at 72h [Figure 26]. 
Caspase inhibitor treatment in combination with dl922-947 was able to 
attenuate dl922-947-induced cell death at 48 and 72hpi, in both cell lines 
[Figure 26]. However, the lack of a complete rescue from virus-induced cell 
death in presence of the drug, suggested that the virus may leverage  additional 
cell death mechanisms to kill the cells. 
To further characterize the reduction of virus-induced cell death in presence 
of a caspase inhibitor, I have also analyzed other apoptotic markers, such as 
Annexin V [Figure 27] and cytochrome C release [Figure 28] by FACS 
analysis, as described above, after 72h of infection.  
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Figure 27. Effects of zVAD-fmk on dl922-947-induced phosphatydilserine exposition on 
plasma membrane 
FRO (upper panel) and BHT 101-5 (lower panel) were infected with dl922-947 at indicated 
pfu/cell for 72h in the presence or not of zVAD-fmk (20 μM). Annexin V binds to living cells 
with exposed phospholipid phosphatidylserine. Caspase inhibition reduced the percentage of 
apoptotic cells with respect to single treatments. Green numbers represent the percentage of 
annexin V positive cells and the standard deviation of three independent experiments. 
The annexin V staining showed that the treatment with zVAD-fmk (20 µM) 
is able to reduce dl922-947-induced annexin V positivity from 27.4 to 20.3 in 
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FRO cells, and from 21.4 to 12.8 in BHT101-5 cells, indicating that caspase 
inhibition attenuates dl922-947-induced cell death. 
 
Figure 28. Effects of zVAD-fmk on dl922-947-induced cytochrome C release from 
mitochondria. 
FRO and BHT101-5 cells were infected with dl922-947 at indicated pfu/cell in the presence or 
not of AZD2281 (1μM). After 72h, cytochrome C release from mitochondria was assessed by 
FACS analysis. Cells with intact mitochondria result positive to the staining for cytochrome C, 
while a lower fluorescence is indicative of cells with higher release of cytochrome C from 
mitochondria (cytochrome C negative cells). Caspase inhibition reduced the percentage of 
cytochrome C negative cells compared to only infected cells. Green numbers represent the 
percentage of cytochrome C negative cells and the standard deviation of three independent 
experiments. 
Accordingly,  quantification of cytochrome C release from mitochondria also 
revealed that cytochrome C release induced by dl922-947, and consequently 
the mitochondrial permeabilization, is reduced when apoptosis is inhibited by 
zVAD-fmk (20 µM) (from 44.2 to 33.0 in FRO cells, and from 20.0 to 12.4 in 
BHT101-5 cells [Figure 28]. 
dl922-947 induces an apoptotic-like cell death mechanism lacking the 
peculiar apoptotic morphology 
Apoptosis is morphologically characterized by membrane blebbing. Blebs 
formation is driven by modulation of actin-myosin activity, that create 
hydrodynamic forces during contraction to induce, collapse at points of 
structural weakness within the cell (Street and Bryan 2011).  
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Figure 29. Effects of dl922-947 on apoptosis morphology 
FRO cells infected with dl922-947 (5 pfu/cell) for 24h or incubated over night with 0.5 µM 
staurosporine (as positive control for apoptosis). After staining with DAPI, nuclei were 
visualized by fluorescence microscope. dl922-947 infected cells showed a different nuclear 
morphology (cells round up and nucleus remain intact) compared to staurosporine treated cells 
(nuclear fragmentation). 
Data shown are representative of three independent experiments. 
As programmed cell death progresses blebs may become packed with cellular 
organelles and condensed chromatin to form the basis of fragmentary 
membrane-clad apoptotic bodies (Wickman et al. 2012). Therefore, I 
investigated the presence of membrane blebbing, as morphological apoptotic 
feature, in infected cells, by immunofluorescence experiment for 
condensed/fragmented chromatin staining cells with DAPI. 
Despite dl922-947 infected cells displayed several apoptotic markers, such as 
caspase 3 and PARP cleavage, Annexin V positivity and cytochrome C release, 
no signs of blebbing formation were found, as indicated by the round shape 
displayed by cell after infection and by the presence of nucleus still intact. As 
positive control for apoptotic blebbing,  I treated FRO cells with the well-
known apoptotic inducer staurosporine (Couldwell et al. 1994, Antonsson and 
Persson 2009). 
ROCK proteins are essential for multiple aspects of apoptotic processes, 
including regulation of cytoskeletal-mediated cell contraction and membrane 
blebbing, nuclear membrane disintegration, modulation of Bcl2-family 
member, caspase expression/activation and phagocytosis of the fragmented 
apoptotic bodies. ROCK proteins are direct targets of caspases that cleave the  
ROCK autoinhibitory C terminal domain (Wickman et al. 2012). This results in 
constitutive kinase activity of ROCK and its subsequent regulation of actin-
myosin cellular contraction. In blebbing cells, an higher ROCK cleavage by 
caspases results in increased phosphorylation of Myosin Light Chain 2 
(MLC2), thus leading to contraction of cortical actin within the cell (Wickman 
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et al. 2012).  
To evaluate molecular mechanisms involved in cellular blebbing, I have 
analyzed caspase-mediated ROCK cleavage and MLC2 phosphorylation, by 
western blot analysis, in FRO cells infected with dl922-947 (5 pfu/cell) for 
48h. Cells treated with staurosporine (0.5 μM) were used as positive control of 
ROCK1 cleavage [Figure 30]. 
 
Figure 30. Effects of dl922-947 on blebbing pathway 
FRO cells were infected with dl922-947 at 5 pfu/cell or incubated over night with 0.5 µM 
staurosporine (as positive control for apoptosis). After 48h, ROCK1 cleavage and MLC2 
phosphorylation were analyzed by western blot, using α-tubulin as a loading control. 
As demonstrated in figure 30 dl922-947 infection induced the formation of 
ROCK1 active form. Surprisingly, phosphorylation levels of ROCK1 target 
MLC2 resulted lower than untreated cells, highlighting the possibility that the 
virus may contrast the blebbing formation. 
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5. DISCUSSION 
Anaplastic Thyroid Carcinoma is one of the most aggressive human 
neoplasia with an average survival time of six months after diagnosis. ATC is 
usually resistant to currently available treatments. So far, the treatment consist 
of surgery, when feasible, combined with radiation and chemotherapy. 
However, this multimodality treatment confers only a short term palliative and 
survival benefit.  
ATC is characterized by a local growth, difficult to control and rapidly 
leading to trachea obstruction, asphyxia and death. Clinical studies have proven 
tumor selective replicating adenoviruses as an effective treatment against 
localized lesions (Russell et al. 2012), highlighting their potential use as 
strategy to improve the therapeutic outcome of ATC 
Replication selective Oncolytic Viruses (OVs) are a rapidly expanding 
therapeutic platform for cancer treatment. As they are replication competent 
viral mutants, OVs are able to complete their life cycle exclusively in tumor 
cells. With respect to classical anti-cancer drugs, OVs present several 
advantages: tumor-selective replication with amplification of the input dose, 
stimulation of anti-tumoral immune responses, and relatively few mild side 
effects when administered to human patients. The development of cross 
resistance is unlikely, since the mechanism of action of OVs is independent 
from conventional anti-cancer therapeutics (Eager and Nemunaitis 2011) 
(Hallden and Portella 2012). Oncolytic viruses have been tested in clinical 
trials confirming their safety and showing varying degrees of success. dl1520 
has been evaluated in phase I and II clinical trials and a related virus, H101, 
has been recently licensed in China for the treatment of head and neck 
carcinoma (Garber 2006). Reovirus and herpes simplex virus are in late phase 
testing. Other viruses, including measles virus and vaccinia virus, have 
completed phase I testing, showing promising results. A first-in-class US 
approval is expected soon for OncoVex, which is being tested in a randomized 
phase 3 clinical trial for the treatment of melanoma that has recently completed 
accrual (http://clinicaltrials.gov/NCT00769704). 
In the last decade, several preclinical studies have demonstrated the 
effectiveness of virotherapy, alone or in combination with rational chosen 
drugs, for the treatment of ATC (Libertini et al. 2007, Lin et al. 2008, Reddi et 
al. 2008, Libertini et al. 2011, Reddi et al. 2012). In this regard, we have 
already demonstrated that the oncolytic adenovirus dl1520 is active against 
ATC cells and tumor xenografts (Portella et al. 2002, Portella et al. 2003, 
Libertini et al. 2007). Moreover, we have also proven that the most effective 
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second generation oncolytic adenovirus dl922-947 exerted a great antitumor 
effect against ATC cells and tumor xenografts (Libertini et al. 2008).  
Although the great antineoplastic potential of oncolytic viruses has been 
confirmed in preclinical and clinical studies, the lack of full efficacy still 
represents a medical challenge. We have already exploited different approaches 
to use in combination with oncolytic adenoviruses, including drugs able to 
ameliorate the vascularization of tumors (anti VEGF antibody), to increase the 
replicative potential of the virus (AZD1152), or able to affect complementary 
cell death pathways (Libertini et al. 2008, Libertini et al. 2011, Botta et al. 
2012).  
Understanding how the neoplastic cells react and counterbalance the 
infection to extend their survival might uncover new insights in the field of 
virotherapy, allowing for novel effectors to be discovered and targeted to  
increase the efficacy of OVs. 
The linear adenovirus genome has double-stranded DNA termini that could 
be targeted by cellular double strand break (DSB) repair pathways. It has been 
observed that the activation of the DSB repair pathway leads to formation of 
viral genome concatamers that impedes viral packaging into virions and the 
consequent viral replication (Lakdawala et al. 2008). To overcome this barrier, 
adenoviruses have evolved different strategies to modulate the DNA damage 
response (Turnell and Grand 2012). For example, the E4 region encodes viral 
factors that prevent concatamer formation through inhibition of the DSB repair; 
indeed, infection with adenoviruses harboring deletions of E4orf3 and E4orf6 
results in concatenation of viral DNA, and prevention of replication and 
packaging (Weiden and Ginsberg 1994).  
Recently, we have shown that dl922-947 infection triggers a DNA Damage 
Response (DDR) in ATC cells (Passaro et al, peding revision). We speculate 
that the DDR system may act as cellular protective mechanism to hinder viral 
infection and/or replication, and that its inhibition could be tested as strategy to 
enhance dl922-947 cytotoxicity. Accordingly, we have demonstrated that the 
ATM inhibitor KU55933 increased the oncolytic activity of dl922-947 and its 
replication (Passaro et al., pending revision). Moreover Connell and colleagues 
(2011) showed that ATR and Chk1 inhibition is able to increase the dl922-947 
cytotoxicity in ovarian cancer cells (Connell et al. 2011).  
All these data further support the hypothesis that the DNA damage system 
could be a target exploitable to increase the efficacy of oncolytic adenoviruses.  
Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme playing  a critical 
role in DNA damage response processes (El-Khamisy et al. 2003). Targeting 
DNA repair using PARP inhibitors has great potential as anticancer therapeutic 
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strategy, either in conjunction with other DNA-damaging agents, or as a single 
agent. In particular, as a single agent, PARP inhibitors could be used in tumors 
with pre-existing homologous recombination pathway defects such a in BRCA-
deficient cancers (Sandhu et al. 2010). This strategy is in the line with the 
concept of synthetic lethality that is a situation when a mutation in one of two 
genes that individually has no effect but combining the mutations leads to cell 
death. Indeed, PARP inhibition leads to the persistence of the SSBs, converted 
to a DSBs at the replication fork. In normal replicating cells, DSBs are 
efficiently repaired by the error free homologous recombination pathway. 
Whereas, cells homozygous for a defect in homologous recombination are 
highly sensitive to PARP inhibition due to persistent multiple unrepaired 
DSBs, a potent stimulus for cell death (Underhill et al. 2011).  
In this work, I induced a synthetic lethality-like effect by combining dl922-
947 with the PARP inhibitor, namely AZD2281, in ATC. Indeed, it is well 
known that an unscheduled DNA synthesis, such as that one induced by viral 
replication, causes the accumulation of single strand break (SSB) as 
replication-associated DNA lesions (Machida and Dutta 2005, Connell et al. 
2011). SSBs accumulation leads to PARP activation, protein PARylation and 
SSB repair. PARP inhibition should prevent the repair of SSBs, which are then 
converted in DSBs at the replication fork. Although ATC cells do not show any 
mutation in DSB repair proteins, I hypothesized that dl922-947 can impair 
DSB repair, causing a persistence of multiple unrepaired DSBs and leading to 
cell death. 
In this work, I demonstrated that the oncolytic adenovirus mutant dl922-947 
is effectively able to push two different ATC cell lines (FRO and BHT101-5) 
to entry in S-phase. This effect is also paralleled by the accumulation of an 
unrepaired DNA damage, demonstrated by an high percentage of γH2AX-
positive cells. Although γH2AX formation has historically been associated 
with the induction DSBs, a number of reports have shown H2AX 
phosphorylation after DNA replication stress (Ward and Chen 2001, Ewald et 
al. 2007). In addition dl922-947 infection induced PARP hyperactivation, 
suggesting SSB formation that should be repaired by BER pathway. 
I have also demonstrated that dl922-947 elicits DSB repair pathway 
activation in the host cell, as suggested by ATM and Chk1 phosphorylation; 
however, the virus also hampers the execution of DSB repair downregulating 
MRN complex protein, probably through protein degradation. In this scenario, 
I combined a PARP inhibitor, AZD2281, with dl922-947, showing that, in both 
ATC cell lines FRO and BHT101-5, the combined treatment further increased 
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the accumulation of an unrepaired DNA damage.  As expected, PARP inhibitor 
alone had no effect on DNA damage accumulation. 
Then, I evaluated the effect of AZD2281 treatment on dl922-947 
cytotoxicity. By performing an isobologram analysis, I showed that effect of 
such combined treatment is synergistic, at all used concentration.  
To deepen our understanding of how AZD2281 is able to enhance oncolytic 
activity, we first monitored viral entry upon drug treatment. Our data show that 
AZD2281 does not affect viral entry. On the contrary, we observed a 
significant increase in viral replication in ATC cells also treated with 
AZD2281. 
These results led me to hypothesize that the inhibition of DNA damage repair 
pathways, mediated by both AZD2281 and the virus itself, may accelerate cell 
cycle, thus enhancing viral replication, given the lack of repair of replication-
associated DNA lesions by host cells.  
However, the increased viral replication may not suffice to entirely explain 
the enhanced cell killing. In this regard, several studied have demonstrated an 
enhancement in viral cytotoxicity without an increase in viral replication 
(Libertini et al. 2011, Botta et al. 2012). Therefore, I evaluated cell death 
mechanisms induced by virus, and how these were affected by the drug. 
First, I analyzed cell cycle profile to quantify the percentage of cell in sub-G1 
phase. Sub-G1 phase is a generic marker of cell death, since it only indicate the 
presence of  DNA fragmentation, that can occur either during necrosis or 
apoptosis.  
The combination between the drug and the virus significantly increased the 
percentage of cells in sub-G1 fraction compared with infected cells. AZD2281 
alone did not induce any effect.  
It has been shown that forcing cells with damaged DNA into mitosis causes 
severe chromosome segregation defects leading to polyploidy. Cell cycle 
profile analysis confirmed a significant increase in polyploidy induced by the 
combined treatment. The polyploidy observed in ATC cells infected with 
dl922-947 or undergoing the combined treatment could be ascribed to a more 
robust entry into mitosis in presence of an unrepaired DNA damage. I also 
hypothesize that dying cells in sub-G1 fraction may arise from polyploid cells.  
I even explored the involvement of apoptotic mechanism in the cell death 
induced in treated/infected cells, by evaluating some apoptotic markers, such as 
Annexin V positivity, PARP and caspase 3 cleavage, and cytochrome C release 
from mitochondria. The association with AZD2281 increased the percentage of 
Annexin V positive cells, as well as the percentage of Cytochrome C negative 
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cells. Accordingly, caspase 3 was found to be more active in cell receiving the 
combined treatment. 
The results clearly indicate that AZD2281 enhances the cytotoxic effects of 
oncolytic viruses either by potentiating the virus-induced cell death 
mechanisms and by increasing viral replication.  
To validate the potential therapeutic use of AZD2281 in association with 
dl922-947, I analyzed the effects of the combined treatment on ATC xenograft 
tumors, by injecting FRO cells in athymic mice. Starting from day 13, I 
observed that the combined treatment AZD2281/dl922-947 significantly 
reduced tumor growth compared to single treatment group and control group. 
Overall, these data clearly demonstrate the efficacy of AZD2281/dl922-947 
combination in ATC both in vitro and in vivo. 
In accordance to Baird and colleagues (Baird et al. 2008), we previously 
observed that infection of ATC cells with dl922-947 led to programmed cell 
death lacking the morphological features of classical apoptosis, but showing 
some apoptotic markers, such as sub-G1 accumulation and caspase-3 activation 
(Libertini et al. 2011). Here, I demonstrate that in ATC cell the virus induces 
the activation of an apoptotic-like cell death, characterized by Annexin V 
positivity, PARP and caspase 3 cleavage, and cytochrome C release from 
mitochondria. However, classical  morphological signs of apoptosis, including 
cell shrinkage, membrane blebbing, cellular disintegration, and chromosome 
condensation are missing. It should be noted that apoptotic blebbing is not a 
universal feature of programmed cell death, some cell types do not appear to 
generate membrane blebs nor undergo fragmentation (Wickman et al. 2012). 
To demonstrated that FRO cell are neither resistant to form membrane blebs 
nor undergo fragmentation, we compared cells infected with dl922-947 to cells 
treated with staurosporine, a well-known apoptosis inducer (Couldwell et al. 
1994, Antonsson and Persson 2009), observing a different nuclear morphology. 
Indeed infected cells rounded up and nucleus remain intact, whereas 
staurosporine treated cells showed a clear nuclear fragmentation. 
Membrane blebbing is a crucial step for apoptotic bodies clearance by 
monocytes and macrophages. Since this phenomena was lacking in dl922-947-
infected cells, I hypothesized that dl922-947 could prevent membrane blebbing 
and apoptotic bodies formation, thus causing a not apoptotic-like morphology. 
To demonstrate my hypothesis, I analyzed the molecular pathway involved in 
membrane blebbing. In blebbing cells, an higher ROCK cleavage by caspases 
results in increased phosphorylation of Myosin Light Chain 2 (MLC2), thus 
leading to contraction of cortical actin within the cell (Wickman et al. 2012). In 
FRO cells, dl922-947 infection induced the formation of ROCK1 active form. 
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Surprisingly, phosphorylation levels of ROCK1 target MLC2 resulted lower 
than untreated cells, highlighting the possibility that the virus may contrast the 
blebbing formation. 
In addition, analysis of cell growth curve showed that the cell death induced 
by dl922-947 is partially reverted by the addition of a pan caspase inhibitor, 
zVAD-fmk. In the presence of the inhibitor, an higher number of living cells 
was observed compared to only infected cells.  This result is further supported 
by the observation that zVAD-fmk reduced the percentage of apoptotic cells 
(Annexin V positive and Cytochrome C negative), although cell death 
processes are still partially active in presence of the inhibitor.  
These data suggest us that dl922-947 infection may concomitantly leverage 
different cell death mechanisms in ATC cells. Future experiments are required 
to clarify these data. Apoptotic process is an established obstacle to viral 
infection, and viruses have evolved genes inhibiting the host cell apoptosis. In 
this scenario, host cells need to activate an alternative cell death mechanism to 
circumvent inhibition of apoptosis in order to curtail viral infection. It is 
conceivable that elucidating the exact death mechanisms activated by the host 
cell after infection might allow the identification of new therapeutic targets, 
able to potentiate oncolytic adenoviral cytotoxicity. 
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6. CONCLUSION 
Anaplastic Thyroid Carcinoma (ATC) is one of the most aggressive human 
malignancies. Multimodality therapy, which includes surgical debulking, 
external radiation therapy and chemotherapy, has failed to show improvements 
in median survival. The development and the validation of novel and more 
effective treatment strategies still represent a medical challenge. 
Oncolytic viruses are replication competent viral mutants able to complete 
their life cycle exclusively in tumor cells. In the present study, I have 
demonstrated that the oncolytic adenovirus dl922-947 induces the 
accumulation of  an unrepaired DNA damage with the concomitant activation 
of Poly(ADP-ribose) Polymerase (PARP), and impairs the pathway implicated 
in the double strand break repair. Exploiting the concept of synthetic lethality I 
combined dl922-947 with the PARP inhibitor AZD2281, proving this drug as 
effective in enhancing the oncolytic activity of dl922-947 in two ATC cell 
lines. Indeed, I have also shown that this effect is paralleled by an increased 
cell death and an increased viral replication. 
Importantly, I successfully validated the therapeutic combination 
AZD2281/dl922-947 against ATC in vivo, demonstrating that AZD2281 
significantly enhances the dl922-947 oncolytic effect in ATC tumor xenograft. 
Basing on these findings, I strongly suggest that AZD2281 could be 
therapeutically used in combination with the oncolytic virus dl922-947 for the 
treatment of ATC. 
Finally, I have also demonstrated that dl922-947 is able to impede the 
apoptotic membrane blebbing activated by cells in response to the infection, 
acting on ROCK 1/Myosin Light Chain 2 pathway.  
Since membrane blebbing is a crucial step for apoptotic bodies clearance by 
monocytes and macrophages and the apoptotic process is an obstacle to viral 
infection, I suggest that ROCK 1 could be an additional therapeutic target to be 
potentially used in combination with oncolytic viruses against anaplastic 
thyroid carcinoma.  
Thus, this project has enabled us to identify novel mechanisms implicated in 
the infection of ATC cells with oncolytic adenoviruses. In future studies, 
additional regulators or downstream effectors of the identified pathways will be 
assessed for their “druggability” in in vitro and in vivo models of ATC. This 
new knowledge will allow the development of new therapeutic strategies to test 
in combination with oncolytic adenoviruses, potentially capable of driving 
benefits for the treatment of ATC, which is still a formidable medical 
challenge.  
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Abstract 
dl922-947 is an oncolytic adenovirus potentially suitable for the treatment of aggressive localized 
tumours, such as Anaplastic Thyroid Carcinoma (ATC).   
In the present study, we have analyzed the effects of dl922-947 in combination with ionizing 
radiations, testing different schedules of administration and observing synergistic cell killing only 
when ATC cells were irradiated 24 hours prior to viral infection. Cell cycle analysis indicates that 
irradiation blocks ATC cells in a more permissive state (G2) for viral infection. Cells undergoing 
combined irradiation and infection treatment exhibit a marked increase in apoptotic cell death as 
quantified by annexinV staining and caspase 3 cleavage, indicating that enhanced apoptosis 
contributes to synergistic cell killing.  
We also show that dl922-947 triggers a DNA damage response, characterized by mobilization of 
the MRN complex, accumulation of γH2AX, and activation of the checkpoint kinases ATM and 
Chk1.  Based on these observations we speculate that the DNA damage response acts as cellular 
protective mechanism to hinder viral infection and replication. To confirm this hypothesis, we 
demonstrate that the ATM inhibitor KU55933 increased the oncolytic activity of dl922-947 and its 
replication. 
Finally, we validate the potential therapeutic utility of this approach by showing that the combined 
treatment slows tumour xenograft growth more potently than either irradiation or infection alone in 
vivo.  
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Introduction 
Anaplastic Thyroid Carcinoma (ATC) represents one of the most aggressive human malignancies. It 
arises from thyroid follicular cells showing morphological features of a malignant neoplasm, high 
proliferation rate and marked aneuploidy. The median survival of patients with ATC is ~6 months 
from diagnosis. Multimodality therapy, which includes surgical debulking, external radiation 
therapy and chemotherapy, has failed to show any improvements in survival and ATC still remains 
a formidable medical challenge (Ain 2000; Smallridge, et al. 2009). Therefore, novel therapies with 
different mechanisms of action are required. 
Oncolytic viruses (OVs) are replication competent viral mutants able to complete their life cycle 
exclusively in tumour cells. With respect to classical anti-cancer drugs, OVs present several 
advantages: tumour-selective replication with amplification of the input dose, stimulation of anti-
tumoural immune responses, and relatively few mild side effects when administered to human 
patients. Also, the development of cross resistance is unlikely since their mechanism of action is 
independent of conventional anti-cancer therapeutics (Eager and Nemunaitis 2011; Hallden and 
Portella 2012). 
A number of oncolytic viruses, such as the vaccinia virus GLV-1h68 (Lin, et al. 2008b) and the 
oncolytic attenuated herpes virus G207 (Lin, et al. 2008a), have shown promising effects against 
ATC cells in preclinical studies. 
We have previously demonstrated that the oncolytic adenoviruses dl1520 and dl922-947 could be 
useful for the therapy of ATC (Libertini, et al. 2011; Libertini, et al. 2007; Libertini, et al. 2008; 
Portella, et al. 2003; Portella, et al. 2002). dl1520, bearing a E1B 55K deletion, is the first mutant 
engineered for tumour specific cytolysis (Heise, et al. 1997). Since its replication is severely 
attenuated not only in normal cells but also in the majority of cancers (O'Shea, et al. 2004), dl1520 
has shown limited utility as single agent. Hence, novel and more effective oncolytic viruses have 
been engineered. dl922-947 is a second generation adenoviral mutant bearing a 24-bp deletion in 
E1A-Conserved Region 2 (CR2) (Heise, et al. 2000a). This region binds to and inactivates the pRb 
tumour suppressor protein, dissociating the pRb-E2F complex and driving S-phase entry and viral 
replication. Because the mutant E1A protein encoded by dl922-947 cannot bind pRb the virus is 
unable to trigger S-phase entry in normal cells and can therefore only replicate in cells with an 
aberrant G1-S checkpoint, a defect observed in over 90% human cancers (Sherr and McCormick 
2002). Superior cell killing potency of dl922–947 with respect to dl1520 has been observed in vitro 
and in vivo in human cancer cells of different origin such as pancreas (Bhattacharyya, et al. 2011), 
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prostate (Radhakrishnan, et al. 2010), ovarian (Lockley, et al. 2006), thyroid (Libertini et al. 2008), 
and brain (Botta, et al. 2012; Botta, et al. 2010; Yong, et al. 2009). In addition other mutants with 
E1ACR2-region deletion have proved effective in experimental models (Jiang, et al. 2009; Oberg, 
et al. 2010). 
Emerging evidences indicate that combining oncolytic viruses with standard chemotherapy and 
other types of anticancer treatments has the potential to increase the antitumor activity (Cheong, et 
al. 2008; Heise, et al. 2000b).  
It has been clearly shown in preclinical and clinical studies that OVs and radiation therapy show 
additional or synergistic antitumour effects. Phase I and II/III clinical trials with replication 
competent oncolytic viruses have been completed (Immonen, et al. 2004; Touchefeu, et al. 2011). 
Despite the encouraging results obtained with such combined treatment modalities, relatively little 
is known about the mechanisms that result in enhanced tumour cell death. Understanding the 
mechanisms that underlie synergistic cell killing could enable further optimization of this strategy 
for future clinical development. 
Ionising radiation is known to induce DNA damage and a subsequent block of the cell cycle 
progression with accumulation of cells either in G1 or G2, depending on the integrity of cell cycle 
checkpoints. After DNA repair, these cell cycle checkpoint arrests are released. It has been reported 
that drugs that block cells in G2/M or inhibit cytokinesis can enhance oncolytic viruses-mediated 
cell killing (Seidman, et al. 2001). For example, we recently demonstrated that the cytopathic 
effects of dl922-947 are enhanced by the Aurora B inhibitor AZD1152, which induces mitotic 
arrest, accumulation in G2/M phase and polyploidy (Libertini et al. 2011).  
Here, we have evaluated the effect of dl922-947 in association with ionising radiation (IR) showing 
that the combination enhances the effect of dl922-947 against ATC cells in vitro. Comparing 
different schedules of treatment (virus administered before or after irradiation), we observed 
synergistic cell killing only when irradiation is administered prior to viral infection. The efficacy of 
the optimal combined treatment has been also confirmed in ATC tumour xenografts in vivo. 
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Material and Methods  
Cells, adenoviruses and drugs 
Human thyroid anaplastic carcinoma cell lines BHT101-5 and FRO have been described and 
authenticated as shown elsewhere (Schweppe, et al. 2008). dl922-947 and AdGFP viral stocks were 
expanded in the human embryonic kidney cell line HEK-293, purified and stored as previously 
reported (Libertini et al. 2007). Viral stocks were expanded, purified, stored and quantified as 
previously reported (Botta et al. 2010). 
 
Cytotoxicity assay  
Cytotoxicity was evaluated using the sulforhodamine B assay as previously described (Seidman et 
al. 2001). Dose–response curves were generated to calculate the concentration of each agent 
required to kill 50% of cells (median lethal dose, LD50). Untreated cells or cells treated with single 
agents were used as a control. 
 
Viral replication  
FRO and BHT101-5 cells were infected with dl922-947, media collected 48 hpi (hours post 
infection) and viral DNA extracted using the High pure viral nucleic acid kit (Roche Diagnostics, 
Indianapolis, IN, USA). Specific primers for the viral hexon gene (from 99 to 242 bp) were used to 
measure viral replication by Real-Time PCR: 5’-GCC ACC GAG ACG TAC TTC AGC CTG-3’ 
(upstream primer) and 5’TTG TAC GAG TAC GCG GTA TCC TCC GCG GTC-3’ (downstream 
primer). A standard curve was constructed by assaying serial dilutions of dl922-947. 
 
FACS analysis 
Cell cycle: FRO and BHT101-5 cells treated as indicated were detached and fixed in 70% (v/v) 
ethanol for at least 1 hour at -20°C. Washed pellets were resuspended in PBS containing RNaseA 
(Roche, Indianapolis, IN, USA) (0.4 U) and propidium iodide (SIGMA, St. Louis, MO, USA) 
(0.015 mol l
-1
), incubated for 20’ at room temperature, and analyzed for emission in the FL3 
channel. To remove artifacts—doublets and aggregates—from the analysis, an electronic doublet 
discrimination was performed using the area and width of the fluorescence (FL3) pulse. 
AdGFP infection: FRO and BHT101-5 cells were infected with AdGFP (25 MOIs) and harvested 
48 hours later. Pellet was resuspend in PBS and emission in the FL1 channel analysed.  
Annexin V/PI staining: Attached and detached FRO and BHT101-5 cells were collected and washed 
with Annexin V binding buffer (Biolegend, San Diego, CA, USA ). Pellet was resuspended in 50µl 
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of Annexin V binding buffer containing 2 µl of FITC-conjugated Annexin V (Biolegend #640906, 
San Diego, CA, USA). After 15’ incubation at room temperature, 250µl of propidium iodide 
solution 0.0015 mol l
-1
 in PBS was added to each sample just before analysis.  
γH2AX/PI staining: FRO cells were detached and fixed in 70% (v/v) ethanol for 2 hours at -20°C. 
Pellet was washed with PBT (0.5% w/v BSA, 0.1% v/v Tween20 in PBS) and resuspended in PBT 
containing γH2AX antibody (Millipore #05-636, 1:100, Billerica, MA, USA). After 1 h incubation 
at room temperature, samples were washed in PBT and then resuspended in PBT containing 
Alexa488 anti-mouse (Invitrogen #A11001, 1:100, Carlsbad, CA, USA) at dark. After further 30 
minutes, cells were washed with PBT and resuspended in PI 0.015 mol l
-1
 for 20’ and analyzed for 
the emission in FL1 and FL3 channels. 
All samples were acquired with a BD LSRFortessa (BD Biosciences, San Jose, CA, USA) and 
analysed using BD FACSDiva Software. 
 
Protein extraction and Western blot analysis 
After the indicated treatments, attached and detached cells were harvested and lysates prepared as 
already described (Botta et al. 2010). 50 µg of lysate proteins were probed with the following 
antibodies: caspase 3 (Abcam #Ab13585, 1:500, Cambridge, UK), p-ATM s1981 (Cell Signaling, 
#4526, 1:1000, Boston, MA, USA), p-chk1 s345 (Cell Signaling, #2348, 1:1000, Boston, MA, 
USA), MRE11 (SantaCruz #sc-5859, 1:1000, Santa Cruz, CA, USA) and α-tubulin (SIGMA 
#T9026, 1:5000, St. Louis, MO, USA). 
 
Tumorigenicity assay 
FRO cells (1x10
6
) were injected into the right flank of 80 athymic mice. After 30 days, tumour 
volume was evaluated and the animals were divided into four groups (20 animals/group) with 
similar average tumour size. At day 0, a single radiation dose of 10 Gy was administered on the 
tumour volume at a distance of 80 cm with a bolus interposition to avoid lower doses at the tumor 
external edge. dl922-947 (2x10
6
 MOIs) was injected in the peritumoural area administered three 
times per week by intratumoural injection to avoid first pass effect in two groups. The control group 
was injected with saline solution. 
Tumour diameters were measured with caliber and tumour volumes (V) were calculated by the 
formula of rotational ellipsoid: V=AxB
2
/2 (A=axial diameter, B=rotational diameter).  
Mice were maintained at the Dipartimento di Biologia e Patologia Cellulare e Molecolare Animal 
Facility. All animal experiments were conducted in accordance with accepted standards of animal 
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care and in accordance with the Italian regulations for the welfare of animals used in studies of 
experimental neoplasia. Study was approved by our institutional committee on animal care. 
 
Statistical analysis 
The analysis of the cytotoxic effect in vitro was made by isobolograms generated to calculate the 
combination index.  
Comparisons among different treatment groups in the experiments in vivo were made by the 
ANOVA method and the Bonferroni post hoc test using commercial software (GraphPad Prism 4). 
Assessment of differences among rate of tumour growth in mice was made for each time point of 
the observation period.  
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Results 
Effects of ionising radiation on dl922-947 
To determine whether Ionizing Radiation (IR) could enhance the oncolytic activity of the mutant 
adenovirus dl922-947, anaplastic thyroid carcinoma cell lines FRO and BHT101-5 were infected 
and irradiated. To identify most appropriate treatment sequence, FRO and BHT101-5 cells were 
infected and then irradiated after 24 hours or vice versa. Cell survival was evaluated seven days 
after infection.  
Combination index showed a potent, statistically significant synergy of cell killing in BHT101-5 
cells at all combinations when cells were infected 24h after irradiation. In FRO cells using the same 
treatment schedule, a statistically significant synergy was observed in two combinations (2Gy plus 
7.5 MOIs and 4 Gy plus 5 MOIs) whereas treating FRO cells with 8 Gy and 2 MOIs an additive 
effect was observed (Fig 1A upper panel). 
In contrast, an antagonist effect was observed in FRO cells when infection was followed by 
irradiation, whereas in BHT101-5 cells only 4 Gy combined with 2.5 multiplicity of infection 
(MOIs) showed synergy with this schedule (Fig 1A lower panel ). These data demonstrate that the 
cytotoxicity of dl922-947 is significantly enhanced when cells are irradiated 24h prior to infection. 
 
Viral entry and viral replication analysis   
It has been proposed that radiations could enhance oncolytic activity by increasing viral entry in 
target cells (Anders, et al. 2003). To monitor this step, FRO and BHT101-5 cells were irradiated 
and after 24h infected with a non-replicating reporter adenovirus transducing GFP (AdGFP). After 
additional 48h, GFP emission was evaluated by cytofluorimetric analysis. As shown in Fig.1B, 
irradiation neither increase the percentage of GFP positive cells nor the average green emission of 
individual cells, except for the 2Gy sample, where a slight, albeit significant positive shift in the 
GFP fluorescence was observed in both cell lines. 
Next, a Real-Time PCR assay was performed to evaluate viral replication. FRO and BHT101-5 
cells were irradiated (2-4-5 Gy) and after 24h infected with different MOIs (1-5-10) of dl922-947. 
After an additional 48h, viral genome copies were evaluated by Real Time PCR. This analysis 
revealed that IR induced a significant (* p<0.05) or highly significant(** p<0.005) dose dependent 
increase of viral replication (Fig 1C). 
 
Analysis of cell cycle profile and cell death 
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It has been reported that drugs able to block cells in G2/M or inhibit cytokinesis can enhance the 
effects of oncolytic viruses (Libertini et al. 2011). Irradiation is known to induce a transitory block 
in G2 phase (Lisby, et al. 2004), therefore we analyzed cell cycle profiles to evaluate differences in 
cell cycle phases and timing of cell death. FRO and BHT101-5 cells were irradiated (8 Gy) and 
after 24h infected with 5 MOIs and 1 MOIs of dl922-947 respectively. Starting from 6 hpi (hours 
post infection), cells were collected, stained with propidium iodide and cell cycle analyzed.  
In irradiated cells at 6 hours most of the cells were in G2/M phase, this checkpoint arrest facilitates 
DNA repair and can be observed up to 24h. G2/M accumulation was reversed at 48h after 
irradiation, when the cell cycle profile again resembled that of untreated cells. dl922-947-infected 
cells also accumulated in G2/M phase at 6 hpi. In contrast to the effect of irradiation alone, at 48hpi 
most of the cells were either still in G2/M phase or had become polyploid (Fig 2A). 
Cells that were irradiated 24h prior to infection accumulated in G2/M phase at 6 hpi and, at 48 hpi 
the cell cycle profile was similar to infected rather than untreated cells (Fig 2A). 
We also observed that cultures that had been irradiated prior to infection exhibited an increased 
percentage of cells in the subG1 fraction, which is indicative of DNA fragmentation and cell death 
either by necrosis or apoptosis. To discriminate between the two types of cell death, unfixed cells 
were stained with propidium iodide (PI) and Annexin V. PI can penetrate only in non-vital cells, 
whereas Annexin V binds to living cells with exposed phospholipid phosphatidylserine. The 
exposure of phosphatidylserine is due to the loss of membrane asymmetry and is considered to be 
an early marker of apoptosis. PI single positivity represents necrosis, single Annexin V staining 
early apoptosis, double positivity (annexin V and PI) indicates late apoptosis.  
At 72 hpi, a strong reduction of the percentage of vital cells (to 19%) was observed in the cultures 
that had been irradiated prior to infection. 34% of cells remained alive in cultures that had been 
infected without irradiation, whereas the figure was 70% after irradiation alone, further confirming 
the efficacy of the combined treatment. An increase in annexin V staining, indicative of apoptosis, 
was observed in the combined treatment with respect to single treatments. Late stage cell death was 
also confirmed by double staining for Annexin V and PI or PI only (Fig 2B). Since the increase in 
annexin V positivity suggested the activation of the apoptotic pathway, we analysed Caspase-3 
activation in FRO cells. A decrease of procaspase-3 and an increased activation of caspase 3 was 
observed in the combined treatment with respect to single treatments (Fig 2C). 
 
DNA damage repair system and dl922-947 infection 
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IR induces DNA damage and, after its detection, cellular pathways are activated to halt cell cycle 
progression and repair the damage. Adenoviral replication also induces DNA damage (Touchefeu et 
al. 2011), therefore we analyzed in FRO cells the effects of viral infection, alone or in combination 
with radiation, on DNA damage repair system. 
The MRN complex (composed by Mre11-Rad50-Nbs1) acts as a Double Strand Breaks (DSBs) 
sensor. It localizes to DNA breaks and activates the ATM dependent signaling pathway, which 
coordinates cell cycle arrest and DNA repair (Lavin 2007). Western blot analysis showed a strong 
reduction of Mre11 levels in infected cells, most probably due to protein degradation. The level of 
Mre11 was not altered in irradiated cells; however a similar decrease occurred when cells were 
subject to both irradiation and infection (Fig 3A). Cells treated with virus, alone or in combination 
with IR, also showed a strong activation of ATM at 24 hpi, whereas irradiated cells showed an 
earlier activation (1-3 hpi), reversed to basal levels by 24 hpi (Fig 3A). 
Activation of the checkpoint kinase Chk1, as judged by phosphorylation on Serine 345 (S345) 
(Smith, et al. 2010), showed strong activation at early points (1-6 hours) that also declined to 
control levels by 24 after irradiation. In marked contrast infection with dl922-947 induced strong 
Chk1 S345 phosphorylation 24 hpi both with and without prior irradiation (Fig 3A). 
Histone 2A is phosphorylated at serine 139 in response to DNA double-strand breaks, forming 
γH2AX. γH2AX marks sites of DNA damage recruits proteins involved in DNA repair and is 
widely accepted as a readout of ATM activation (Touchefeu et al. 2011). After DNA repair, histone 
H2AX is dephosphorylated. We therefore evaluated γH2AX levels by cytofluorimetric analysis to 
quantify both the percentage of positive cells (shown in green in Figure 3B) and the mean 
fluorescence value of the positive population (in red). After irradiation γH2AX levels reached a 
maximum after 3h and then progressively decline from 6h to 24h post irradiation, confirming that 
irradiation-induced DNA damage was repaired within this time frame. In infected cells, we 
observed an increase of γH2AX levels at 6 hpi and by 24 hpi most of the cells showed strong 
γH2AX positivity, indicating accumulation of DNA damage (Fig 3B). In cells subject to both 
irradiation and infection, a more rapid increase of γH2AX levels was observed at 6 hpi with respect 
to single treatments. However, at 24 hpi, γH2AX levels remained high as in cells infected with 
dl922-947 alone.  
 
Pharmacological inhibition of ATM activation and dl922-947 infection 
The reduction of Mre11 levels together with ATM phosphorylation suggests that viral genomes are 
recognized as DNA damage in infected cells and that viral function may target the MRN complex to 
prevent DNA repair processes interfering with viral replication.  
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To test whether activation of ATM signaling pathway hampers viral replication, infected cells were 
treated with a pharmacological inhibitor of ATM: KU55933. The specificity of KU55933 has been 
demonstrated by the ablation DNA damage-induced phosphorylation of a range of ATM substrates, 
including p53 and H2AX (Hickson, et al. 2004). 
FRO and BHT101-5 cell lines were infected in combination with two different concentrations of the 
drug (5-10 µM). As shown in Figure 4A, KU55933 treatment potentiates the cytotoxic effects of 
dl922-947. KU55933 treatment alone did not show any cytotoxic effect on both cell lines, therefore 
combination index was not evaluated.   
We also examined the effect of KU55933 on γH2AX formation after infection in FRO cells. As 
shown in Figure 4B, KU55933 almost completely inhibited the H2AX phosphorylation induced by 
the virus up to six hours; however after 24h H2AX phosphorylation levels were similar in infected 
cells with or without KU55933 treatment. This effect can be explained by a rapid drug catabolism, 
or to the activation of ATM-independent mechanism(s) of H2AX phosphorylation. Similar results 
were obtained with BHT101-5 cells (not shown).  
Genome equivalent copies of dl922-947 in cells treated with KU55933 showed that the drug 
significantly enhanced viral replication in a dose dependent manner (Fig. 4C). 
 
IR increases dl922-947 oncolytic activity in vivo  
To evaluate the therapeutic potential of synergism between dl922-947 and ionising radiation, we 
analyzed the effects of the combined treatment on xenograft tumours. 
Athymic mice were inoculated subcutaneously with FRO cells. Two groups were irradiated with a 
single radiation dose (10 Gy) on the tumor volume. A low viral dose (2x10
6
 pfu) was used to better 
visualize the effects of the combined treatment versus dl922-947 infection alone. As shown in Fig. 
5, the combined treatment group showed a significant reduction of tumour growth with respect to 
single treatments and to the untreated group. This difference was first evident by day 11, and by day 
21 growth inhibition was highly statistically significant compared to control group (Fig.5).  
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Discussion 
ATC represents one of the most aggressive human malignancies, with a poor prognosis, and its 
treatment still represents a major challenge (Ain 2000; Smallridge et al. 2009). Currently available 
treatments are considered palliative because of poor response rates and lack of demonstrable 
survival benefits, highlighting the need for more effective treatments (Ain 2000; Smallridge et al. 
2009; Taccaliti, et al. 2012). 
Oncolytic viruses represent a promising approach as anti-cancer therapeutics, however, preclinical 
and clinical studies have demonstrated limited efficacy of oncolytic viruses alone, prompting effort 
to combine them with other anti-cancer agents to improve their antitumor effects (Eager and 
Nemunaitis 2011; Hallden and Portella 2012). We have previously demonstrated that the oncolytic 
adenoviruses dl1520 and dl922-947 are active against ATC in vitro and in vivo(Libertini et al. 2007; 
Libertini et al. 2008). 
Radiotherapy is frequently used for the treatment of ATC (Taccaliti et al. 2012) and we have also 
demonstrated that mutated adenovirus dl1520, despite its limited efficacy, enhances the effects of 
IR against ATC cells and xenograft tumours (Portella et al. 2003). Here, we have analyzed the 
effects of a more potent second generation oncolytic virus, dl922-947, in combination with IR. We 
show that both the cytopathic activity and replication of dl922-947 is significantly enhanced by IR.  
The potentiating effect of irradiation on the cytopathic potential of oncolytic viruses, other than 
dl922-947, has already been demonstrated. However, optimal strategies for combining these 
therapeutic modalities still remain to be established as evidence suggests that they interact in 
complex ways that vary in a cell line- or virus-dependent fashion (Touchefeu et al. 2011). Here we 
have identified the most effective treatment sequence for ATC cells showing that irradiation prior to 
dl922-947 infection results in enhanced viral replication and synergistic cell killing. Irradiation after 
viral infection did not show synergistic or even additive effects. 
It has been proposed that irradiation can increase viral uptake (Zhang, et al. 2003) either by 
enhancing CAR (coxsackie and adenovirus receptor) and integrins expression on cell membranes or 
by modulating the expression of Dynamin 2, an intracellular protein involved in adenoviral 
internalization (Qian, et al. 2005). In a study using a telomerase specific replication selective 
adenovirus (OBP-301), viral infection was shown to result in radiosensitivity in A459 small-cell 
lung cancer cells (Kuroda, et al. 2010). In the same study, a dose dependent increase of adenoviral 
uptake and coxsackie adenovirus receptor expression was also observed. 
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By infecting the cells with an AdGFP virus, we evaluated the effects of IR on viral uptake on ATC 
cells. In contrast to previous studies, we observed only very modest effects of IR on viral uptake. At 
2 Gy a small increase was observed, whereas higher radiation doses do not significantly modify 
viral uptake. Moreover, CAR receptor levels were not modified by IR (data not shown). Differences 
in treatment sequence, virus and cell lines may explain the discrepancies with other studies.  
Despite this, we did observe a significant increase in viral replication in irradiated cells. Existing 
data regarding the effect of radiation on viral replication are conflicting. Enhanced viral replication 
following IR has been reported in some studies (Advani, et al. 1998; Bieler, et al. 2008; Liu, et al. 
2007), but not in others (Geoerger, et al. 2003; Lamfers, et al. 2002), suggesting that increased viral 
replication is not an absolute prerequisite for enhanced cell killing (Geoerger et al. 2003; Lamfers et 
al. 2002). 
Subversion of the host cell cycle is an important feature of adenoviral infection. The expression of 
E1A gene products drives an unscheduled DNA synthesis followed by an abortive cytokinesis, thus 
inducing G2 accumulation (Davy and Doorbar 2007). The potential benefit of the G2 accumulation 
is represented by the pseudo S phase which maintains host cells in a replicative state (Davy and 
Doorbar 2007; Nichols, et al. 2009). It has been proposed that drugs blocking cells in G2 phase 
could enhance the effects of oncolytic viruses. Indeed, we have demonstrated that the inhibitor of 
the mitotic kinase Aurora B, AZD1152, enhances the effects of dl922-947 by inducing a G2 arrest 
(Libertini et al. 2011). Accordingly, the accumulation in G2 phase induced by radiation likely 
enhances the cytopathic effects of dl922-947. This hypothesis is further supported by the 
observation that infection followed by irradiation did not potentiate cell killing or viral replication 
(data not shown).  
We have analyzed the effects of the different treatments, showing an increase of cells in sub G1 
phase and a sharp reduction in the number of vital cells subject to irradiation followed by infection 
compared to either treatment alone. Double staining with Annexin V and propidium iodide 
confirmed that the combination treatment induces a cell death pathway with features of apoptosis. 
Irradiation and infection alone also triggered apoptosis, although with lesser efficiency. Activation 
of an apoptotic like cell death has been previously reported in cells infected by dl922-947 (Baird, et 
al. 2008; Libertini et al. 2011). 
It is known that the cells respond to adenovirus infection by activating a classical DNA damage 
response (Lilley, et al. 2007; Nichols et al. 2009; Touchefeu et al. 2011). It has been proposed that 
the prolonged S-phase induced by the virus could resemble the cellular environment occurring in 
response to replication associated DNA damage. Since IR is also known to induce activation of the 
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DNA damage signaling pathway, we analyzed the effects of the combined treatment on key 
components of DSB repair signaling pathway.  
ATM, ATR and DNA-PK (double strand DNA-activated protein kinase) are considered the initial 
responders to cellular DNA damage (Botta et al. 2012; Botta et al. 2010; Oberg et al. 2010; Yong et 
al. 2009), whilst the ultimate step is phosphorylation of histone H2AX leading to recruitment of 
multiple DNA processing and repair enzymes. In particular the MRN protein complex, composed of 
Mre11-Rad50-Nbs1, localizes to DNA breaks, contributing to DNA repair.  
After the infection with dl922-947, a strong reduction of Mre11 protein levels were observed, likely 
due to degradation induced by viral proteins (Nichols et al. 2009). Infection led to an accumulation 
of γH2AX positive cells at 24 hpi, indicating the persistence of unrepaired DNA, in agreement with 
previous studies (Nichols et al. 2009; Touchefeu et al. 2011). 
In cells subject to irradiation prior to infection, a similar pattern was observed, although a more 
rapid increase of γH2AX positive cells at 6 hpi was also seen, probably due to more rapid IR-
induced DNA damage combined with that induced by viral infection at later times. Interestingly, it 
has been proposed that γH2AX could function as a determinant of repair/survival versus apoptotic 
responses to DNA damage and its increase can correlate with apoptosis in response to DNA 
damaging agents (Cook, et al. 2009). 
ATM and Chk1 activation was observed in infected cells or undergoing the combined treatment. 
This observation is in contrast with other studies showing no activation of ATM after infection with 
telomerase driven adenovirus OBP301 (Kuroda et al. 2010). It is possible that dl922-947 is not able 
to fully suppress the early events in DNA damage signaling, as MRN complex degradation may not 
in itself be sufficient to preclude ATM and ATR kinase activation, as previously reported (Nichols 
et al. 2009). 
It has been hypothesized that cellular DNA repair machinery can function as an obstacle to 
adenovirus infection. E4orf3 and E4orf6 interact with the adenovirus E1B55K protein forming 
complexes that degrade or delocalize the MRN complex and interfere with the DNA damage repair 
system. Therefore, we have hypothesized that a block of DNA damage signaling could enhance the 
replication and toxicity of dl922-947. Indeed, a pharmacological inhibitor of ATM, KU55933, 
significantly increased the replication and cytopathic potency of dl922-947 confirming that the 
DNA damage response restrains the cell killing of this oncolytic virus. 
Finally, we confirmed the therapeutic potential of combining irradiation with dl922-947 infection 
using xenografts formed using ATC cells. Although the subcutaneous implant of neoplastic cells do 
not fully reproduce the stromal response and the pattern of spread of the neoplastic cells to lymph 
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nodes and other metastatic sites as in orthotopic models, the data obtained clearly demonstrate the 
efficacy of the combination therapy in vivo. 
A majority of patients with ATC die from aggressive local regional disease, primarily from upper 
airway respiratory obstruction (Taccaliti et al. 2012). For this reason, radiotherapy has been used to 
control local growth, evolving from palliation on to preoperative or/and postoperative therapy to 
prolong survival.  
Given the importance of radiotherapy in the control of ATC, our results suggest that dl922-947 
could be combined with this modality in order to improve local control and offer the possibilities of 
new clinical trials for this intractable disease. 
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Figure legends 
Figure 1 
IR enhances the cytophatic effects of dl922-947 
A. Combination index of FRO and BHT101-5 cells were irradiated and after 24h infected (upper 
panel) at different MOIs of dl922-947 or vice versa (lower panel). A synergistic effect was observed 
only in cells infected 24h after irradiation (CI<1). 
B. FRO and BHTH101-5 were irradiated (2-4-8Gy) and after 24h infected with 25 MOIs of 
AdGFP. The histogram on the left shows the percentage of GFP positive cells; whereas on the right 
GFP emission is reported. The percentage of GFP positive cells and GFP emission, with the 
exception of 2 Gy, were not increased in irradiated cells. The data are the mean of three different 
experiments. (*p<0.01) 
C. Real Time PCR genome equivalent analysis. FRO and BHTH101-5 cells were irradiated (2-4-5 
Gy) and then infected with dl922-947, (1-5-10 MOIs). Irradiated cells showed significant or highly 
significant differences in viral replication levels with respect to non irradiated cells. The data are the 
mean of three different experiments. (*p<0.05; **p<0.005) 
 
Figure 2 
IR increases the cell death induced by dl922-947 
A. Cell cycle analysis of FRO and BHT101-5 cells. SubG1, G2/M and polyploidy are represented 
by histograms. IR (8 Gy) induced an accumulation in G2 phase up to 24h post irradiation. At 48h 
the block is recovered. Infected cells (5MOIs) or cells undergoing the combined treatments show a 
G2 accumulation at 24 hpi. At 48 hpi, the block is not reversed and most of the cells show 
polyploidy. The percentage of cells in sub-G1 phase was increased by the combined treatment. 
The data are the mean of three different experiments. 
B. Annexin V-FITC/PI staining. FRO cells were irradiated with 8 Gy and after 24h infected with 5 
MOIs of dl922-947 for 72h. Apoptotic cells are positive for Annexin V or double positive for 
Annexin V and PI (Right panels); Necrotic cells positive for PI only (upper left panel); vital cells 
(lower left panel). The combined treatment increases the percentage of apoptotic cells (44.2%) with 
respect to single treatments (32.6% infection alone; 12% irradiation alone). 
Tables show the percentage of the different stained population after 24 and 48h of treatment.  
Data are the representation of three different experiments. 
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C. Western blot analysis of procaspase 3 and caspase3 levels. Data are the representation of three 
different experiments. 
 
Figure 3   
dl922-947 infection activates the DNA damage signaling pathway and impairs DNA damage repair 
A. Western blot analysis of pATM (Serine 1981), pChk1(serine 345), Mre11 levels . 
B. Fixed cells stained with antibody for γH2AX and PI were analyzed using FACS. FRO cells were 
irradiated (8Gy) and infected with dl922-947 (5 MOIs) for 1-3-6-24h. IR increase dl922-947-
induced γH2AX levels already at 1h after infection. 
 
Figure 4   
ATM inhibitor, KU55933, enhances the cytopatic effects of dl922-947 
A. FRO and BHT101-5 cells were treated with KU55933 (5-10 µM) and infected at increasing MOIs 
(1-2.5-5-10 for FRO cells and 0.5-1-2.5-5 for BHT101-5 cells). Survival was evaluated after 7 days 
by sulforhodamine B method.  
Data are the mean of three different experiments.  
B. FRO cells were treated with KU55933 (5µM) and infected with dl922-947 (5 MOIs) for 3-6-24h. 
Fixed cells stained with antibody for γH2AX and PI were analyzed using FACS. Percentage of 
γH2AX positive cells (green) and median of FITC emission (red) are shown. Treatment with the 
ATM inhibitor reduces dl922-947-induced γH2AX levels, particularly as median of FITC emission.  
Data are the representation of three different experiments. 
C. Real Time PCR genome equivalent analysis. ATC cells were treated with KU55933(0.5-1-5 µM) 
and then infected with dl922-947 (5-10 MOIs). A highly significant difference in viral replication 
levels was observed with respect to cells not treated with KU55933, (*p<0.005; **p<0.0001). 
The data are the mean of three different experiments. 
 
Figure 5  
The combined treatment (IR and dl922-947) reduces tumour growth  
The difference between animals receiving the combined treatment and single treatment groups and 
control group becomes statistically significant (*p<0.05) from day 11. At day 21, a highly 
significant difference (**p<0.005) was observed. 
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IR enhances the cytophatic effects of dl922-947  
A. Combination index of FRO and BHT101-5 cells were irradiated and after 24h infected (upper panel) at 
different MOIs of dl922-947 or vice versa (lower panel). A synergistic effect was observed only in cells 
infected 24h after irradiation (CI<1).  
B. FRO and BHTH101-5 were irradiated (2-4-8Gy) and after 24h infected with 25 MOIs of AdGFP. The 
histogram on the left shows the percentage of GFP positive cells; whereas on the right GFP emission is 
reported. The percentage of GFP positive cells and GFP emission, with the exception of 2 Gy, were not 
increased in irradiated cells. The data are the mean of three different experiments. (*p<0.01)  
C. Real Time PCR genome equivalent analysis. FRO and BHTH101-5 cells were irradiated (2-4-5 Gy) and 
then infected with dl922-947, (1-5-10 MOIs). Irradiated cells showed significant or highly significant 
differences in viral replication levels with respect to non irradiated cells. The data are the mean of three 
different experiments. (*p<0.05; **p<0.005)  
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IR increases the cell death induced by dl922-947  
A. Cell cycle analysis of FRO and BHT101-5 cells. SubG1, G2/M and polyploidy are represented by 
histograms. IR (8 Gy) induced an accumulation in G2 phase up to 24h post irradiation. At 48h the block is 
recovered. Infected cells (5MOIs) or cells undergoing the combined treatments show a G2 accumulation at 
24 hpi. At 48 hpi, the block is not reversed and most of the cells show polyploidy. The percentage of cells in 
sub-G1 phase was increased by the combined treatment.  
The data are the mean of three different experiments.  
B. Annexin V-FITC/PI staining. FRO cells were irradiated with 8 Gy and after 24h infected with 5 MOIs of 
dl922-947 for 72h. Apoptotic cells are positive for Annexin V or double positive for Annexin V and PI (Right 
panels); Necrotic cells positive for PI only (upper left panel); vital cells (lower left panel). The combined 
treatment increases the percentage of apoptotic cells (44.2%) with respect to single treatments (32.6% 
infection alone; 12% irradiation alone).  
Tables show the percentage of the different stained population after 24 and 48h of treatment.  
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Data are the representation of three different experiments.  
C. Western blot analysis of procaspase 3 and caspase3 levels. Data are the representation of three different 
experiments.  
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dl922-947 infection activates the DNA damage signaling pathway and impairs DNA damage repair  
A. Western blot analysis of pATM (Serine 1981), pChk1(serine 345), Mre11 levels .  
B. Fixed cells stained with antibody for γH2AX and PI were analyzed using FACS. FRO cells were irradiated 
(8Gy) and infected with dl922-947 (5 MOIs) for 1-3-6-24h. IR increase dl922-947-induced γH2AX levels 
already at 1h after infection.  
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ATM inhibitor, KU55933, enhances the cytopatic effects of dl922-947  
A. FRO and BHT101-5 cells were treated with KU55933 (5-10 µM) and infected at increasing MOIs (1-2.5-5-
10 for FRO cells and 0.5-1-2.5-5 for BHT101-5 cells). Survival was evaluated after 7 days by sulforhodamine 
B method.  
Data are the mean of three different experiments.  
B. FRO cells were treated with KU55933 (5µM) and infected with dl922-947 (5 MOIs) for 3-6-24h. Fixed cells 
stained with antibody for γH2AX and PI were analyzed using FACS. Percentage of γH2AX positive cells 
(green) and median of FITC emission (red) are shown. Treatment with the ATM inhibitor reduces dl922-947-
induced γH2AX levels, particularly as median of FITC emission.  
Data are the representation of three different experiments.  
C. Real Time PCR genome equivalent analysis. ATC cells were treated with KU55933(0.5-1-5 µM) and then 
infected with dl922-947 (5-10 MOIs). A highly significant difference in viral replication levels was observed 
with respect to cells not treated with KU55933, (*p<0.005; **p<0.0001).  
The data are the mean of three different experiments.  
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The combined treatment (IR and dl922-947) reduces tumour growth  
The difference between animals receiving the combined treatment and single treatment groups and control 
group becomes statistically significant (*p<0.05) from day 11. At day 21, a highly significant difference 
(**p<0.005) was observed.  
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Inhibition of Autophagy Enhances the Effects
of E1A-Defective Oncolytic Adenovirus dl922–947
Against Glioma Cells In Vitro and In Vivo
Ginevra Botta,1 Carmela Passaro,1 Silvana Libertini,1,* Antonella Abagnale,1 Sara Barbato,1
Angela Serena Maione,1 Gunnel Hallden,2 Francesco Beguinot,1 Pietro Formisano,1 and Giuseppe Portella1
Abstract
Oncolytic viruses represent a novel therapeutic approach for aggressive tumors, such as glioblastoma multi-
forme, which are resistant to available treatments. Autophagy has been observed in cells infected with oncolytic
viruses; however, its role in cell death/survival is unclear. To elucidate the potential therapeutic use of au-
tophagy modulators in association with viral therapy, we analyzed autophagy induction in human glioma cell
lines U373MG and U87MG infected with the oncolytic adenovirus dl922–947. dl922–947 infection triggered
an autophagic cellular response, as shown by the development of acidic vesicular organelles, LC3-I/LC3-II
conversion, and reduction of p62 levels. However, on infection, the Akt/mTOR/p70s6k pathway, which neg-
atively regulates autophagy, was activated, whereas the ERK1/2 pathway, a positive regulator of autophagy,
was inhibited. Accordingly, MEK inhibition by PD98059 sensitized glioma cells to dl922–947 effects, whereas
autophagy induction by rapamycin protected cells from dl922–947-induced death. Treatment with two inhibitors
of autophagy, chloroquine and 3-methyladenine, increased the cytotoxic effects of dl922–947 in vitro. In vivo, the
growth of U87MG-induced xenografts was further reduced by adding chloroquine to the dl922–947 treatment. In
conclusion, autophagy acts as a survival response in glioma cells infected with dl922–947, thus suggesting
autophagy inhibitors as adjuvant/neoadjuvant drugs in oncolytic virus-based treatments.
Introduction
Malignant glioma of astrocytic origin or glioblastomamultiforme (GBM) is one of the most aggressive human
tumors (Furnari et al., 2007; Brandes et al., 2008), with a me-
dian survival time of about 12–15 months. The standard
treatment protocol for newly diagnosed GBM includes sur-
gical resection, radiotherapy, and chemotherapy (Furnari
et al., 2007; Brandes et al., 2008). However, this therapeutic
approach has achieved only a moderate increase in survival
(Ahmadi et al., 2009), highlighting the need for the develop-
ment of novel and more effective treatments.
Conditionally replicating oncolytic viruses (OVs) repre-
sent a promising approach for the treatment of cancer, and
the feasibility and safety of this therapeutic strategy in glio-
blastoma patients have been demonstrated in previous
studies (Haseley et al., 2009). dl922–947 is a replication-
selective oncolytic adenoviral mutant, harboring a 24-bp
deletion in E1A conserved region-2 (CR2), that is responsible
for binding and inactivation of the retinoblastoma protein
pRb (Heise et al., 2000), which regulates the G1-to-S phase
transition. Thus, dl922–947 virus is unable to induce G1-to-S
phase transition in normal cells, but can efficiently replicate in
cells with an abnormal G1–S checkpoint. Previous studies
have confirmed the efficacy of E1A CR2-deleted adeno-
viruses, such as D24 (Fueyo et al., 2000; Jiang et al., 2007), for
glioma cells, and we have demonstrated that dl922–947 exerts
antineoplastic activity against the glioma cell lines U373MG
and U343MG (Botta et al., 2010). A phase I clinical trial for
the use of an E1A CR2-deleted mutant (Ad5-D24RGD) in
recurrent malignant gliomas has been completed (http://
clinicaltrialsfeeds.org/clinical-trials/show/NCT00805376).
Although the efficacy and safety of OVs have been clearly
demonstrated in preclinical and clinical studies, most of the
molecular and/or biochemical pathways activated in cancer
cells, including the cell death mechanisms, are not fully un-
derstood. A better understanding of such mechanisms would
be advantageous for future selection of novel drugs or
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treatments to further enhance the efficacy of oncolytic viru-
ses. In various studies it has been shown that OVs activate
the autophagic machinery in some cancer cells (Ito et al.,
2006; Jiang et al., 2007; Baird et al., 2008; Tyler et al., 2009).
Autophagy is a catabolic process whereby cytoplasm and
cellular organelles are degraded through lysosomal ma-
chinery, allowing amino acid and energy recycling (Mi-
zushima, 2007). It is well known that autophagy provides an
alternative energy source, thus representing a temporary
survival mechanism under stressful conditions. However, it
has also been reported that autophagy plays an active role in
cell death (Baehrecke, 2005; Loos and Engelbrecht, 2009).
Here we show that, on infection with the oncolytic virus
dl922–947, formation of acidic vesicular organelles and the
conversion of the cytosolic form of microtubule-associated
protein-1 light chain-3 to the autophagosomal membrane-
associated form (LC3-I/LC3-II) occur, indicative of a cel-
lular autophagic response to viral infection.
Regulation of autophagy requires multiple signaling
pathways (Meijer and Codogno, 2004). Akt/mTOR/p70s6k
is the main pathway involved in the negative regulation of
autophagy (Blommaart et al., 1995; Yang et al., 2005). Class I
phosphatidylinositol-3-phosphate kinase (PI3K) is activated
by ligand binding to growth factor receptors. PI3K activates
the downstream target Akt, leading to activation of mam-
malian target of rapamycin (mTOR) (Dı´az-Troya et al., 2008).
TOR is a serine/threonine kinase that negatively affects the
autophagic process, which is achieved by controlling trans-
lation and transcription or by either directly or indirectly
affecting the Atg (autophagy-related genes) proteins (Dı´az-
Troya et al., 2008). p70 S6 kinase (p70s6k) is considered a
candidate among the substrates of mTOR and in the control
of autophagy downstream of mTOR (Blommaart et al., 1995).
In the presence of amino acids, mTOR promotes phosphor-
ylation of S6 through activation of p70s6k, thus facilitating
the translation initiation of mRNAs (Dı´az-Troya et al., 2008).
On the other hand, the extracellular-signal regulated kinase-
1/2 (ERK1/2) pathway has been described as a positive
regulator pathway of autophagy (Pattingre et al., 2003).
Surprisingly, we found that, despite the autophagy acti-
vation in dl922–947-infected cells, viral infection activates the
main negative regulator of autophagy—the Akt/mTOR/
p70s6k pathway—and inhibits the positive regulator, the
ERK1/2 pathway. In line with this, viral cytotoxicity is de-
creased by rapamycin (an mTOR inhibitor) and increased by
ERK1/2 inhibitor PD98059, as well as by specific inhibitors
of autophagy (3-methyladenine and chloroquine) or genetic
tools such as Atg5 small hairpin RNA (shRNA). Although
these data seem to contrast with previous results suggesting
autophagy as a cell death mechanism induced by oncolytic
viruses in glioma cells (Ito et al., 2006), our results led us to
speculate that autophagy might play a survival/defensive
role in glioma cells infected with dl922–947. Consistently, we
demonstrated that chloroquine treatment of athymic mice
bearing glioma tumor xenografts enhances the effects of
dl922–947 in reducing tumor growth.
Materials and Methods
Cell lines and reagents
Human glioma cell lines U373MG and U87MG were
purchased from the American Type Culture Collection
(Manassas, VA) and grown as described (Botta et al.,
2010).
Acridine orange, 3-methyladenine (3-MA), PD98059, and
rapamycin were purchased from Sigma-Aldrich (St. Louis,
MO). Chloroquine (CQ) was purchased from Fluka (Buchs,
Switzerland).
Preparation of adenoviruses, infection,
and viability assay
dl922–947 is a second-generation adenoviral mutant that
has a 24-bp deletion in E1A conserved region-2 (CR2).
AdGFP is a nonreplicating E1A-deleted adenovirus encoding
green fluorescent protein. dl312 is a nonreplicating adeno-
virus (DE1A, DE3B) (Cheong et al., 2008). Viral stocks were
expanded, purified, and stored as previously reported (Botta
et al., 2010), and a plaque-forming units (PFU) assay was
performed on HEK-293 cells to determine viral titer.
To evaluate the dl922–947 cytotoxic effect, 1 · 103 cells
were seeded in 96-well plates. After 24 hr, the cells were
treated with 3-MA (1 mM) or CQ (10 lM) for 2 hr and then
infected. After 7 days, the cells were fixed with 10% tri-
chloroacetic acid (TCA), stained with 0.4% sulforhodamine B
in 1% acetic acid, and solubilized as previously reported
(Libertini et al., 2011). Cell death rates, expressed as a per-
centage of treated cells, were calculated. Dose–response
curves were generated to calculate the concentration of each
agent required to kill 50% of cells (median lethal dose, LD50);
untreated cells or cells treated with single agents were used
as a control.
Quantification of acidic vesicular organelles
with acridine orange
The development of acidic vesicular organelles is a par-
ticular feature of autophagy. The cytoplasm and nucleoli of
acridine orange-stained cells fluoresce bright green and dim
red, respectively, whereas acidic compartments fluoresce
bright red (Paglin et al., 2001). To assess autophagy in
U373MG and U87MG cells, the acidic compartment was
quantified by supravital acridine orange staining. Treated
cells were trypsinized and stained with acridine orange
(1.0 lg/ml) for 15 min at 37C. Data were collected on a
CyAn flow cytometer and analyzed using Summit software
version 4.3 (both from Dako Cytomation, now Beckman
Coulter, Miami, FL).
Generation of stable clones
To investigate autophagy induction, overexpression of
GFP-tagged LC3 was induced in U373MG cells (Kabeya
et al., 2000). The LC3 expression vector (pCAG-LC3) was
kindly provided by N. Mizushima and T. Yoshimori (Osaka
University, Suita, Japan). To obtain pGFP-LC3, LC3 cDNA
was inserted into the BglII and EcoRI sites of pEGFP-C1, a
GFP fusion protein expression vector (Clontech, Mountain
View, CA) (Kabeya et al., 2000). Stable expression of GFP-
LC3 cDNA in U373MG cells (U373 GFP-LC3) was accom-
plished by the Lipofectamine (Invitrogen, Carlsbad, CA)
method, in accordance with the manufacturer’s instructions.
Cells were cultured in 60-mm dishes (Corning, Corning, NY)
and incubated in serum-free Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 5lg of cDNA and
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15 ll of Lipofectamine reagent. After 5 hr, DMEM supple-
mented with 20% fetal bovine serum was added and 1 day
later was replaced with DMEM–10% serum. At 48 hr after
the medium change, cells were selected in medium con-
taining GIBCO G418 (400 mg/ml; Invitrogen) and G418-
resistant clones were obtained. Expression of GFP-LC3 in the
selected clones was evaluated by Western blot analysis using
anti-GFP antibody.
To stably inhibit the expression of the Atg5 gene, APG5
shRNA (sc-41445-sh) and control shRNA (sc-108060) plas-
mids (Santa Cruz Biotechnology, Santa Cruz, CA) were
transfected/selected in U373MG and U87MG cell lines as
described previously.
Analysis of LC3 localization
by immunofluorescence staining
U373 GFP-LC3 cells were seeded in 24-well dishes. After
treatment, cells were fixed with 4% paraformaldehyde for
15 min at room temperature, washed three times with
phosphate-buffered saline (PBS), permeabilized for 10 min
with PBS containing 0.5% Triton X-100, and then washed
three times with PBS. The cells were blocked with bovine
serum albumin (BSA) blotting buffer (1% BSA in PBS) for
30 min and then incubated with BSA blotting buffer plus
primary antibody overnight at 4C (mouse monoclonal anti-
hexon, diluted 1:50; US Biological, Swampscott, MA). After
washing three times with PBS, cells were incubated with
rhodamine-conjugated anti-mouse secondary antibody
( Jackson ImmunoResearch, West Grove, PA). Images were
acquired with an LSM510 inverted confocal microscope
(Zeiss, Oberkochen, Germany), using a · 40 oil objective and
processed with LSM software (Zeiss).
Western blot analysis and antibodies
Protein extraction and tumor tissue homogenization were
performed as previously described (Botta et al., 2010; Oriente
et al., 2011).
Total homogenates were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) under
reducing conditions. Membranes were incubated overnight
with the following primary antibodies: LC3-I/II (ab51520, di-
luted 1:3000) and caspase-3 (ab13585, diluted 1:500) from
Abcam (Cambridge, UK); p62 (#5114, diluted 1:1000), p-
ERK1/2 (#9101S, diluted 1:1000), p-Akt (#9271, diluted 1:1000),
and p-p70s6k (#9205S, diluted 1:500), from Cell Signaling
(Danvers, MA); Atg5 (sc-8666, diluted 1:500), ERK1/2 (sc-93-
G, diluted 1:1000), and b-actin (sc-10731, diluted 1:2000) from
Santa Cruz Biotechnology; and Akt (#28745, diluted 1:1000)
from Upstate Biotechnology (Billerica, MA).
Quantitative real-time PCR of adenovirus
Twenty-four, 48, and 72 hr after infection, viral genomes
were collected from the cell medium, using a QIAamp DNA
mini kit (Qiagen, Valencia, CA), and then quantified by real-
time PCR, using the following primers: 5¢-GCC ACC GAG
ACG TAC TTC AGC CTG-3¢ (upstream primer) and 5¢-TTG
TAC GAG TAC GCG GTA TCC T-3¢ (downstream primer)
for the amplification of a 143-bp sequence of the viral hexon
gene. Serial dilutions of dl922–947 were used to construct a
standard curve for quantification.
In vivo antitumor activity and statistical analysis
CD-I athymic mice were obtained from Charles River
(Wilmington, MA), and all experiments were carried out
with 6-week-old females. Twenty days postinjection with
U87MG cells (5· 106), 80 mice with similar tumor size were
randomized into four groups: untreated, treated with CQ,
treated with dl922–947, or treated with both. CQ (45 mg/kg)
was administered intraperitoneally every third day. A viral
dose (2· 106 PFU) was administered three times a week by
intratumoral injection to avoid any first-pass effect (Libertini
et al., 2007, 2008, 2011). Saline solution was administered to
the control groups. Tumor diameters were measured with
calipers and tumor volume (V) was calculated by the for-
mula for a rotational ellipsoid: V =A ·B2/2 (A, axial diame-
ter; B, rotational diameter). The experiment was terminated
when tumors reached 1 cm3 in volume and/or symptomatic
tumor ulceration occurred. Statistical analysis were done by
ANOVA (analysis of variance) and the Bonferroni post hoc
test, using commercial software (Prism 4; GraphPad Soft-
ware, San Diego, CA). Differences in the rate of tumor
growth in mice were assessed for each time point of the
observation period.
Results
Induction of autophagy in malignant glioma cells
by dl922–947
First, we evaluated the cytotoxic effects of dl922–947 in
U87MG and U373MG glioma cells, confirming its efficacy.
The U373MG cell line is more sensitive to dl922–947, with an
LD50 of 0.008 PFU/cell, compared with the U87MG LD50 at
0.09 PFU/cell (Fig. 1A).
Next, we evaluated the activation of autophagy in glioma
cells infected with dl922–947. To this end, we analyzed the
formation of acidic vesicular organelles (AVOs), a particular
feature of autophagy, after infection with dl922–947. Quan-
tification of AVOs in U373MG and U87MG cells was per-
formed by acridine orange supravital cell staining. U373MG
and U87MG cells were infected at 1, 5, and 10 multiplicities
of infection (MOIs) with dl922–947 and acridine orange vital
staining was performed 72 hr postinfection. FACS analysis
showed an increase in bright red fluorescence in infected
cells, in a MOI-dependent manner, up to 18% (U373MG) or
up to 14% (U87MG). Untreated cells exhibited mainly green
fluorescence (Fig. 1B) as the cells were infected with the
nonreplicating control adenovirus, dl312 (data not shown).
This indicates an accumulation of AVOs in glioma cells in-
fected with dl922–947.
In amino acid starvation-induced autophagy, the micro-
tubule-associated protein-1 light chain-3, LC3-I, is converted
to LC3-II through some ubiquitination-like reactions. LC3-I is
a cytosolic protein, whereas LC3-II is a protein membrane
tightly attached to preautophagosomal (PAS) and autopha-
gosomal membrane structures. The amount of LC3-II reflects
the abundance of autophagosomes and variations in the ratio
of LC3-II to LC3-I are indicative of autophagy induction
(Kabeya et al., 2000). LC3-I/LC3-II conversion was ana-
lyzed by Western blotting 72 hr after infection of U373MG
and U87MG cells with dl922–947. An increase in LC3-II levels
was observed in infected U373MG and U87MG cells, in an
MOI-dependent manner (Fig. 1C).
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On autophagy activation, LC3-II is recruited to autopha-
gosome membranes; therefore we decided to monitor LC3
localization during dl922–947 infection. U373MG clones ex-
pressing LC3 fused to green fluorescent protein were gen-
erated (U373 GFP-LC3) by stable transfection and GFP-LC3
tracked by immunofluorescence.
In untreated U373 GFP-LC3 cells or in cells infected with
the nonreplicating adenoviral mutant dl312, a diffuse and
mostly cytosolic distribution of fluorescence was observed
(Fig. 1E). A less diffuse and more punctate pattern was ob-
served 72 hr after infection with 0.1 PFU of dl922–947, indi-
cating that LC3-II is recruited to the autophagosomal
membranes; cells were costained with anti-hexon antibody
as a control for viral infection. As a positive control, U373
GFP-LC3 cells were treated with the autophagy inducer ra-
pamycin, showing the typical LC3-II localization pattern.
The accumulation of LC3-II could be due to autophagy
flux or to interference with autophagosomal/lysosomal
function. To discriminate between the two options, we
evaluated the levels of the specific autophagy substrate p62/
SQSTM1. During autophagy, p62 levels are reduced
whereas, in the absence of autophagy, p62 levels are
unmodified (Komatsu and Ichimura, 2010). As shown in Fig
1C, a clear decrease in p62 levels was observed, demon-
strating that in dl922–947-infected cells the autophagic flux is
enhanced.
Glioma cells were infected with a nonreplicating ade-
novirus expressing green fluorescence protein (AdGFP).
AdGFP infection did not induce changes in LC3-II/LC3-I
ratio or in p62 levels (Fig. 1D). This observation confirms that
autophagy is a specific a feature occurring in infected cells in
response to dl922–947 replication.
Taken together, these data demonstrate that glioma
cells infected with the dl922–947 virus activate autophagic
processes.
dl922–947 infection modulates autophagic signaling
pathways and its effects are modified by specific
pharmacological inhibitors
We evaluated the effects of dl922–947 infection on the
Akt/mTOR/p70s6k and ERK1/2 pathways, which are,
FIG. 1. dl922–947 induces cell death and autophagy in malignant glioma cells. (A) U373MG and U87MG cells were infected
at the indicated MOIs and cell survival was analyzed 7 days postinfection. The percent survival rates of cells exposed to the
virus were calculated by assuming the survival rate of untreated cells to be 100%. (B) U373MG and U87MG cells were
infected with dl922–947 for 72 hr, stained with acridine orange for 15 min, and then subjected to flow cytometric analysis.
Red-positive cells in upper quadrants were considered to be acidic vesicular organelles (AVOs) and the calculated per-
centages are shown. (C and D) Cells were infected with dl922–947 (C and D) or with AdGFP (D) and LC3-I/LC3-II
conversion and p62 expression were analyzed after 72 hr. Numbers represent the ratio of the values obtained by densito-
metric analysis of LC3-II and LC3-I immunoblots. b-Actin was used as a loading control. (E) Immunofluorescence assay of
stable clones of U373MG cells expressing fusion protein GFP-LC3 (U373 LC3-GFP) with anti-hexon antibody (red). Cells were
infected with dl922–947 (0.1 PFU/cell) or dl312 (0.1 PFU/cell), or were treated with rapamycin (500 nM) for 72 hr, and green
and red fluorescence was analyzed by confocal microscope. Data shown are representative of three independent experiments.
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respectively, negative and positive regulatory pathways of
autophagy.
U373MG and U87MG cells were infected with dl922–
947 in a dose–response experiment. Phosphorylation of
p70s6k and Akt increased in a dose-dependent manner
(Fig. 2A) in both cell lines, indicating activation of the
negative regulatory pathway. Conversely, ERK1/2 phos-
phorylation was reduced on infection with dl922–947 in a
dose-dependent manner (Fig. 2A), indicating inhibition
of the positive regulatory pathway. AdGFP infection
did not induce any of these effects (Fig. 2B). To better
evaluate the role of ERK1/2 phosphorylation, a time-
course experiment was performed, confirming a dose- and
time-dependent reduction of ERK1/2 phosphorylation
(Fig. 2C).
These data suggested to us that dl922–947 acts on
autophagic pathways with compensatory mechanisms to
counterbalance the cellular response. To clarify the role of
the ERK1/2 pathway on the autophagic cellular response
in infection, glioma cells were infected with dl922–947 in
the presence of MEK-1 (MAPK [mitogen-activated pro-
tein kinase]/ERK kinase-1) inhibitor PD98059. An inhib-
itory dose of 25 lM was used for all the experiments.
PD98059 enhanced dl922–947-induced cytotoxicity, lead-
ing to a significant reduction of LD50 values in both cell
lines: from 0.008 to 0.001 PFU/cell in U373MG cells, and
from 0.14 to 0.05 PFU/cell in U87MG cells (Fig. 3A). This
observation confirms that blockage of the autophagic
positive regulatory pathway favors viral cell-killing ac-
tivity. Moreover, the combined treatment led to a further
reduction of ERK-1/2 phosphorylation (Fig. 3B), along
with a reduction on LC3-I/LC3-II conversion; con-
versely, in uninfected cells, the drug did not modify the
LC3-II/LC3-I ratio (Fig. 3B).
To investigate the role of the Akt/mTOR/p70s6k pathway
in dl922–947 infection, glioma cells were treated with the
mTOR inhibitor rapamycin, a well-known autophagy in-
ducer (Meijer and Codogno, 2004), and then infected with
FIG. 2. Autophagy signaling path-
ways are modulated in response to
dl922–947 infection in glioma cells. (A)
U373MG and U87MG cells were in-
fected with dl922–947 at the indicated
MOIs for 72 hr. (B) Cells were infected
with dl922–947 or AdGFP at the indi-
cated MOIs for 72 hr. Expression of
total and phosphorylated (p-) p70s6k,
Akt, and ERK1/2 was analyzed by
Western blot, using b-actin as a load-
ing control. (C) U373MG and U87MG
cells were infected with dl922–947 (1
PFU/cell for U373MG and 5 PFU/cell
for U87MG). Levels of phosphorylated
(p-) and total ERK1/2 was analyzed in
a time course by Western blot. Results
shown are representative of three in-
dependent experiments.
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dl922–947. Treatment with rapamycin led to a reversion of
p70s6k phosphorylation induced by the virus, paralleled
by an increase in the LC3-II/LC3-I ratio (Fig. 4A). In both
cell lines, rapamycin treatment led to a significant re-
duction of viral cytotoxicity, with an increase in LD50, 42-
fold for U373MG and 23-fold for U87MG (Fig. 4B). These
results demonstrate that autophagy acts as a survival
mechanism in glioma cells infected with dl922–947 and
that the attenuation of autophagic response could increase
viral cytotoxicity.
FIG. 3. Inhibition of the
ERK1/2 pathway inhibits au-
tophagy and enhances dl922–
947-induced cytotoxicity. (A)
Cells were treated with
PD98059 (25lM) and after
2 hr were infected with dl922–
947 at the indicated MOIs.
Cell survival was evaluated
after 7 days. (B) U373MG and
U87MG cells were treated
with PD98059 (25lM) for 2 hr
and then infected with dl922–
947 at the indicated MOIs.
Expression of total and phos-
phorylated (p)-ERK1/2, and
of LC3-I and LC3-II, were
analyzed by Western blot
after 72 hr. Numbers represent
the ratio of the values ob-
tained by densitometric anal-
ysis of LC3-II and LC3-I
immunoblots. Results shown
are representative of three in-
dependent experiments.
FIG. 4. Inhibition of the mammalian target of rapamycin (mTOR) pathway induces autophagy and decreases dl922–947-
induced cytotoxicity. (A) U373MG and U87MG cells were treated with rapamycin (500 nM) for 2 hr and infected with dl922–
947 at the indicated MOIs. Expression of total and phosphorylated (p-) p70s6K, and of LC3-I/II, was analyzed by Western
blot after 72 hr. Numbers represent the ratio of the values obtained by densitometric analysis of LC3-II and LC3-I immu-
noblots. (B) Cells were treated with rapamycin (500 nM) and infected with dl922–947 after 2 hr at the indicated MOIs. Cell
survival was evaluated after 7 days. A significant increase in LD50 values was obtained in both cell lines in the presence of
rapamycin: from 0.019 to 0.802 in U373MG cells, and from 0.068 to 1.383 in U87MG cells. Results shown are representative of
three independent experiments.
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FIG. 5. Pharmacological autophagy inhibitors enhance dl922–947-induced cytotoxicity. (A) U373MG cells (left) and U87MG
cells (right) were treated with chloroquine (CQ, 10lM) or 3-methyladenine (3-MA, 1 mM) for 2 hr and infected with various
MOIs of dl922–947 for 72 hr. LC3-I/II levels and AVO formation were analyzed by Western blot (top) and FACS analysis
(bottom), respectively. Numbers represent the ratio of the values obtained by densitometric analysis of LC3-II and LC3-I
immunoblots. (B) Cells were treated with CQ or 3-MA for 2 hr and then infected with various MOIs of dl922–947. Cell survival
was evaluated after 7 days. (C) U373MG and U87MG clones stably expressing a scrambled control shRNA (shCTR) or a specific
shRNA for Atg5 (shAtg5) were infected with various MOIs of dl922–947 and cell survival was evaluated after 7 days. Results
shown are representative of three independent experiments. Color images available online at www.liebertonline.com/hum
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Inhibition of autophagy increases dl922–947
cytotoxicity in glioma cells
Next, we evaluated the effect of pharmacological inhibi-
tion of autophagy on dl922–947 infection. To this end, we used
two well-known inhibitors of autophagy: 3-methyladenine
(3-MA) and hydroxychloroquine (CQ), acting at early and late
stages of autophagy, respectively. CQ blocks the formation of
autolysosomes, where LC3-II degradation occurs, thus in-
ducing LC3-II accumulation (Amaravadi et al., 2007), whereas
3-MA, an inhibitor of class III phosphatidylinositol-3 kinase
(PI3KIII), blocks early autophagic signaling, preventing LC3-
I/LC3-II conversion (Kondo et al., 2005).
Accordingly, dl922–947-mediated LC3-I/LC3-II conver-
sion induction and AVO formation were further increased by
CQ, whereas they were partially reverted by treatment with
3-MA (Fig. 5A).
Treatment with a single dose of CQ (10lM) or 3-MA
(1 mM) increased dl922–947-induced cytotoxicity, with a re-
duction of LD50 values ranging from 2- to 5-fold (Fig. 5B). At
the concentrations used, CQ or 3-MA treatment alone did not
induce any toxic effect (data not shown).
Because CQ and 3-MA have a wide range of effects, not
only specifically linked to autophagy, we have evaluated
the effects of autophagy inhibition by generating stable gli-
oma cells clones expressing Atg5 shRNA. We chose Atg5
because this gene is involved in both canonical and non-
canonical autophagy (Scarlatti et al., 2008). Although we did
not obtain complete gene silencing, in all transfected clones a
strong increase in virus-induced cell death was observed
(Fig. 5C).
Our data confirm that inhibition of autophagy sensitizes
glioma cells to the oncolytic effects of dl922–947.
Viral replication is not increased
by autophagy modulation
It has been proposed that the results of oncolytic viro-
therapy are correlated with the efficacy of viral replication
within cancer cells. Therefore, we evaluated viral replication
in glioma cells treated with rapamycin, PD98059, and CQ. A
slight, albeit not statistically significant, decrease in genome
copies number on treatment was observed (Fig. 6A). It has
been already demonstrated that inhibition of autophagy with
3-methyladenine (3-MA) resulted in decreased synthesis of
adenoviral structural proteins, and thereby poor viral repli-
cation (Rodriguez-Rocha et al., 2011).
We have previously demonstrated that Aurora B inhibitor
AZD1152 enhanced caspase-3-dependent cell death of thy-
roid carcinoma cells infected with dl922–947, without an in-
crease in viral replication (Libertini et al., 2011). Moreover,
several studies have shown that apoptosis and autophagy
can be connected by a double switch (Dı´az-Troya et al., 2008;
Tyler et al., 2009) and that the inhibition of autophagy in-
creased apoptotic cell death in cancer cells (Cardenas et al.,
1999; Shigemitsu et al., 1999; Kondo et al., 2005). Analysis of
FIG. 6. (A) U373MG and U87MG cells were treated with rapamycin (500 nM), PD98059 (25lM), or CQ (10lM) and then
infected with dl922–947 (1 PFU/cell). The number of viral copies was evaluated over time by real-time PCR. (B) Cells were
treated with PD98059 or CQ for 2 hr and then infected with dl922–947 at the indicated MOIs. After 72 hr, caspase-3 levels
were analyzed by Western blot, using b-actin as a loading control.
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caspase-3 activation in glioma cells infected with dl922–947
showed that the inhibition of autophagy with PD98059 or
CQ leads to a reduction of procaspase-3 levels, suggestive of
caspase-3 cleavage (Fig. 6B). These results indicate that the
increase in viral cytotoxicity in the presence of autophagy
inhibitors might be due to the activation of apoptosis, rather
than increased viral replication.
Chloroquine enhances dl922–947 oncolytic activity
in vivo
To validate the potential therapeutic use of antiautophagic
drugs in association with dl922–947, we analyzed the effects
of the virus combined with CQ in U87MG xenograft tumors.
Athymic mice were injected with U87MG cells and after 20
days the animals were randomized into four groups (T = 0
days).
In mice receiving the single treatments (dl922–947 or CQ),
a nonsignificant reduction of tumor growth was observed,
whereas CQ and dl922–947 combination treatment resulted
in highly significant tumor growth inhibition (Fig. 7A).
Starting from T = 11 days, the differences in tumor volume
among the untreated group, the groups receiving the single
treatments, and the group receiving the combined treatment
were significant (*p < 0.05), and became highly significant
(**p < 0.01) at T = 23 days.
CQ treatment and dl922–947 treatment were both able to
increase the LC3-II/LC3-I ratio, and this effect was further
increased by the combined treatment (Fig. 7B).
Studies have demonstrated that apoptosis-mediated cell
death is increased by inhibition of autophagy in cancer cells
(Kanzawa et al., 2004; Boya et al., 2005; Dalby et al., 2010;
Platini et al., 2010). By analyzing caspase-3 activation in
treated tumors, we showed that cleaved caspase-3 levels
were undetectable in control tumors and barely detectable in
dl922–947-infected tumors. In contrast, in CQ-treated tumors
dl922–947 led to a more intense caspase-3 activation, com-
pared with the tumors undergoing the CQ single treatment
(Fig. 7B), thus indicating that chloroquine is effective in in-
creasing the antitumor activity of dl922–947 and in inducing
apoptosis in experimental glioma in vivo.
Discussion
Glioblastoma multiforme (GBM) is one of the deadliest
human cancers (Furnari et al., 2007). The therapy for GBM,
which includes surgical resection, radiotherapy, and che-
motherapy, has shown limited success. Consequently, the
development of novel therapeutic approaches to improve
patient survival is urgently required. A number of promising
oncolytic viruses have demonstrated antiglioma activity in
both preclinical and clinical settings (Brandes et al., 2008).
In the present study, we have analyzed the effects of
E1A-mutated adenovirus dl922–947 against glioma cells,
confirming its efficacy and showing that glioma cells
undergo autophagy in response to dl922–947 infection, as
confirmed by the dose-dependent development of acidic
vesicular organelles, the increase in LC3-II levels, and the
reduction of p62 levels. These effects were not observed on
infection with control nonreplicating adenovirus (AdGFP or
dl312), indicating that the activation of autophagy is depen-
dent on viral replication.
In contrast to the induction of autophagy observed in in-
fected cells, we show that dl922–947 infection activates the
Akt/mTOR/p70s6k pathway, which is considered the main
negative regulatory mechanism for autophagy (Blommaart
et al., 1995; Yang et al., 2005), and simultaneously inhibits the
ERK1/2 pathway, which is known to promote it (Pattingre
et al., 2003). The nonreplicating control adenovirus AdGFP
did not induce these effects. This apparent discrepancy could
be due to compensatory mechanisms selectively operated by
glioma cells to escape dl922–947 killing, although it is not
possible to exclude that other pathways contribute to the
cellular autophagic response to dl922–947 infection.
To address the role of these modulatory pathways in
dl922–947-infected cells, we have used pharmacological
inhibitors. The MEK-1 inhibitor PD98059 induced a block
of autophagy, as shown by a reduction of LC3 conversion.
Interestingly, this block was paralleled by an increase in
FIG. 7. Chloroquine enhances the activity of dl922–947 and
delays the growth of glioma tumor xenografts. (A) Animals
bearing U87MG tumor xenografts were randomized into
four groups. Two groups received CQ (45 mg/kg) intraper-
itoneally every third day. dl922–947 (1· 107 PFU, in a volume
of 200ll) was injected three times per week into one CQ-
treated group and one untreated group. The difference be-
tween the untreated group and the group receiving the
combined treatment become statistically significant (*p< 0.05)
from day 11. From day 17, until the end of the treatment, the
difference became highly significant (**p< 0.01). A statistically
significant difference was also observed between the group
receiving the combined treatment and the single-treatment
groups (*p< 0.05) from day 11 and from day 17 (**p< 0.01). No
statistically significant difference was observed between the
groups receiving the single treatments and the untreated
control group. (B) Animals bearing U87MG xenograft were
treated or not with CQ (45 mg/kg) and intratumorally in-
jected with dl922–947 (1· 107 PFU) after 24 hr. Tumor tissue
samples from two different animals from each treatment
group were homogenized after 48 hr and LC3-I/II or caspase-
3 levels were analyzed by Western blot. b-Actin was used as
loading control.
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dl922–947 cytotoxicity. Conversely, treatment of infected
cells with rapamycin, a well-known autophagy inducer,
sharply increased cell survival. All together, our data suggest
that autophagy plays a defensive/survival role during the
infection with dl922–947, the autophagic machinery probably
being involved in the destruction of viral structures. On the
other hand, the effects exerted by dl922–947 infection on in-
tracellular signals could likely represent an attempt of the
virus to overcome the cellular autophagic response. Indeed,
adenoviral infection can trigger an indirect cellular autop-
hagy defense response and specific viral mechanisms have
developed to prevent this response. Our data are in agree-
ment with a study showing activation of mTOR and p70s6k
pathway on adenoviral infection to ensure translation initi-
ation of viral mRNAs (O’Shea et al., 2005). Moreover, the
early-expressed viral E3 gene product RID-a can insert into
the autophagosomal membrane and arrest maturation by
preventing fusion to the lysosome, thereby decreasing
basal autophagy levels (Cianciola and Carlin, 2009). This
latter mechanism can be excluded since dl922-947 lacks the
E3 gene.
It is known that autophagy and viral infections have
complex interconnections. It has been suggested that some
viruses could use autophagosomes as sites for replication,
and therefore autophagy can support viral replication and
assembly (Lin et al., 2010). Moreover, it has been observed
that hepatitis C virus (Dreux et al., 2009; Tanida et al., 2009),
polio virus (Suhy et al., 2000), and dengue virus serotypes 2
and 3 (Panyasrivanit et al., 2009) are able to sustain their
replication by creating membrane alterations through sub-
verting or inducing autophagy. On the other hand, it has
been suggested that autophagy can act as a host defense
against intracellular pathogens (xenophagy) (Lin et al., 2010),
because viral replication may be confined within autophagic
vesicles. An antiviral effect of autophagy has been confirmed
during neurotropic Sindbis virus infection and in herpes
simplex virus (HSV)-1 encephalitis (Lin et al., 2010).
Oncolytic viruses can modulate autophagy in target cells,
including glioma cells. D24-RGD oncolytic adenovirus
has been shown to induce autophagic cell death in brain
tumor stem cells ( Jiang et al., 2007, 2011). Autophagosome-
mediated cell death was also observed in glioma cells in-
fected with an oncolytic adenovirus driven by the survivin
promoter (Ulasov et al., 2009). Furthermore, hTERT-Ad, an
oncolytic adenovirus regulated by the human telomerase
reverse transcriptase promoter, induced autophagic cell
death in human malignant glioma through inactivation of
the Akt/TOR pathway (Ito et al., 2006), and the inhibition of
autophagy reduced viral cytotoxicity (Yokoyama et al., 2008).
These results have suggested a role for autophagy as the
main pathway of cell death in cells infected with replicating
adenoviral vectors (Ito et al., 2006). In line with this hy-
pothesis, in vitro studies showed that autophagy inhibition
can decrease the oncolytic activity of D24-RGD in glioma cell
lines ( Jiang et al., 2011) and of the E1B-deleted adenovirus
Adhz60 in lung carcinoma cell lines (Rodriguez-Rocha et al.,
2011).
Here, we show in vitro and in vivo that inhibition of au-
tophagic pathways increases the activity of the E1A-deleted
oncolytic virus dl922–947, indicating that autophagy acts as a
cell survival response. Our observation is consistent with
Baird and colleagues (2008), who have already shown that
3-MA and chloroquine enhance the effects of dl922–947 in
ovarian carcinoma cells, but are in contrast with those of the
above-mentioned studies from Jiang and colleagues (2011)
and Rodriguez-Rocha and colleagues (2011). The dis-
crepancies could be due to the different oncolytic adeno-
viruses analyzed. It is also conceivable that different viruses
elicit different cellular responses depending on the cancer cell
type. In this regard, in anaplastic thyroid carcinoma cells,
we did not observe autophagy after dl922–947 infection
(Libertini et al., 2011), suggesting that the activation of the
autophagic process and the subsequent cellular fate are most
likely virus and cell type dependent. Further studies are re-
quired to better understand how adenoviruses interact with
host cells.
Autophagy inhibition is receiving attention as a novel
strategy for cancer treatment. New autophagy inhibitors
have been reported to act as potent anticancer drugs and/or
to sensitize cancer cells to the activity of anticancer agents
(Amaravadi et al., 2007; Carew et al., 2007; Rubinsztein et al.,
2007; Shingu et al., 2009). Chloroquine itself is emerging as a
potential anticancer agent against various cancers, including
gliomas (Degtyarev et al., 2008; Solomon and Lee, 2009).
Here, we show that chloroquine strongly enhances the on-
colytic effects of dl922–947 both in vitro and in vivo, encour-
aging the use of antiautophagic drugs for the development of
therapies based on the use of dl922–947 oncolytic virus for
the treatment of gliomas.
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AZD1152 negatively affects the growth
of anaplastic thyroid carcinoma cells
and enhances the effects of oncolytic
virus dl922-947Silvana Libertini*, Antonella Abagnale, Carmela Passaro, Ginevra Botta,
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*(S Libertini is now at The Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61 1BD, UK)AbstractNovel therapeutic approaches are required for the treatment of anaplastic thyroid carcinoma
(ATC), an incurable disease resistant to current available therapies. Aurora B is an important
mitotic kinase involved in chromosome segregation and cytokinesis. It is overexpressed in many
cancers including ATC and represents a potential target for chemotherapy. The effects of
AZD1152, a specific Aurora B kinase inhibitor, have been evaluated against ATC, showing G2/M
accumulation, polyploidy and subsequent cell death by mitotic catastrophe upon drug treatment.
Only three administrations of AZD1152 significantly reduced the growth of ATC tumour
xenogratfs. Oncolytic viruses in association with other forms of treatment have proven highly
promising in preclinical and clinical reports. The oncolytic adenovirus dl922-947 is active against
ATC cells, and we have evaluated the effects of the association between AZD1152 and dl922-947.
In cells treated with virus and drug, we report additive/synergistic killing effects. Interestingly,
the phosphorylation of histone H3 (Ser10), the main Aurora B substrate, is inhibited by dl922-947
in a dose-dependent manner, and completely abolished in association with AZD1152.
The combined treatment significantly inhibited the growth of ATC tumour xenografts with respect
to single treatments. Our data demonstrate that the Aurora B inhibitor AZD1152, alone or in
combination with oncolytic virus dl922-947, could represent a novel therapeutic option for the
treatment of ATC.Endocrine-Related Cancer (2011) 18 129–141Introduction
Anaplastic thyroid carcinoma (ATC) is one of the most
aggressive human malignancies, responsible for up
to 40% of mortality from thyroid cancer. Although
multimodality treatments are successfully applied for
well-differentiated thyroid carcinomas, ATC survival
rates have not been improved for decades: after
diagnosis, patients have a median survival time of
4–6 months (Smallridge et al. 2009). Development
and evaluation of novel therapeutic strategies are,
therefore, desperately required.Endocrine-Related Cancer (2011) 18 129–141
1351–0088/11/018–129 q 2011 Society for Endocrinology Printed in GreatSeveral approaches of gene therapy have been
studied for ATC, such as differentiating therapy to
restore radioiodine uptake, suicide therapy and
oncolytic viruses. The latter are viral mutants able to
replicate selectively in, and destroy tumour cells. The
most common approach to achieve selectivity is the
deletion of viral genes whose product is necessary for
replication in normal cells, but expendable in cancer
cells (Mullen & Tanabe 2002).
dl922-947 is an oncolytic adenovirus, which bears a
deletion of 24 bp in E1A-conserved region 2 (CR2)Britain
DOI: 10.1677/ERC-10-0234
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(Heise et al. 2000). This region normally binds to, and
inactivates, host cell Rb, thus causing the release of
E2F, followed by S-phase entry and subsequent viral
DNA replication. Lacking a functional E1A-CR2
region, dl922-947 mutant is unable to trigger S-phase
entry of quiescent normal cells, but can actively
replicate in cells with an aberrant G1–S checkpoint.
This checkpoint is lost in almost all cancer cells, and
several in vitro and in vivo studies demonstrate the
efficacy of dl922-947 in a range of cancer cell lines
(Heise et al. 2000). Its killing activity exceeds that of
adenovirus 5 wild type (Ad5wt) and of the first
generation virus dl1520 (Heise et al. 2000); a phase I
trial of dl922-947 in women with relapsed ovarian
cancer is under way (Baird et al. 2008).
We have shown that dl922-947 is active against
ATC cell lines and tumour xenografts (Libertini et al.
2008). However, data accumulated so far suggest that
the oncolytic activity of viruses, although impressive,
requires assistance in order to reach full efficacy. Using
viruses in association with other forms of treatment has
proven highly promising in preclinical and clinical
reports. The association of viruses with specific drugs,
not only able to directly kill tumour cells but also to
increase viral oncolytic activity, would represent a
powerful therapeutic tool.
The mitotic serine–threonine kinase Aurora B is
a chromosomal passenger protein (Keen & Taylor
2009). Together with INCENP, Borealin and survivin,
it exerts essential functions during mitosis, such as
modifying histones at the chromatin, correcting
misattachments while at the centromere, and regulat-
ing cytokinesis at the central spindle and later
midbody (Keen & Taylor 2009). Aurora B is over-
expressed in several human cancers, and its expression
directly correlates with malignancy (Katayama et al.
1999, Araki et al. 2004, Chieffi et al. 2004, 2006,
Kurai et al. 2005, Smith et al. 2005, Sorrentino
et al. 2005, Lo´pez-Rı´os et al. 2006, Vischioni et al.
2006, Qi et al. 2007, Tanaka et al. 2008). Upon
Aurora B depletion or inhibition, the cells with intact
checkpoint function arrest with 4N DNA content,
while those with compromised p53-dependent
pathway undergo endoreduplication and apoptosis
(Keen & Taylor 2004).
Cells lacking a p53-mediated post-mitotic check-
point are highly responsive to Aurora B inhibition, thus
suggesting a wide therapeutic window between normal
and tumour cells (Keen & Taylor 2004). In human
ATC, alterations of the p53 tumour suppressor gene are
a constant feature (Smallridge et al. 2009), and we
have previously shown that Aurora B is overexpressed
in ATC (Sorrentino et al. 2005). All these data indicate130that the treatment of ATC could benefit from the use
of an Aurora B inhibitor.
It has been reported that the block in G2/M phase
improves viral entry and replication (Seidman et al.
2001); therefore, we have hypothesized that Aurora B
inhibition could enhance the oncolytic effects of
dl922-947 adenovirus. We selected AZD1152 as an
Aurora B inhibitor due to its high selectivity for Aurora
B and its good solubility, which makes it appropriate
for clinical use (Wilkinson et al. 2007). Recent studies
showed that AZD1152 significantly reduces tumour
growth in a panel of solid human cancer xenograft
models (Wilkinson et al. 2007).
In this report, we show that AZD1152 is active
against ATC cells, inducing cell death through
mitotic catastrophe. We also demonstrate that the
drug is able to enhance the anti-neoplastic effects of
dl922-947 oncolytic virus in both in vitro and in vivo
models of ATC. Our data hint towards a mechanism
of how AZD1152 and dl922-947 can synergistically
kill ATC cells.Materials and methods
Cells, adenoviruses and drugs
Human ATC cell lines such as BHT101-5, Cal62, FRO
and 8505C have been authenticated as shown pre-
viously (Schweppe et al. 2008). All ATC cell lines
used have a non-functional p53 gene: in BHT101-5
cells, a 251 Ile/Thr substitution has been reported,
8505C cells present an Arg/Gly in position 248,
Cal62 cells are characterized by A161D mutation
while FRO cells are p53 null (Schweppe et al. 2008).
dl922-947 has a 24-bp deletion in E1A-CR2 (Heise
et al. 2000). AdGFP is a non-replicating E1-deleted
adenovirus encoding green fluorescent protein (GFP;
Libertini et al. 2007). Viral stocks were expanded,
purified, stored and quantified as previously reported
(Libertini et al. 2007).
AZD1152-HQPA was dissolved in DMSO to a final
concentration of 10 mM and stored at K20 8C.
AZD1152 was dissolved in 0.3 M Tris–HCl (pH 9) to
a final concentration of 10 mg/ml, each mouse received
300 ml of suspension i.p., i.e. 3 mg of prodrug,
corresponding to 2.5 mg of active drug.
Viability assay
BHT101-5, Cal62, FRO and 8505C cell lines have
been treated with a different range of drug concen-
trations since their sensitivity to AZD1152 treatment
varies. Treated cells were fixed with 50% TCA and
stained with 0.4% sulforhodamine B in 1% aceticwww.endocrinology-journals.org
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acid as already described (Libertini et al. 2008). The
percentages of surviving cells after treatment were
calculated by assuming that the number of surviving
untreated cells is 100%.FACS analysis
PH3 and cell cycle
Cells treated with AZD1152, virus or both were
harvested by trypsinization, fixed in 70% cold ethanol
and prepared as already described (Esposito et al. 2009)
using antibodies anti-phospho-histone H3 (Ser10)
and anti-histone H3 (Upstate, Biotechnology Inc,
Waltham, MA, USA).
AdGFP infection
FRO cells were treated for 24 h with AZD1152 25 nM,
washed and then infected with AdGFP (0, 25 or
50 pfu/cell). Forty-eight hours post infection, cells
were trypsinized, washed, resuspended in 300 ml of
PBS and analysed for the emission in FITC channel.
Samples were acquired with a CYAN flow
cytometer (DAKO Corporation, San Jose, CA, USA)
and analysed using SUMMIT software.Micronuclei counting
Cells grown on cover slips and treated as described
were fixed 15 0 in 3% paraformaldehyde, permeabilized
with 0.2% Triton X-100 10 0 and then stained 5 0 with
Hoechst 33258 (1 mg/ml, Sigma–Aldrich). The washes
were followed by mounting the cover slips onto glass
slides with glycerol:PBS 1:1.Synchronization
Cells were treated for 12 h with thymidine (2 mM),
released for 10 h in fresh media and retreated
for further 12 h with thymidine. Cells were washed
twice in fresh media, then treated and harvested
as indicated.Antibodies for western blot
Procaspase-3 (sc-56053; 1:100, Santa Cruz Biotech-
nology Inc, Santa Cruz, CA, USA), caspase-3 (ab13585,
1:500, Abcam, Cambridge, MA, USA), phospho-histone
H3 (Ser10) (06570, 1:500, Upstate Biotechnology Inc,
Waltham, MA, USA), histone H3 rabbit polyclonal
IgG (31949; 1:1000, Upstate) and actin (sc-10731, 1:500,
Santa Cruz) are the antibodies used for western blot.www.endocrinology-journals.orgTumourigenicity assay, viral replication and
distribution
Experiments were performed in 6-week-old female
athymic mice (Charles River Laboratories Inter-
national Inc, MA, USA). Mice were maintained at
the Dipartimento di Biologia e Patologia Animal
Facility. Animal experiments were conducted in
accordance with accepted standards of animal care
and in accordance with the Italian regulations for the
welfare of animals used in the studies of experimental
neoplasia. The study was approved by our institutional
committee on animal care.
To evaluate the effects of dl922-947 in combination
with AZD1152, FRO cells (1!107) were injected into
the right flank of 80 athymic mice. After 40 days,
tumour volume was evaluated, and the animals were
divided into four groups (20 animals/group) with
similar average tumour size. Tumour diameters
were measured with callipers, and tumour volumes
(V) were calculated by the formula of rotational
ellipsoid: VZA!B2/2 (A is the axial diameter and
B is the rotational diameter).
Viral replication and distribution were evaluated
as previously described (Libertini et al. 2008).Statistical analysis
The analysis of the cell killing effect in vitro was
made by isobolograms generated to calculate the con-
centration of each agent killing 50% of cells (EC50) using
untreated cells or cells treated with one agent only as
controls, as previously described (Cheong et al. 2008).
Comparisons among different treatment groups in
the experiments in vivo were made by the ANOVA
method and the Bonferroni post hoc test using
commercial software (GraphPad Prism 4, GraphPad
Software Inc, La Jolla, CA, USA). Differences in the
rate of tumour growth in mice were assessed for each
time point of the observation period.Results
AZD1152 treatment induces cell death in
ATC cells
Aurora B kinase is overexpressed in ATC, and blocking
its expression or activity reduces ATC cell growth
(Sorrentino et al. 2005). To confirm Aurora B as a
therapeutic target, we have evaluated the effects of
Aurora B inhibitor AZD1152 on the survival of human
ATC cell lines FRO, BHT101-5, 8505C and Cal62.
All cell lines are highly sensitive to AZD1152, with
an IC50 ranging from 8 to 50 nM for Cal62 and131
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FRO cells respectively (Fig. 1A). Aurora B inhibition
induces endoreduplication thus increasing cell dia-
meter; this could underestimate drug effects when
standard proliferation assays are used. Therefore, the
anti-proliferative effect of AZD1152 was also
determined by cell counting. As shown in Fig. 1B,
the inhibitor significantly reduces cell number after
1 day of treatment, further confirming the high efficacy
of the drug.
AZD1152 blocks Ser10 H3 phosphorylation
and induces mitotic catastrophe
Aurora B phosphorylates histone H3 on serine 10
during mitosis (Prigent & Dimitrov 2003). To confirm
AZD1152 effects on Aurora B activity, we treated FRO
and BHT101-5 cells for 24 h and performed a FACS
analysis by using a specific anti-phospho-Ser10 histone
H3 antibody (Fig. 1C).100
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As shown in Fig. 2A and B, a dose- and time-
dependent increase in polyploid cells was observed;
this increase was paralleled by the reduction in Ser10
H3 phosphorylation levels (Fig. 1C). After 24 h of
treatment, a subG1 fraction and G2/M accumulation
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Endocrine-Related Cancer (2011) 18 129–141chromosome segregation and cell division, and leads
to the formation of large non-viable cells charac-
terized by micronuclei (Castedo et al. 2004a).
Micronuclei are nuclear envelopes around clusters
of missegregated chromosomes (examples in
Fig. 2C). By immunofluorescence, we have quantified
the number of FRO- and BHT101-5-micronucleated
cells after AZD1152 treatment (Fig. 2D). A clear
dose- and time-dependent increase in the number of
micronucleated cells was observed.AZD1152 and dl922-947 show synergistic effects
on ATC cells
It has been proposed that drugs interfering with mitosis
and cytokinesis could potentiate viral oncolysis
(Seidman et al. 2001). Therefore, we hypothesized
that the association with AZD1152 could positively
affect the activity of the oncolytic adenovirus
dl922-947.www.endocrinology-journals.orgFRO and BHT101-5 cells were treated with
AZD1152 and simultaneously infected with dl922-947;
cell survival was evaluated after 7 days, showing
additive/synergistic effects (Fig. 3A, Table 1). In order
to understand whether AZD1152 sensitizes cells
to viral action, we have treated FRO and BHT101-5
cells with AZD1152 for 24 h and then infected with
dl922-947. The effects were evaluated after 6 days: the
data obtained show that 24 h pre-treatment is sufficient
to significantly increase the killing activity of dl922-
947 (Fig. 3B, Table 2), confirming that the inhibitor
sensitizes cells to viral action. It is also worth noting
that 24 h treatment with AZD1152 alone significantly
affects cell survival.AZD1152 does not affect cellular infectivity
It has been proposed that drugs can enhance viral
oncolytic activity by increasing viral entry in target
cells (Anders et al. 2003). To monitor this step, FRO133
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Figure 3 AZD enhances the oncolytic activity of dl922-947 but does not increase cellular infectivity. (A) FRO and BHT101-5 cells
were treated with five fixed combination ratios of dl922-947 and AZD1152, and cell viability was determined by sulforhodamine B
assay 7 days post infection. Dose–response curve and EC50 values were used to construct isobolograms and calculate combination
indexes (CI) for each ratio. Ratios are expressed as virus (pfu/cell) to drug (nM). A line is drawn connecting the EC50 values of the
virus and drug as a single agent. A ratio producing a CI%0.8 is considered synergistic, a ratio producing CIs between 0.8 and 1.2 is
considered additive and a ratio producing CIR1.2 is considered antagonistic. (B) Cells were treated for 24 h with the drug; then, the
media were replaced with media containing the virus alone. Survival was evaluated after 6 days with isobolograms obtained as
above. (C) FRO cells were treated for 24 h with AZD1152, and then infected with AdGFP. Viral entry was quantified bymonitoring the
percentage of GFP-positive cells (numbers on the bars) and the average expression in FITC channel (numbers on top right) after
24 h. The percentage of GFP-positive cells does not significantly change upon AZD1152 pre-treatment, beingw85% for 25 pfu/cell
andw95% for 50 pfu/cell, regardless of drug pre-treatment. The FITC ratio in infected and uninfected cells upon drug treatment
showed no significant change (75G31-fold increase versus 68G19 for 25 pfu/cell and 466G246-fold increase versus 458G182
for 50 pfu/cell).
S Libertini et al.: dl922-947 and AZD1152cells were pre-treated for 24 h with AZD1152 at a low
concentration (able to induce G2/M block but not death
after 48 h) and then infected with a non-replicating
reporter adenovirus transducing GFP (AdGFP). After
additional 24 h, GFP emission was evaluated by
cytofluorimetric analysis. The percentage of GFP
cells was not modified by AZD1152 pre-treatment,
although a positive shift in FITC channel was observed
(Fig. 3C). This increase is apparent, since AZD1152
treatment enlarges the cells thus enhancing basal
fluorescence. Indeed, analysis of the FITC ratio in
infected and uninfected cells treated or not with134AZD1152 showed no significant difference. Similar
results were obtained with BHT101-5 cells (data
not shown).dl922-947 and AZD1152 induce subG1 phase
population in treated cells
Next, cell cycle profiles in infected cells, treated or not
with AZD1152, were evaluated. To better discriminate
differences in cell cycle phases, timing and cell death, a
double thymidine block was performed to synchronize
cells in G1. As shown in Fig. 4, in untreated cells, 10 hwww.endocrinology-journals.org
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Table 1 Simultaneous treatment with AZD1152 and dl922-947
Cell line
Ratio
((pfu/cell)/(nM))
EC50
dl922-947
(pfu/cell)
EC50
AZD1152
(nM) CI
BHT101-5 AZD1152 alone 0 13
dl922-947 alone 10 0
1:50 0.2 10 0.79
1:16 0.5 8 0.67
1:6 1 6 0.56
1:1 5 4 0.8
4:1 8 2 0.95
FRO AZD1152 alone 0 50
dl922-947 alone 1 0
1:400 0.1 40 0.9
1:120 0.25 30 0.85
1:40 0.5 20 0.9
1:14 0.7 10 0.9
1:6 0.8 5 0.9
Table 2 AZD1152 pre-treatment on dl922-947-infected cells
Cell line
Ratio
((pfu/cell)/(nM))
EC50
dl922-947
(pfu/cell)
EC50
AZD1152
(nM) CI
BHT101-5 AZD1152 alone 0 24
dl922-947 alone 10 0
1:500 0.04 20 0.84
1:167 0.06 10 0.42
1:114 0.07 8 0.34
1:62 0.08 5 0.21
1:20 0.2 4 0.19
FRO AZD1152 alone 0 100
dl922-947 alone 1 0
1:5000 0.01 50 0.51
1:667 0.06 40 0.46
1:300 0.1 30 0.4
1:50 0.4 20 0.6
1:12 0.8 10 0.9
Endocrine-Related Cancer (2011) 18 129–141after thymidine release, about 30% of the population
re-entered G1 phase; a similar profile was observed
in infected cells. Conversely, after 10 h, AZD1152
induced a G2/M accumulation that was not modified
by the association with dl922-947. Starting from 20 h,
a significant increase in subG1 phase was observed in
both AZD1152- and dl922-947-treated cells. Interest-
ingly, the combination between drug and virus
increased the percentage of cells in subG1 fraction
compared with single treatments. It is also worth
noting that, in the combined treatment, the increase in
subG1 fraction at later time points is associated with a
decrease in polyploidy fractions, suggesting that
dying cells (subG1 fraction) are the ones that escaped
G2/M block.
Caspase-3 activation has been observed in some
models of mitotic catastrophe (Castedo et al. 2004a,b),
and dl922-947 induces subG1 accumulation and
caspase-3 cleavage in ovarian cancer cells (Baird
et al. 2008). Therefore, we analysed caspase-3
activation in treated ATC cells. As shown in Fig. 5A,
while dl922-947 induces caspase-3 cleavage,
AZD1152 does not. Interestingly, in the combined
treatment, an earlier decrease of procaspase-3 with
respect to virus treatment alone was observed. This
observation suggests that the inhibitor could enhance
viral-induced cell death by accelerating the activation
of caspase-3 pathway.
dl922-947 reduces H3 phosphorylation
FRO cells infected with dl922-947 show G2/M
accumulation and tetraploidy (Fig. 4), suggestive of a
mitotic block. During a normal mitosis, histone H3 is
phosphorylated on Ser 10 (28–29); the viral effects onwww.endocrinology-journals.orgcell cycle prompted us to analyse whether dl922-947
acted on this substrate.
We treated FRO cells for 24 h with different
amounts of virus and drug, alone or in combination.
Cells were stained with propidium iodide and with
anti-phospho-Ser10 H3 histone antibody to monitor
the percentage of PH3-positive cells during the cell
cycle (Fig. 5B). dl922-947 alone is able to decrease
the percentage of PH3-positive cells and, together
with AZD1152, Ser10 H3 phosphorylation is almost
completely abolished: FACS data were confirmed by
western blot analysis of PH3 levels (Fig. 5C).AZD1152 increases dl922-947 oncolytic
activity in vivo
To further validate the potential therapeutic use of
AZD1152 in association with dl922-947, we analysed
the effects of the combined treatment on xenograft
tumours. To study the effect of the association in the
worst possible scenario, FRO cells were chosen, being
the least sensitive to AZD1152 effect (Fig. 1) and
viral infection (Libertini et al. 2008). A low viral dose
(1!106 pfu) was used to better evaluate the effects
of the combined treatment; virus was administered by
i.t. injection to avoid first pass effect.
Animals were divided into four groups: untreated,
treated with AZD1152, dl922-947 or both. As shown
in Fig. 6A, AZD1152 and dl922-947 in combination
have a stronger anti-tumour activity than when used
alone. As already described, no toxicities were
observed in virus-treated animals (Libertini et al.
2008). Drug-treated animals showed slight weight loss
and dehydration on the third day of treatment, but135
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Figure 4 AZD1152 and dl922-947 induce tetraploidy and cell death. FRO cells were synchronized in G1 phase and treated with
AZD1152 10 nM, dl922-947 (25 pfu/cell) or both. FACS analysis was performed to analyse the cell cycle.
S Libertini et al.: dl922-947 and AZD1152recovered after 2–3 days. In the combined treatment
group, animals took longer to recover (4–5 days), but
no other symptoms were observed.
Viral replication analysis in animals pre-treated
with AZD1152 showed an increase of genome copies
(Fig. 6B). However, this effect was not observed
in vitro (data not shown). It has been hypothesized that
the pre-treatment with anti-neoplastic drugs could
improve intratumoural viral diffusion by reducing
the number of neoplastic cells (Va¨ha¨-Koskela et al.
2007). To address this point, FRO xenografts animals,
pre-treated or not with AZD1152, were injected
intratumourally with AdGFP. GFP expression was
evaluated by fluorescence microscopy analysis
(Fig. 6C). In control tumours, a faint fluorescence
signal was observed, whereas in AZD1152-treated
tumours, a more intense fluorescence signal wasProcaspase-3
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136detected. It is worth noting that both viral replication
and distribution were increased three times upon drug
treatment (Fig. 6B and C).Discussion
ATC is one of the most lethal neoplasia and leads to
death in a short time. Active therapies are not available,
making the development of novel therapeutic strategies
imperative (Smallridge et al. 2009).
AZD1152 is a reversible ATP-competitive Aurora
inhibitor, which is 1000-fold more selective for Aurora
kinase B than for Aurora kinase A (Wilkinson et al.
2007). The effects of AZD1152 have been already
assessed in in vivo models of human leukaemia
(Wilkinson et al. 2007, Yang et al. 2007, Walsby et al.
2008, Oke et al. 2009), breast cancer (Gully et al. 2010),B
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Figure 6 AZD1152 delays tumour growth and facilitates
dl922-947 replication and distribution. (A) Tumour bearing
mice were randomized into four groups. Two groups received
AZD1152 (100 mg/kg per day) i.p. from T1 to T3 and from T15 to
T17. dl922-947 (1!106 pfu, in a volume of 300 ml) was injected
at T4, T8, T11 and T15 into one AZD1152-treated group and
one untreated group. The control group was injected with saline
solution. Tumour volume is expressed as a percentage of the
volume observed at day 0 in the control group. The difference
between treated and untreated groups becomes statistically
significant (P!0.05) from day 17 for virus versus control and
drug versus control, and from day 8 for combined treatment
versus control. At day 21, a significant difference (P!0.05) was
observed between the combined treatment group and single
treatment groups. From day 23 till the end of the treatment, the
difference became highly significant (P!0.01). (B) FRO cells
(1!107 cells) were injected intratumourally within ten athymic
mice. Forty days later, when tumours were detectable, animals
were divided into two groups, which received respectively
AZD1152 (2.5 mg/mouse) or saline solution i.p. After 24 h,
dl922-947 (1!106 pfu, in a volume of 300 ml) was injected
intratumourally in both groups. Two days later, animals were
killed. DNA was extracted from 100 mg of tumour tissue, and
the number of viral copies was evaluated by real-time PCR. The
data are the mean of three different experiments. (C) Ten FRO-
induced xenograft tumours were injected i.p with AZD1152
(100 mg/kg per day) or saline solution for 3 consecutive days
and, after 2 days, AdGFP (1!107 pfu, in a volume of 300 ml)
was injected intratumourally in both groups. Twodays later, animals
were killed, tumours were excised and GFP distribution was
evaluatedbyconfocalmicroscopy.Thequantificationof thedigitized
signal showed a threefold increase upon AZD1152 treatment.
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www.endocrinology-journals.orghepatocellular carcinoma (Aihara et al. 2010), and
colon and lung cancers (Wilkinson et al. 2007).
AZD1152 and other Aurora inhibitors are currently in
early clinical evaluation, showing reversible neutropenia
as a major side effect (Keen & Taylor 2009).
In the present study, we have demonstrated that
AZD1152 is active against ATC cells and that the
effects are observed within 24 h. These data are
consistent with the high levels of Aurora B expression
(Sorrentino et al. 2005), the lack of a functional
p53 pathway (Schweppe et al. 2008) and the short
doubling time (10 h) of ATC cells. In the present
study, we have also shown that just three doses of
AZD1152 significantly delay the growth of ATC
tumour xenografts.
Another Aurora inhibitor, VX-680, has been
previously evaluated on ATC cell lines showing
inhibition of cell proliferation and cell death; however,
the drug was not evaluated in vivo (Arlot-Bonnemains
et al. 2008). Cells treated with VX-680 showed an
increase in DNA content (O4N), reduction of Ser10
H3 phosphorylation, subG1 accumulation and acti-
vation of caspase-3 (Arlot-Bonnemains et al. 2008).
The authors concluded that VX-680 activated the
apoptotic cascade in ATC cells, and suggested that the
effects reported were due to the inhibition of Aurora A
rather than Aurora B. VX-680 inhibits Aurora kinases
with comparable inhibition constants, ranging from
0.6 nM for Aurora A to 18 nM for Aurora B; hence, it
is plausible that the effects exerted by VX-680 on ATC
cells are due to the inhibition of both Aurora kinases.
In addition, it has been previously reported in other
cell models that effects seen with VX-680 closely
resemble those described for Aurora B inhibition
(Keen & Taylor 2004) and mirror the effects described
here with AZD1152 on ATC cells. Moreover, the IC50
of VX-680 on ATC cells ranged from 25 to 150 nM:
these concentrations are also sufficient to inhibit the
kinase FLT3 (Harrington et al. 2004, Arlot-Bonnemains
et al. 2008). On the other hand, the IC50 of AZD1152
in this study ranges from 5 to 30 nM, indicating that
AZD1152 could achieve a therapeutic effect at lower
and less toxic concentrations. Therefore, our results
clearly indicate using both in vitro and in vivo
models that selective inhibition of Aurora B could
represent a therapeutic option for the treatment of ATC.
Oncolytic viruses are emerging as new therapeutic
tools for the treatment of cancer, and we previously
demonstrated that the mutants dl1520 and dl922-947
are active against ATC in vitro and in vivo (Libertini
et al. 2007, 2008). It has been reported that drugs
able to block cells in G2/M or inhibit cytokinesis
could enhance the effects of oncolytic viruses137
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(Seidman et al. 2001). Since AZD1152 has a clear
effect on cell division, we wondered whether it could
positively affect dl922-947 activity. The data presented
in this manuscript demonstrate the efficacy of this
combination both in vitro and in vivo.
To understand how AZD1152 enhances oncolytic
activity, we first monitored viral entry upon drug
treatment. Our data show that AZD1152 does not affect
viral entry. The synchronization in G2/M phase leads to
modest, but significant, translocation of CAR receptor
to the cell surface of A549 lung carcinoma cells
(Seidman et al. 2001). Although AZD1152-treated
cells accumulate in G2/M phase, membrane levels of
CAR and its co-receptors integrins avb3, avb5 and avb1
do not increase after AZD1152 treatment (data not
shown). By using AdGFP, we did not observe any
difference in viral entry during each cell cycle phase
(data not shown). Our observation is not in agreement
with Seidman et al. (2001); this discrepancy could be
due to the different cellular system used or to a very
slight increase in receptor levels hidden by the increase
in cellular size.
Secondly, we analysed cell death mechanisms
induced by virus and drug, alone or in combination.
AZD1152 induces a G2/M block and tetraploidy in
ATC cells. This aberrant mitotic phenotype, the
presence of micronuclei and the appearance of subG1
population demonstrate that AZD1152-treated cells
die through mitotic catastrophe. According to the
literature, mitotic catastrophe could share biochemical
hallmarks with apoptosis, such as mitochondrial
membrane permeabilization (MMP) and caspase
cleavage (Castedo et al. 2004a,b). In our study, despite
the clear induction of mitotic catastrophe, AZD1152
did not induce caspase-3 activation (Fig. 5) and
MMP (data not shown). Like AZD1152-treated cells,
ATC-infected cells show enlargement and polyploidy.
However, it is possible to exclude death by mitotic
catastrophe since, upon infection, cells detach, a
feature not observed in mitotic catastrophe. Moreover,
in the few adhering cells, we have not observed the
presence of micronuclei (data not shown). We have
also excluded autophagic cell death, since neither
beclin 1 activation nor LC3I–II conversion were
induced, and accumulation of autophagic vesicular
organelles was not observed by FACS analysis in
acridine orange-stained cells (data not shown). Our
data extend to ATC cells the observation of Baird
et al. (2008) that infection with mutant oncolytic
adenovirus leads to programmed cell death lacking
the features of classical apoptosis, but showing some
apoptotic markers, such as subG1 accumulation and
caspase-3 activation. Interestingly, the association with138AZD1152 accelerates the appearance of cleaved
caspase-3 and increases the percentage of cells in
subG1 phase. Our results indicate that AZD1152
enhances the cytotoxic effects of oncolytic viruses,
although the cell death mechanisms are not yet defined.
During mitosis, Aurora B is involved in phosphoryl-
ation of histone H3 on Ser10 (Ditchfield et al. 2003,
Hauf et al. 2003). Accordingly, AZD1152 strongly
reduces H3 phosphorylation. It has been reported that
the oncolytic herpes virus G47D decreases phospho-
Ser10 H3 levels (Passer et al. 2009), and we observed
that the oncolytic adenovirus dl922-947 (Fig. 5B) and
Ad5wt (personal observation) have a similar effect.
These data suggest that modulation of PH3 levels is a
common feature of viral infections; it is conceivable
that viruses prematurely end mitosis in order to switch
cell machinery to viral replication.
The first oncolytic adenovirus described, dl1520
(Heise et al. 1997), has shown improved effects in
clinical trials in combinations with chemotherapy
(Kumar et al. 2008). In 2005, China approved the
world’s first oncolytic virus therapy for cancer
treatment, with modified adenovirus H101, similar to
dl1520 (Yu & Fang 2007). In a phase III trial, a 79%
response rate for H101 plus chemotherapy, compared
with 40% for chemotherapy alone, was observed (Yu
& Fang 2007). Other oncolytic viruses have entered
into clinical trials: their efficacy and safety, and
synergistic effects in association with other drugs
have been demonstrated, confirming virotherapy as
a promising direction for the treatment of cancer
(Liu et al. 2007). Oncolytic viruses target neoplastic
cells using a mechanism different from that of anti-
neoplastic drug; therefore, the combination treatment
could contribute to avoid the development of resistant
cancer cells, thus increasing the cure rate.
Data presented here demonstrate that the selective
inhibitor of Aurora B kinase AZD1152 is highly
effective against ATC cell lines and tumour xenografts,
and could represent a novel therapeutic option for the
treatment of this dismal disease. We have also shown
that AZD1152 enhances the effects of dl922-947
against ATC; similar combined approaches could be
used for the treatment of ATC and other aggressive and
incurable human cancers.Declaration of interest
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